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Introduction
1
2 Introduction
1.1 Breast cancer
Breast cancer is one of the leading causes of cancer death (deaths of any cancer type)
in the western world1,2. In the Netherlands, one out of 6.6 women faces the diagno-
sis of breast cancer during her life, assuming a lifespan of 95 years1,2. When breast
cancer develops, it starts off in the inner lining of the milk ducts or in the lobules that
supply these ducts with milk (see Figure 1.1). The two most common types of breast
cancer are invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC),
which account for 90% of all identified breast cancers3. IDC differs from ILC in epi-
demiology, molecular alterations, clinico-pathological aspects and natural history4.
Several other (rarer) types of breast cancer exist (medullary, tubular, mucinous, etc.).
According to the World Health Organization classification, breast cancer can be clas-
sified in up to 21 distinct histological types on the basis of cell morphology, growth
and architecture patterns5. Moreover, ductal carcinoma in situ (DCIS) is described as
a precursor of invasive cancer and is commonly detected in mammography screen-
ing, as these tend to be identifiable as calcifications in approximately 25% of cases6.
In the Netherlands, the general female population between 50 and 75 years of age is
currently invited for breast cancer screening with biennial mammography. Screen-
ing was introduced in 1988. The regimen is structured in a one-size-fits-all approach,
which has shown to be only partly appropriate for breast cancer screening in the en-
tire population because independent patient-related factors like breast density (BD)
have a profound effect on the screening accuracy7.
Today, research focuses on personalizing breast cancer screening programs, for ex-
ample, by changing towards risk-based screening and adding supplemental screen-
ing modalities for women with dense breasts9,10. Currently, breast MRI is consid-
ered to be the most sensitive imaging method for the early detection of breast cancer.
Therefore, women at increased breast cancer risk are recommended to start screen-
ing at an early age. In addition, the sensitivity of mammography is relatively poor
in these young women due to the large amount of fibroglandular tissue within the
breast and consequent masking of breast cancers11,12. Since breast MRI is a rather
expensive imaging modality, it is only proven to be cost-effective in the highest
risk categories. According to the guidelines, these categories include women with
a germ-line BRCA mutation; other genetic syndromes associated with a high risk
of developing breast cancer; or a lifetime risk of ≥ 20-25% based upon family his-
tory11,12. This will be discussed in more detail in Chapter 2.
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Normal duct Usual ductal hyperplasia Atypical ductal hyperplasia
Invasive carcinomaDuctal carcinoma in-situ
Figure 1.1: Progression of ductal-type breast cancer at different stages. Ductal-type
breast cancer is thought to progress from atypical hyperplasia and ductal carcinoma
in situ (DCIS) to invasive cancer8.
1.2 Mammography
Mammography is a fast, relatively inexpensive, widely available, and non-invasive
technique yielding a 2D x-ray image of the breast. The x-rays are attenuated differ-
ently depending on the composition of the breast tissue they pass. The x-rays are
recorded by an x-ray sensitive detector. These attenuation differences among can-
cerous tissue, glandular, and fatty tissue allow the visualization of breast lesions,
which predominantly present as soft tissue masses, grouped calcifications, architec-
tural distortions, or focal asymmetries. The main strengths of mammography are the
very high spatial resolution and the possibility to depict microcalcifications that may
indicate the presence of in situ or invasive carcinoma13. Breast cancer population-
based screening using mammography aids in detecting cancers before they become
symptomatic. This reduces breast cancer-related mortality by approximately 30%2.
However, since the attenuation of cancer and fibroglandular tissue is very similar,
mammography lacks sensitivity in dense breasts due to tissue overlap and conse-
quent masking of relevant disease (see Figure 1.2).
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(a) MLO-view (b) CC-view
Figure 1.2: Mammography image of the right breast in MLO (a) and CC view (b) of a
woman (aged 38) with breast parenchyma of the highest density grade
1.3 Breast MRI
Since the first tests of contrast-enhanced breast MRI with gadolinium diethylenetri-
amine penta-acid (Gd-DTPA) were performed in the early eighties, its use has ex-
panded worldwide. Nowadays, dynamic contrast-enhanced breast MRI (DCE-MRI)
is widely known as the most effective imaging modality for the early detection of
breast cancer12,14,15. Initial evaluations showed not only that DCE-MRI was capable
of showing most cancers, but also yielded significantly more information than mam-
mography and ultrasound. In prospective studies, a sensitivity of over 90% was doc-
umented15, and more recent reports provide even higher numbers16,17, likely due to
continuously increasing the quality of MRI protocols as well as increased experience
with the technique.
The performance of MRI is dependent on the underlying physics. An MRI system
consists of several components:
1. A large magnet to generate the magnetic field (B0). The magnetic field aligns
the hydrogen nuclei within the body to generate images.
2. The radio-frequency coil to transmit a radio signal into the body.
3. A receiver coil to detect the radio signals that are emitted by the relaxation of
excited nuclei.
4. Gradient coils to provide spatial information of the signals.
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5. A computer to reconstruct the received radio-signals into images (by means of
Fourier transforms).
The detection of breast cancer in dynamic contrast-enhanced breast MRI is highly
improved by the administration of an intravenous contrast agent. This is explained
by the fact that tumors are relatively fast-growing and, thus, in need of a lot of nutri-
ents and oxygen. Therefore, they tend to stimulate blood vessel growth. Moreover,
the blood vessels that are created by the tumor are leaky, which allow the contrast
agent to leak into the surrounding tissue. Thus, the cancerous region will contain
more contrast agent, resulting in an increased signal on contrast sensitive sequences.
Very indolent lesions may not cause sufficient neovascularization and, thus, contrast
leakage to be detected at breast MRI. Moreover, regular breast MRI sequences are
not capable of detecting microcalcifications in the breast. This explains why not all
lesions detected at mammography are depicted at breast MRI, since MRI, in the case
of DCIS, predominantly detects high-grade disease18.
In the case of enhancing lesions at breast MRI, morphologic evaluation and dynamic
series are used to distinguish cancer from benign enhancing lesions. The dynamic
series aid evaluation by capturing the peak enhancement and wash-out behavior of
the enhancing lesions (see Figure 1.3). The time course of the signal enhancement
is of diagnostic value in clinical practice. Morphological (lesion appearance) and
kinetic information (enhancement-time curve) of breast lesions are assessed accord-
ing to the ACR Breast Imaging and Data System (BI-RADS) MRI lexicon19. A more
detailed elaboration on the current protocols used in breast MRI screening will be
presented in Chapter 2.
The high sensitivity of MRI led to the rapid spread of applications and indications
for breast MRI. It was recognized as an excellent screening technique as it does not
use any ionizing radiation, unlike mammography, and has a very high negative pre-
dictive value (the power to predict that there is no breast cancer present). Breast
MRI screening is currently only indicated for women at increased risk of breast can-
cer. International guidelines11,12 advise women with a lifetime risk of ≥ 20 - 25%
to be screened with breast MRI and mammography, this includes BRCA mutation
carriers, women with radiation to the chest at a young age and women with a very
high risk due to family history. Women with previously diagnosed high-risk lesions
and women with a personal history of breast cancer are also at increased risk and are
therefore commonly enrolled in such screening protocols20. Due to the many differ-
ent guidelines available, practice varies from hospital to hospital. Mainly due to the
associated costs, the Dutch national guidelines are more restrictive in the population
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Figure 1.3: Breast MRI acquisition scheme. One volume is acquired before the ad-
ministration of contrast agent (V0) and several volumes are acquired after contrast
injection (V1-VN ). With these data, contrast enhancement curves can be computed
for a lesion of interest, and lesions can be classified as showing persistent enhance-
ment (green), plateau enhancement (blue), or washout (red)21.
selected for breast MRI screening and include only women with a lifetime risk of >
50%. In BRCA mutation carriers, this screening already starts at the age of 25 with
a yearly breast MRI and at the age of 30, a yearly mammography exam is added to
this regimen. In women at high familial risk, screening starts at 35 - 45 years, and in
women with a personal history of breast cancer, it starts one year after the diagnosis
of breast cancer.
1.4 BI-RADS
The Breast Imaging Reporting and Data System (BI-RADS) lexicon is used to report
on findings detected in breast imaging. The American College of Radiology devel-
oped the first version of this BI-RADS lexicon in 1993 to standardize breast imaging
reports, to improve communication with referring physicians, and to provide a qual-
ity assurance tool. The lexicon descriptors were designed to predict both benign and
malignant disease, eliminate ambiguity, allow automated data collection, and facil-
itate communication with referring physicians. Structured reports are categorized
into several categories, including the description of findings and a final decision-
oriented assessment. The first version only included mammography, but currently,
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it also includes ultrasound and breast MRI22. The final assessment of the exam de-
fined by the BI-RADS lexicon consists of 6 possible categories of which the radiol-
ogist needs to choose one, ranging from BI-RADS 1 as being normal to BI-RADS 6
as already proven to include breast cancer. A temporary assessment of BI-RADS 0,
meaning that more imaging is required, can also be given.
1.5 Density and background parenchymal enhancement
The BI-RADS lexicon described by the American College of Radiology has a number
of standard requirements for the reporting of breast imaging. These include breast
density on mammography and background enhancement in breast MRI. Previous
research already showed a clear correlation between mammographic breast density
and breast cancer risk7. However, mammography is a 2D technique and estimating
breast density might be inaccurate. Measuring density or the so-called amount of
fibroglandular tissue on a 3D technique as breast MRI is more precise, and there-
fore this might be preferred in for example risk modeling. In addition, case-control
studies indicate that background parenchymal enhancement (BPE) on breast MRI
might be associated with breast cancer23,24. These results show that both breast den-
sity measured on mammography and BPE on breast MRI might be potential risk
stratification factors for breast cancer.
1.6 Other imaging modalities
As already mentioned, mammography and breast MRI are currently the modalities
of choice for high-risk screening, but there are also other potential imaging modali-
ties. First of all, breast tomosynthesis is a relatively new technique that is being im-
plemented into clinical practice and population-based screening programs around
the world. For the average risk population, preliminary studies found an increase
in sensitivity and an equal or even improved specificity compared to mammogra-
phy25. Tomosynthesis can be described as a special mammography exam that par-
tially overcomes the 2D-limitations (e.g. tissue overlap) by producing a pseudo-3D
image of the breast. In tomosynthesis, multiple low dose x-ray projections are ob-
tained at different angles, which are subsequently reconstructed into the final diag-
nostic images (usually slices of 1 mm thickness). The breast is compressed in the
same manner as for mammography, but some studies suggest that a reduction in
compression force can be applied in tomosynthesis without losing clinical perfor-
mance because tissue overlap is less of an issue26. Although multiple low dose pro-
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jections are acquired, the dose of the exam is comparable or slightly higher than that
of a standard mammography exam27. Furthermore, there is still debate whether the
visibility of calcifications is lower than in mammography28–30. Due to the slightly
higher dose and the lack of gain in detecting microcalcifications, tomosynthesis is
still not used for screening the population at increased risk, and further research is
needed to focus on the added value of tomosynthesis when breast MRI is available.
Another modality, which was previously investigated for the implementation of
high-risk screening programs, is 3D automated breast ultrasound (ABUS). Ultra-
sound is a relatively inexpensive, radiation-free, and widely available imaging modal-
ity. ABUS is less user-dependent than hand-held ultrasound, which is used in clinical
practice, and can be performed by a technician instead of a radiologist, potentially
saving time and money. ABUS acquires three-dimensional B-mode US volumes by
using a large linear array transducer. Multiple acquisitions are needed to cover the
entire breast (usually 2 to 5). The images are then processed to present multiplanar
reformats in the coronal and sagittal plane. Especially in women with dense breasts,
this technique was speculated to increase cancer detection compared to mammog-
raphy. This was confirmed by the study of Brem et al.31. However, in the study of
van Zelst et al.32 it was shown that, in BRCA mutation carriers, ABUS did not lead to
the detection of additional cancers beyond that available with mammography and
breast MRI, while it did lead to more false positive findings. Similar findings were
reported for supplemental hand-held ultrasound15. Consequently, the performance
of currently available ultrasound techniques for screening the high-risk population
that is also screened with breast MRI is not recommended. Van Zelst and coworkers
discussed the potential cause of this limited value of ultrasound in high-risk screen-
ing explaining that this might be caused by the relatively benign appearance of the
typical BRCA-related cancers.
1.7 Quality control of screening programs
Quality control in screening programs mainly uses defined performance measures,
described by Roseberg et al.33. These performance measures include recall rate,
biopsy rate, positive predictive value of recall, positive predictive value of biopsy,
cancer detection rate, sensitivity, and specificity. These measures have been used in
Chapter 3 and can be explained as:
• Recall rate (RR), which is described as the number of recalls per 1000 screening
examinations.
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• Biopsy rate (BR), which is described as the number of biopsies performed per
1000 screening examinations.
• Positive predictive value of recall (PPV1) is calculated by dividing the number
of correct recalls (resulting in cancer diagnosis) by the total number of recalls.
• Positive predictive value of biopsy (PPV3) is calculated by dividing the num-
ber of correct biopsies (resulting in cancer diagnosis) by the total number of
biopsies.
• Cancer detection rate (CDR), which is described as the number of breast can-
cers detected per 1000 screening examinations.
• Sensitivity, which is described as the number of true positives (breast cancers
detected in screening examinations) divided by the total number of positives.
Positives can be divided into true positives and false negatives, where false
negatives are the examinations that were reported to be negative but a cancer
was subsequently found.
• Specificity, which is described as the number of true negatives (screening ex-
aminations that not include a breast cancer, checked with the proper follow
up) divided by the number of negatives. Negatives can be divided into true
negatives and false positives, where false positives are described as the exam-
inations that were reported to be suspicious for breast cancers, but no breast
cancer was detected after appropriate follow-up.
Guidelines describe accepted and desired levels for all these performance measures
for mammography screening34. Recently, auditing guidelines were also described
for breast MRI19, however, evaluation of prior examinations was not mentioned.
Although these quality controls/audits are regularly performed in mammography
screening, in breast MRI these are rare. When reported, these are mainly reported
in prospective trials with sharply defined population groups. At present, quality
control results for breast MRI screening programs on a hospital level do not exist.
1.8 Thesis outline
This thesis aims to evaluate and optimize breast MRI screening practice, and analy-
ses the performance of a breast MRI screening program at a single academic hospital.
For several chapters (Chapter 3 to 5) the audit practice of the Dutch national screen-
ing program for breast cancer was used as a blueprint. Subsequent chapters analyze
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methods to optimize screening practice by including background parenchymal en-
hancement into the risk stratification. Finally, the last study investigated a novel MRI
sequence, developed for optimizing screening practice.
In detail, Chapter 2 provides an introduction to breast MRI screening and the pro-
tocols used for breast MRI screening. In Chapter 3 the performance of the current
high-risk screening program at our institution was assessed, providing detailed per-
formance measures for women in different risk categories. Chapter 4 subsequently
describes, within the same population, the (lack of) added value of mammography
when breast MRI is available. In Chapter 5, we performed a more in-depth audit
of cancers detected in the high-risk screening program, investigating the visibility
of these cancers on prior MRI scans that were reported to be normal. In Chapter 6,
we started exploring the possibility to use BPE as a risk stratifier for breast cancer,
evaluating whether the assessed BPE is independent of tumor type. In Chapter 7,
we subsequently investigated, in a prognostic cohort study, whether BPE is indeed
an independent risk factor for breast cancer. Finally, Chapter 8 introduces different
approaches for increasing the cost-effectiveness of breast MRI and introduces Chap-
ter 9, which discusses the potential of a new MRI sequence for breast MRI screening,
possibly increasing patient comfort and cost-effectiveness, while still providing ex-
cellent diagnostic capacity. A general discussion regarding the studies in this thesis
is provided in Chapter 10, while Chapter 11 and Chapter 12 provide summaries in
both English and Dutch.
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Abstract
Magnetic resonance imaging (MRI) techniques for breast cancer screening keep evolv-
ing. At present, guidelines state only minimal requirements for breast MRI screening
protocols. There is still no consensus on the optimal protocol to be used for breast
MRI screening. New breast MRI screening sequences and shorter protocols are in-
troduced to optimize breast cancer detection and to minimize false-positive recalls.
In this chapter, recent advances in breast MRI protocols and sequences are discussed
to get a better understanding of what is possible and what is needed in breast MRI
for screening. We discuss the current state-of-the-art of breast MRI for screening and
evaluate the requirements for basic sequences. Subsequently, novel approaches for
breast MRI screening that are currently on the brink of clinical implementation are
presented. Finally, techniques that are now only used for research purposes, but
yield promise for future implementation are discussed.
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2.1 Introduction
Magnetic resonance imaging (MRI) is nowadays widely known as the most effec-
tive imaging modality for the early detection of breast cancer. Contrast-enhanced
breast MRI has been increasingly used since the Eighties when an excellent breast
lesion conspicuity after intravenous injection of gadopentetate dimeglumine (Gd-
DTPA) was firstly shown35. Thanks to the acquisition of multiple series of contrast-
enhanced images, the method rapidly evolved into dynamic contrast-enhanced (DCE)
breast MRI36. Initial evaluations showed not only that DCE-MRI was capable of
showing most cancers, but also yielded significant additional information over mam-
mography and ultrasound. In subsequent studies, a sensitivity of over 90% was doc-
umented for breast malignancies.
The high sensitivity led to the rapid spread of applications and indications for breast
MRI. It was thought to be an excellent screening technique, as it does not use any
ionizing radiation and has a very high negative predictive value. A standard pro-
tocol for DCE-MRI was adopted, consisting of at least one T1-weighted acquisition
before contrast injection and several acquisitions after contrast injection. Other con-
trast materials than the original Gd-DTPA were occasionally used.
Multiple prospective trials investigated the value of DCE-MRI using variations of
this protocol for breast cancer screening in women at various classes of increased
risk and reported a sensitivity in the range of 71% to 91% (see Table 2.1).
Using the results of early studies, skeptics pointed at the so-called low specificity
of breast MRI as a flaw that prevented the use of MRI in screening. Since in screen-
ing most scans are normal, a high number of false positives would lead to a very
high recall rate, and this would pose an unacceptable burden on healthy women
and large logistic issues to health care systems. This led to a wide range of addi-
tional acquisitions, including not only old and new T2-weighted sequences but also
diffusion-weighted imaging (DWI), and even proton spectroscopy, each of which
was shown to have a potential for reducing false positives of breast MRI. Therefore,
the current state-of-the-art protocols in breast MRI are multi-parametric in nature.
Nonetheless, the so-called low specificity of breast MRI is a complex questionable
phenomenon to which the readers inexperience and the absence of prior screening
MR studies also gave critical contributions.
Even though the performance of MRI screening with multi-parametric protocols
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Table 2.1: Sensitivities and specificities for breast MRI screening of women with an
elevated breast cancer risk
Authorref. Year No. of women
screened
No. of cancers Sensitivity
(%)
Specificity
(%)
Kriege14 2004 1909 45 71 90
Leach37 2005 649 35 77 81
Kuhl38 2005 529 43 91 97
Rijnsburger39 2010 2157 75 71 90
Trop40 2010 184 12 83 94
Sardanelli41 2011 501 52 91 97
Passaperuma42 2012 496 57 86 90
Riedl15 2015 559 40 90 89
seems excellent, the scan-time required, as well as the time needed for evaluation,
and thus the associated costs, are high, and this currently contributes to limit the use
of breast MRI as a screening tool in high-risk women.
Current research, therefore, focuses on the development of shorter imaging protocols
to reduce scan-times and to cut costs. In addition, imaging biomarkers are extracted
focusing on the evaluation of aggressiveness of breast cancer, in order to open a way
for characterizing those cancers that are biologically active. Finally, new techniques
that aim at excluding contrast agent administration from the acquisition are under
development. Updates on the recent developments on these topics will be discussed
in this chapter.
2.2 Indications for breast MRI screening
The risk-level of women included in various MRI screening studies is highly hetero-
geneous. The MRISC trial14 included all women with a lifetime risk of 15% or more,
whereas for example the Canadian trials42 only included women with BRCA muta-
tions and their first-degree relatives. In 2007, the American Cancer Society (ACS)
published a guideline12 on screening with supplemental MRI. They concluded that
MRI as an adjunct to mammography was indicated for all women with a lifetime risk
of 20 - 25% as assessed with BRCAPRO or similar tools that mainly focus on fam-
ily history. In 2008, these guidelines were also adopted by the European society for
breast imaging (EUSOBI), as the recommendations were mainly based on European
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studies11. The group of high-risk women considered by these guidelines consists
of women with either a proven BRCA1 or BRCA2 germline mutation, other genetic
syndromes associated with a high incidence of breast cancer, or a≥ 20 - 25% lifetime
risk of developing breast cancer. Women with a history of chest radiation therapy
between the ages of 10 and 30 also have a similar risk and should be screened with
supplemental MRI.
For women at intermediate risk (defined as 15 - 20% lifetime risk, or a personal his-
tory of invasive or in-situ carcinoma, lobular neoplasia, or atypical hyperplasia) the
use of breast MRI for screening is still under investigation, and there has been no
clear statement yet. It is agreed on that breast MRI screening should currently not
be used in women with a lifetime risk lower than 15%43. However, screening trials
with MRI for women at average risk, but with very dense breast are on their way,
thus introducing risk factors for stratification that were not used in previous screen-
ing studies or risk models. Whether or not screening guidelines should be expanded
to also include these women will become evident in the upcoming years.
Despite the above-mentioned guidelines, national guidelines are often more con-
servative as they focus more on cost-effectiveness. While there is a clear increase
in breast cancer detection in all risk groups, cost-effectiveness is only proven for
women at the highest risk (e.g. those with a BRCA mutation and their first degree
relatives, and those with a history of chest radiation therapy before 30), and hence
several current national breast cancer screening guidelines only state that a yearly
breast MRI is appropriate for women at very high risk for developing breast cancer.
2.3 Requirements for breast MRI
The European Society of Breast Imaging (EUSOBI)11, the European Society of Breast
Cancer Specialists (EUSOMA)44, and the American College of Radiology (ACR)45
have specified requirements for the performance of breast MRI. So far, these require-
ments are general and not specifically focused on breast MRI for screening. In light
of the current diversion of MRI for screening, MRI for staging, and other indications,
these guidelines will likely be adapted in the near future to be more specific for the
indication for which breast MRI was performed. However, the minimal require-
ments as specified by these organizations remain vital as they are very liberal. All
breast MRI protocols should include T1-weighted pre- and post-contrast sequences
to report on lesion morphology and enhancement features with sufficient spatial
and temporal resolution. All other sequences are deemed supplemental, however,
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the use of additional T2-weighted acquisitions is generally endorsed.
Minimal requirements are as follows11,44:
• Field strength
A 1.5T magnet is considered a minimum technical requirement because of the
relationship between field strength and resolution (the advantages and disad-
vantages of 3.0T imaging will be discussed later in this chapter).
• Spatial resolution
High spatial and temporal resolution are needed to detect and characterize
small abnormalities. The EUSOBI guidelines state that the slice thickness should
not be higher than 2.5 mm and the in-plane resolution should be 1 mm2 or less,
thus, minimizing the problem of volume averaging effects. Other guidelines
still accept up to a 3 mm slice thickness.
• Scan plane
No absolute preference for scan plane is recommended by guidelines. While in
past times some technical issues favored the use of coronal planes with the aim
of optimizing both temporal and spatial resolution, currently axial and sagittal
planes are preferred, also for the evaluation of symmetry.
• Fat saturation and temporal subtraction
Spectral fat saturation can be used to reduce the fat signal while preserving
the signal-to-noise ratio (SNR), however, it is not mandatory. The guidelines
state that radiologists must not solely rely on temporal subtraction images for
the assessment of enhancement, since this may result in misregistration due to
patient motion. When motion artefacts do appear, motion correction might be
helpful in reducing artefacts encountered with image registration.
• Radiofrequency coils and simultaneous bilateral imaging
Guidelines state that simultaneous bilateral high-resolution images should be
acquired as breasts are symmetric organs and comparison between the two
breasts can be performed. The use of a multichannel dedicated bilateral breast
coil is mandatory38,40,46,47. These are commercially available and provide ex-
cellent spatial and temporal resolution for improved visualization of small le-
sions48.
• Contrast agent
Breast MRI without contrast is not acceptable according to current standards,
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except for the evaluation of implant integrity. Therefore, all screening examina-
tions should be contrast-enhanced studies. As a contrast agent, a two-compart-
ment (vascular/ interstitial) gadolinium-chelate should be administered intra-
venously as a bolus with the standard dose of 0.1 mmol/kg with an injection
rate of 2 - 3 ml/s, followed by saline flushing (20 - 30 ml at 2 ml/s), preferably
using an automatic injector.
• Temporal resolution
The time interval between images series for DCE studies should be no longer
than 120 s44.
• Volume of MRI studies per institution
The EUSOMA44 recommends that a minimum number of 150 cases needs to
be performed per institution per year. Despite the lack of recommendations
from the other societies, this seems a wise recommendation, especially when
considering the screening setting. Even in very high-risk screening, the cancer
detection rate is only in the order of 2 - 3%, and hence at a rate of 150 screening
examinations, only 3 cancers are detected per year. Therefore, some centraliza-
tion and significantly larger volumes are recommended.
2.4 MRI sequences
2.4.1 T1-weighted sequences
To understand the basics of sequences used for screening, some knowledge of MRI
physics is desirable. One of the most common pulse sequences in MRI is the T1-
weighted sequence, also referred to as the spin-lattice relaxation sequence. The im-
ages obtained from this sequence display the differences in T1 relaxation times of dif-
ferent tissues. This sequence relies upon the longitudinal relaxation of the tissues net
magnetization vector (T1 relaxation describes the spin relaxation in the z-direction).
T1-weighting is achieved with short echo times and repetition times. As fat quickly
realigns its longitudinal magnetization with B0 (the main magnetic field), it appears
bright on a T1-weighted image. Conversely, water has a much slower longitudi-
nal magnetization realignment after a radiofrequency pulse, and therefore, has less
transverse magnetization. Thus, water has a low signal and appears dark. Figure
2.1 shows examples of the different images obtained using a T1-weighted sequence
either with or without fat suppression. Gadolinium-based contrast media have a
paramagnetic effect on the tissue and hence reduce the T1 relaxation time (i.e., the
time needed for longitudinal relaxation). This increases the signal of the tissue and
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hence, a high signal (that appears bright on the image) is produced in areas of con-
trast agent uptake49.
In breast MRI screening protocols, T1-weighted sequences are, thus, used for de-
tection of areas where the contrast agent accumulates, such as malignant breast le-
sions11,45. Several T1-weighted sequences are obtained in dynamic succession to vi-
sualize the course of tissue contrast-enhancement.
In the early years of breast MRI, it was necessary to choose between either tem-
poral or spatial resolution. Two fundamentally different protocol designs evolved,
the static design and the dynamic design. The static design was most popular in
the United States and specifically evaluated the morphologic features of enhancing
lesions at high spatial resolution. The dynamic design was instead mostly favored
in European countries with the aim of using dynamic enhancement characteristics to
distinguish benign lesions from malignant lesions50. Nowadays, thanks to the tech-
nical progress that has been made, it is possible, to a certain extent, to integrate these
demands, and the final evaluation is virtually always based upon a combination of
morphologic and dynamic enhancement features50.
The BI-RADS MRI-lexicon51 states the different enhancement patterns that have to
be rated based on T1-weighted sequences. All findings should be viewed on both
pre- and post-contrast scans and both morphologic and kinetic characteristics should
be evaluated. Malignant lesions tend to enhance rapidly, typically reaching 90% of
peak enhancement within 60 seconds following injection, while fibroadenomas and
other benign lesions tend to enhance at a lower rate. Strong early enhancement with
a relative signal increase of over 140% and a peak of enhancement before 3 minutes
together with an early washout (signal decrease of more than 10% following maxi-
mum enhancement)46 is highly suggestive of malignancy.
Different T1-weighted sequences exist, as shown in Table 2.2. Spin-echo sequences
are generally not recommended as these are too slow to achieve the spatial and tem-
poral resolution required for breast MRI screening. The EUSOBI recommends at
least a T1-weighted spoiled gradient echo (GE) pulse sequence before the adminis-
tration of contrast agent, one at peak enhancement approximately 90 seconds after
contrast agent administration, and one 5 to 7 minutes after contrast agent adminis-
tration in order to investigate the morphology and the dynamics of enhancement.
Most protocols that are currently in use include one pre-contrast T1-sequence and 3
to 5 post-contrast T1-sequences for the dynamic evaluation11,50,52–55.
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Figure 2.1: Axial T1-weighted images in a 42-years-old BRCA2 mutation carrier with
relatively fatty breast, using a sequence without fat suppression (a) or with fat sup-
pression (b).
In order to obtain a more reliable T1-weighting, GE sequences used for DCE breast
imaging use the so-called spoiler (typically a radiofrequency spoiler) that disrupts
transverse coherences that may persist from cycle to cycle of the sequence. Thus,
immediately before each radiofrequency pulse, the steady-state magnetization has
no transverse components, while the longitudinal magnetization reaches a steady-
state56.
However, spoiled gradient-echo sequences exist in both two-dimensional (2D) and
three-dimensional (3D) acquisition modes. It is still unknown which of the two is
the best, or most appropriate one for breast MRI, in particular for screening. Both
methods have their own advantages and disadvantages. When comparing 2D to 3D
sequences, 3D sequences are known for their higher T1-contrast and higher SNR,
resulting from shorter repetition times and echo-times. The higher SNR can be
used to improve the spatial resolution, both in-plane (pixel size) and through-plane
(partition thickness). However, 3D imaging may suffer from image degradation
(pulsation-, susceptibility-, and ghosting artefacts) and therefore, some prefer 2D
imaging56.
2.4.2 T2-weighted sequences
Most of the current breast MRI screening protocols include a T2-weighted sequence
(examples are presented in Figure 2.2). In the EUSOBI guidelines for breast MRI, it
is stated that this sequence can be useful in the differentiation between benign and
malignant lesions (and, thus, increasing specificity and positive predictive value),
as in most cases cancer does not yield a high signal on turbo spin-echo T2-weighted
images without fat suppression, whereas many benign lesions do. However, as most
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Table 2.2: T1-weighted sequences
Sequence Characteristics
Spin-echo
(SE)
• T1-weighting is maximized by setting repetition time
(TR) to be similar to or slightly shorter than the T1
values of the tissue of interest, while setting echo-time
(TE) as short as possible
• It takes time to rephase the signal, thus increasing the
scan time
Turbo spin-echo
(TSE)
• Because of the long scan time of SE sequences, TSE
meets the demand for faster imaging. Multiple echoes
are formed and measured by adding several 180◦
pulses and measuring a spin-echo after each pulse,
rather than measuring a single echo after each 90◦-180◦
combination
Fast advanced spin-echo
(FASE)
• Half Fourier imaging is used, which shortens scan time
even more than TSE
Gradient-echo
(GE, GRE)
• Similar to spin-echo sequences with two main
differences:
1. Use of an initial 70◦ pulse, rather than a 90◦ pulse
2. Use of gradient reversal, instead of a 180◦ pulse to form
an echo, thus eliminating the need to wait to allow a
regrowth of the longitudinal magnetization
• T1-weighting is achieved by using a short TR, very short
TE, and a moderate flip angle
• Due to higher T1 contrast and shorter acquisition times,
these sequences are generally preferred over spin-echo
sequences and are therefore recommended by guidelines
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of these lesions can also be identified in T1-weighted images, the EUSOBI guidelines
state that there is no clear evidence of the added value of T2-weighted sequences in
screening yet11.
In 1999, Christiane Kuhl and coworkers were the first investigators to evaluate the
added value of T2-weighted imaging for breast MRI57. They investigated whether
T2-weighted pulse sequences can help in the differential diagnosis of enhancing le-
sions on dynamic breast MRI. Fibroadenomas and well-circumscribed breast cancers
may have a similar appearance, as both may present as a rapidly and strongly en-
hancing focal lesion. Fibroadenomas and breast cancers tend to demonstrate differ-
ent signal intensities on T2-weighted imaging. In practice, if a well-circumscribed
enhancing lesion is detected in breast MRI, high signal intensity in the correspond-
ing T2-weighted image can be used to support the diagnosis of a benign lesion. In
the higher age groups (over 40), a low T2-weighted signal should arouse suspicion
of malignancy, even though the lesion is well circumscribed. The authors concluded
that T2-weighted turbo spin-echo sequences can be helpful as an adjunct to the dy-
namic breast MRI protocol, and it should not be used as a stand-alone approach but
in conjunction with and secondary to criteria like enhancement kinetics and mor-
phological data. Laura Heacock and coworkers54 came to similar conclusions. In
their study, the addition of a T2-weighted sequence to the dynamic protocol resulted
in a higher lesion conspicuity but had no effect on cancer detection. Unfortunately,
the effect of the T2-weighted images on specificity was not evaluated.
The use of spectral fat-saturation as added to T2-weighted sequences was specifically
evaluated in the above-mentioned work by Kuhl and coworkers57. They stated that
the turbo spin-echo (TSE) pulse sequence without fat suppression is the only suitable
sequence to assist in lesion characterization. If used cautiously, T2-weighted imaging
should improve the diagnostic accuracy of diagnostic breast MRI by helping to avoid
false-positive diagnoses, particularly in young women. Therefore, a T2-weighted
turbo (also called fast) spin-echo sequence can be performed as a start of a breast
MRI screening, before the dynamic protocol. In combination with fat-saturation,
this sequence can also be used to identify cysts, as cysts have extremely long T1 and
T2 values relative to other breast tissues. Cysts typically have a few macromolecules
to shorten T1 and lack of cellular structure to shorten T2. Thus, cysts appear darker
on T1-weighted sequences, while they appear much brighter than other tissues on
T2-weighted sequences due to their longer T2-values and higher hydrogen densities.
Hence, cysts are easily identifiable on fat-suppressed T2-weighted imaging58. How-
ever, the necessity to detect cysts in a screening protocol remains questionable and
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Figure 2.2: Axial T2-weighted image in a 38-years-old woman at familial risk of breast
cancer with dense breasts, using a sequence without fat suppression (a) or with fat
suppression (b).
this alone should not be used as an argument to perform a T2-weighted acquisition.
2.4.3 Diffusion-weighted imaging (DWI) and other additional se-
quences
DWI is sensitive to the mobility of water molecules in tissue. Water motion is most
commonly quantified by means of an apparent diffusion coefficient (ADC), a model
using the principle that tissue-confined water behaves similarly to free water, but
with reduced diffusivity (see Figure 2.3). This is used as a marker of cellularity in
oncologic imaging, as it represents a decrease in extracellular space relative to the
more viscous intracellular fluid of proliferating cells. Measurement of diffusivity
does not require application of contrast agents. Thus, DWI might be a suitable tech-
nique for non-contrast breast MRI, as we will discuss below.
Notably, the signal obtained by DWI sequences is based on a T2-weighted acquisi-
tion. Diffusivity is measured by applying a strong spoiler gradient to excited hydro-
gen protons. After a certain period of time, this spoiler gradient is reversed. Strength
and duration of the spoiler gradient together determine the so-called b-value: the
higher the b-value, the stronger the signal positive correlation with tissue diffusiv-
ity. In fact, protons that do not move regain their signal, whereas moving protons
experience a different gradient at both instances and hence lose their signal59. Some
studies60,61 focused on the choice of b-values for DWI of the breast. A b-value near to
zero (or 50 to reduce signal from vessels) and a b-value around 800-850 are sufficient
for clinical imaging. However, for more elaborate DWI techniques such as diffusion
tensor imaging (DTI) or intra-voxel incoherent motion (IVIM) imaging, multiple and
higher b-values are required.
Studies have shown the potential of DWI to increase breast MRI specificity. As
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discussed by Gurpreet S. Dhillon and coworkers48, DWI has a higher specificity
to differentiate benign from malignant lesions than contrast-enhanced MRI. How-
ever, to not lose in terms of sensitivity, a feasible way to implement DWI in a multi-
parametric protocol appears to adapt BI-RADS scores based on ADC values as pro-
posed by Katja Pinker and coworkers62. Differences in ADC values may be able to
distinguish ductal carcinoma in situ (DCIS) from both normal tissue and invasive
ductal carcinoma. The ADC value is lowered in DCIS compared to normal breast
parenchyma, but is still significantly higher than the ADC values seen in invasive
ductal carcinoma. However, this intermediate ADC value is not specific to DCIS and
might overlap with other benign and malignant lesions63.
Several studies investigate the added value of DWI when DCE-MRI is available.
Sibel Kul and coworkers64 applied that this strategy to 84 breast lesions, showing
that the combination of DWI and DCE-MRI had the potential to increase the speci-
ficity of breast MRI, a result which was confirmed by Richa Bansal and coworkers65
in a larger study including 232 lesions.
Other sequences have been proposed to further improve the specificity, including
dynamic susceptibility contrast (DSC) imaging, which is a kind of perfusion imag-
ing based on the T2* effect of contrast agent (contrast uptake reduces the T2* value,
thus resulting in a lowered signal) and susceptibility-weighted imaging (SWI), which
is based on the tissue inhomogeneities and calcifications (again resulting in a low-
ered signal on T2*-weighted images)66,67, as well as various types of mainly 1H-
based magnetic resonance spectroscopy (MRS) approaches68–70. Although each of
the techniques has some merits, none of these approaches really made it into clinical
practice. Especially for screening purposes, they are currently obsolete. Faster ap-
proaches and techniques to increase the signal might, however, in the future render
these techniques viable again.
A recent comparison between the evidence in favor of DWI and that in favor of
spectroscopy found that DWI is certainly the winner71. As mentioned above, DWI,
considering both the robustness and short acquisition times, entered breast MRI clin-
ical protocols as the most used additional sequence.
2.5 Breast MRI at 3.0T: advantages and disadvantages
As 3.0T systems become more widely available throughout the world, many facilities
may consider performing breast MRI, including screening protocols, at this higher
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Figure 2.3: Axial diffusion-weighted images in a 42-years-old BRCA2 mutation carrier
using DWI (b=850 (a) and the corresponding ADC map (b).
field. In fact, it is widely known that a higher field strength results in a higher SNR.
The improved SNR should, in theory, allow for a better visualization and charac-
terization of enhancing lesions, which may improve the detection of breast can-
cers45. However, this higher field strength also causes an increased field inhomo-
geneity, which is a clear disadvantage. In the case of 3.0T imaging, several image
artefacts can be categorized according to their main underlying mechanism, such as
increased SNR, susceptibility variation, chemical shift, or decreased radiofrequency
wavelength72,73.
Increased SNR can result in more pronounced Gibbs ringing artefacts at 3.0T com-
pared to 1.5T. These artefacts occur when Fourier transforms are used to reconstruct
MR signals into images. Any signal (and thus every image) can be represented as an
infinite summation of sine waves of different amplitudes, phases, and frequencies.
In MRI, we sample a finite number of frequencies and we approximate the image
by using relatively few sine waves in its Fourier representation. In other words,
the Fourier series is cut short. Gibbs ringing artefacts are prominent at high-contrast
interfaces, manifested by variable undershoot and overshoot oscillations. These arte-
facts can have a variety of forms, including false widening of edges, enhancement of
the edges, or distortion of tissues.
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Ghosting artefacts are associated with parallel imaging (commonly used in MRI with
the aim to decrease acquisition times at both 1.5T and 3.0T) and are usually more se-
vere at 3.0T. In fact, the increased SNR at 3.0T, especially in combination with a high
channel count (8 or more coils, which is currently standard of care in most clinical
practices) used for parallel imaging can worsen the problem.
Chemical shift artefacts are more often present at 3.0T. At a fixed receiver bandwidth,
the fat-water chemical shift will be twice as many pixels compared to 1.5T.
Susceptibility variations due to the presence of implanted foreign bodies can also
cause local non-uniformity of the main magnetic field resulting in several artefacts,
including non-planar 2D slices, in-plane image distortion, and local regions of hypo-
and hyperintensity. These artefacts are also stronger at 3.0T. Sequences with long
echo trains suffer the most from susceptibility variations. To decrease these arte-
facts, parallel imaging could be used, taking the comments on the above-mentioned
ghosting artefacts into account.
Because 3.0T imaging is already well introduced in clinical imaging, most of these
artefacts can be overcome by several already available methods72. Clinical 3.0T im-
ages are adequate in general, even though it remains uncertain whether these are
better than 1.5T images.
There are only a few comparisons between breast imaging at 1.5 and 3.0T. Chris-
tiane Kuhl and coworkers74 described intra-individual results in 37 women with 53
lesions. At 3.0T, the image quality was slightly but significantly better and the di-
agnostic confidence as measured at receiver operating characteristics analysis was
significantly higher. No susceptibility effects were observed. Motion artefacts were
observed at 3.0T and 1.5T at the same rate and degree. The smaller pixel size in pa-
tients who were examined at 3.0T with high in-plane imaging matrices could result
in subtraction artefacts due to motion and therefore, degraded the image quality.
Nevertheless, the higher spatial resolution at 3.0T helped to improve classification
of 11 of 51 lesions (2 were excluded because of insufficient enhancement).
Ana P. Lourenco and coworkers47 reported on a comparison of 495 3.0T versus 650
1.5T breast MRI screening scans. They found a significant increase in both biopsy rec-
ommendation rate and the positive predictive value of biopsy at 3.0T. Notably, can-
cer detection rate was significantly higher at 3.0T (2.6%), compared with 1.5T (0.9%).
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These results, even limited by the retrospective inter-individual design, showed a
potential for a greater efficacy of breast MRI screening at 3.0 T.
Thus, despite existing disadvantages from scanning at a higher field strength, 3.0T
breast MRI still improves the diagnostic confidence and the cancer detection rate in a
screening population. However, 1.5T breast MRI remains adequate in most settings
when updated protocols and breast coils are used.
2.6 Screening sequence protocols
Examples of breast MRI screening sequence protocols screening protocols used at
1.0T, 1.5T, and 3.0T are reported in Table 2.3. However, we should consider that a
large variety of technical options were used, although all of them were mainly based
on a 2D or 3D spoiled gradient-echo dynamic series.
2.7 Abbreviated screening protocols
While breast MRI screening, as currently implemented, has shown great potential
for early detection of cancer in women at increased risk of breast cancer, its wide im-
plementation remains difficult. This is largely caused by the high costs of MRI itself.
In addition, the huge amount of image series produced lengthens the reading time
and makes actual mass screening very difficult.
Therefore, several research groups focused on reducing the time required for scan-
ning and evaluating breast MRI. Evidence is mounting that shorter protocols, in fact,
are just as good for screening as the much lengthier multiparametric protocols that
are currently in use. This could potentially increase the access to breast MRI by
significantly reducing the cost and time associated with the examination, both the
acquisition time and the radiologists reading time.
Several abbreviated protocols were described by different groups of authors52–54,76
(see Table 2.4). In 2014, Christiane Kuhl and coworkers76 presented the first and
simplest version of abbreviated breast MRI. The protocol is condensed into one pre-
contrast and one post-contrast acquisition. The subsequent generation of subtraction
images and maximum intensity projections (MIPs) also renders reading exception-
ally fast. Reading time of the MIPs was reported to be below 2 seconds. In their
study, it was evaluated whether this abbreviated protocol would be sufficient to
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Table 2.3: Examples of screening protocols
First author ref.# Breast MRI protocol Sequence parameters
Sardanelli 41∗ 1.0 T or 1.5T
1. 3D T1-weighted
spoiled gradient echo
(1 pre-contrast and 5
post-contrast)
1. Transverse or coronal plane; TR: 13ms, flip angle: 20-30◦;
partition thickness: ≤3mm, number of partitions: 40-128;
acquisition time up to 120s; pixel size up to 1.4 x 1.4 mm
Kuhl 75 1.5T
1. 2D or 3D T-weighted
spoiled gradient echo
series (1 pre- and ≥ 4
post-contrast)
1. Spatial resolution ≤1x1mm (in-plane), ≤ 3 mm (through-
plane); acquisition time 120s
2. T2-weighted sequence 2. Spatial resolution ≤1x1mm (in-plane), ≤ 3 mm (through-
plane)
Total acquisition time 15 min
Emaus 9 3T
1. T2-weighted sequence
(optional)
1. Acquisition VS ≤ 1.11 x ≤ 1.46 x ≤ 4.00 mm
Reconstruction VS ≤ 0.90 x ≤ 0.90 x ≤ 4.00 mm
Acquisition time 147-248s
2. DWI sequence 2. Acquisition VS ≤ 2.25x ≤ 2.51 x ≤ 5.00 mm
Reconstruction VS ≤ 1.55 x ≤ 1.70 x ≤ 4.00 mm
Acquisition time 215-301s, b-values 0, 50 or 150, and
800 s/mm2
3. DCE data sets
(a) High spatial resolution
pre-contrast
(a) Acquisition VS ≤ 1.00 x ≤ 1.00 x ≤ 2.00 mm
Reconstruction VS ≤ 1.00 x ≤ 0.94 x ≤ 1.00 mm
Acquisition time 80-152s
(b) High temporal resolution
series before and during
the first seconds after
contrast injection
(b) Acquisition VS ≤ 2.58 x ≤ 2.82 x ≤ 6.00 mm
Reconstruction VS ≤ 1.18 x ≤ 1.18 x ≤ 3.00 mm
Acquisition time 147-248s, pre-contrast acquisitions
(N=1), post-contrast acquisitions (N=15-19)
(c) High spatial resolution
series
(c) Acquisition VS ≤ 0.90 x ≤ 1.00 x ≤ 1.80 mm
Reconstruction VS ≤ 1.00 x ≤ 0.80 x ≤ 1.00 mm
Acquisition time 147-248s, acquisitions (N=5-6)
VS; voxel size
∗ Although not considered in the final report 41 (the BI-RADS classification was mainly based on
DCE-imaging), a T2-weighted sequence was also included in the protocol.
identify breast cancer in a screening cohort. The full diagnostic protocol included
a T1-weighted pre-contrast and 5 post-contrast scans followed by a T2-weighted se-
quence and a coronal T1-weighted sequence. While the full protocol needed about
17 min, the abbreviated protocol needed only 184 seconds. The overall sensitivity of
the abbreviated protocol was 100% (negative predictive value 99.8%) with a speci-
ficity of 94.3%. However, only 11 cancers were detected overall. With the use of the
full diagnostic protocol the characterization of findings classified as possibly benign
(BI-RADS 3) was improved, showing that the additional pulse sequences in the full
protocol are mainly needed for lesion characterization.
28 MRI protocols for breast cancer screening
In 2015, Victoria L. Mango and coworkers52 looked into the sensitivities per sequence
of the abbreviated protocol. They found a mean sensitivity of cancer detection of the
first post-contrast sequence of 96%, equal to the first post-contrast subtracted se-
quence. Sensitivity using only the MIPs was significantly inferior (93%), which must
be taken into account when deciding to screen using only MIPs.
In the same year, Lars J. Grimm and coworkers53 tested two different abbreviated
protocols in a specifically designed case series of 48 patients selected from high-risk
screening. One protocol consisted of a T2-weighted sequence, as well as the pre-
contrast and the first post-contrast T1-weighted sequences. In the other protocol, the
second post-contrast T1-weighted sequence was added to the sequences of the first
protocol. They found no significant differences in sensitivity and specificity between
each of the two abbreviated protocols (86 and 89%, respectively) and the full proto-
col (95%). However, the case series was relatively statistically underpowered while
the enriched series (especially the proportion of malignant lesions, much higher than
seen in screening practice) could have influenced the reader performance, likely ex-
plaining the remarkable low specificity, ranging from 45% to 52%.
In 2016, Laura Heacock and coworkers54 retrospectively evaluated the utility of an
abbreviated T1-weighted imaging protocol in detecting 107 known breast cancers
(88% invasive and 12% in situ) as well as to analyze the impact of adding clinical his-
tory and prior imaging to cancer detection and determine the impact of T2-weighted
imaging in cancer detection and lesion conspicuity. The abbreviated protocol, con-
sisting of a T2-weighted fat-suppressed sequence and a pre- and post-contrast T1-
weighted sequence, reached a sensitivity of 97.8 - 99.4%, comparable to previously
mentioned studies52,53,76. In addition, in the Heacocks study54, information about
prior imaging and clinical history increased detection rates. T2-weighted imaging
increased confidence and lesion conspicuity, however, it did not increase detection
rates. Initial enhancement rate was significantly correlated with tumor grade, in-
vasive disease, and lesion conspicuity, supporting the idea that rapid wash-in char-
acteristics of malignancy may underpin the efficacy of abbreviated MRI sequences.
This finding raises the possibility that cancers detected by an abbreviated MRI ex-
amination only may be of higher grade, i.e. more biologically active lesions, po-
tentially counteracting the drawback of overdiagnosis intrinsically associated with
every screening program.
From the studies investigating abbreviated protocols, we can conclude that there
is still no clear consensus in which sequences are beneficial and needed for an ab-
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Table 2.4: Abbreviated and full breast MRI protocols
First author Protocol Dynamic
pre-contrast
Dynamic 1st
post-contrast
Dynamic 2nd
post-contrast
Dynamic
3rd-5th
post-contrast
T1 TSE T2 DWI
Kuhl 76
Abbreviated x x
Full x x x x x x
Mango 52
Abbreviated x x
Full x x x x x x x
Grimm 53
Abbreviated1 x x x
Abbreviated2 x x x x
Full x x x x x x
Heacock 54
Abbreviated x x x
Full x x x x x x
breviated protocol. Studies reporting on abbreviated protocols varied widely in ac-
quisition times ranging from approximately 3 minutes to 15 minutes. In particular,
the role of a T2-weighted sequence for screening purposes needs to be investigated.
In addition, the number of patients scanned and the number of cancers detected is
currently still too low to draw solid conclusions. Future larger prospective trials
need to prove the non-inferiority of abbreviated protocols. Nevertheless, shortened
breast MRI protocols could play a relevant role in lowering costs and allowing more
widespread availability of MRI as a screening tool.
2.8 Ultra-fast breast MRI
All the abbreviated protocols discussed in the previous paragraph discard dynamic
information. Only one of those investigated by Grimm and coworkers53 used the
second dynamic post-contrast scan. This is not problematic for larger malignant le-
sions, which are generally well recognized based upon their morphological features.
However, in particular for the classification of small mass lesions, which are typi-
cal findings in breast screening, additional dynamic information is important. This
implies that dynamic information is appreciated, while imaging time should not be
extended.
Conventional dynamic information cannot be obtained, as this requires acquisition
of the wash-out phase of contrast which takes up to 6 - 7 minutes after contrast ad-
ministration. However, even in the early days of breast MRI, it was already shown
that dynamic information obtained from the inflow phase had better discriminating
capacity than the wash-out phase. Nevertheless, in previous years the temporal res-
olution, typically in the range of 60 - 75 seconds of high spatial resolution bilateral
images was not sufficient to document this inflow phase. Therefore, acquiring scans
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Figure 2.4: Ultrafast axial images in a 42-years-old BRCA2 mutation carrier, using a
TWIST sequence (temporal resolution 4.57s). The central slice of each of the first 12
acquisitions after aorta enhancement are shown, numbered from 1 to 12. The corre-
sponding volumetric MIPs are shown at every time point, below the original central
unsubtracted images. These clearly show the arrival of the contrast, first in the tho-
racic vessels and the heart, subsequently in the breasts and liver. No suspicious early
enhancement is visible in the breasts.
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at a high temporal resolution re-enables the use of contrast dynamics for the classifi-
cation of suspicious breast lesions77.
Karl-Heinz Herrmann and coworkers78 were among the first to describe a new ultra-
fast sequence named time-resolved angiography with stochastic trajectories (TWIST)
for breast MRI (see Figure 2.4). With this technique, the outer part of k-space is
heavily under-sampled and data points are shared between successive time points
to increase the obtained spatial resolution to diagnostic quality. Sophisticated sam-
pling patterns are used to minimize the disadvantage of data sharing. These authors
showed, in a pilot study of 14 patients, that this TWIST sequence can be used to ob-
tain dynamic images at a very high temporal resolution (5.7 seconds). Furthermore,
they showed that benign lesions enhance at a later time point than malignant lesions.
Luminita A. Tudorica and coworkers79 reduced the temporal resolution to 18 s, show-
ing that the dynamic images were very comparable with the images provided by the
conventional protocol. Yuan Le and coworkers80 showed that a TWIST sequence can
be combined with a dual-echo (two-point) Dixon technique to obtain fat-suppressed
images with a high temporal resolution. Our group55 investigated the use of maxi-
mum slope of the contrast enhancement versus time curve obtained from the TWIST
sequence at a temporal resolution of 4.3 seconds as a novel dynamic parameter for
the differentiation between benign and malignant lesions. The total acquisition time
was 102 seconds. Of the 199 enhancing lesions included, 95 were proven benign
and 104 malignant. We found that maximum slope achieved a much higher accu-
racy in differentiating benign and malignant lesions than the BI-RADS curve type
does, thus, solidifying the use of ultrafast breast MRI, and allowing the creation of
new protocols with a short post-contrast period (∼ 85 seconds). While we did not
evaluate TWIST for morphological features, the technique meets every breast MRI
requirement that is stated in guidelines. Results of a recently presented reader study
in which four radiologists evaluated 200 screening cases showed that the use of ultra-
fast MRI alone was just as accurate as evaluating a full diagnostic protocol including
high spatial resolution acquisitions, T2-weighted imaging, and DWI81.
Federico D. Pineda and coworkers77 investigated a bilateral, fat-suppressed ultrafast
acquisition with a time resolution of 6.9-9.9 s during the first minute after contrast
injection, followed by four high spatial resolution acquisitions with a time resolu-
tion of 60-79.5 s. They confirmed that first-minute ultrafast dynamic imaging can
add valuable information, increasing the radiologists confidence in identifying le-
sions in the presence of marked background parenchymal enhancement. A hybrid
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construction, where ultrafast acquisitions are interleaved in an abbreviated breast
MRI protocol, allows the collection of dynamic data for lesion classification without
a penalty in acquisition time.
Further improvements of ultrafast MRI are still increasing image quality. Radial
imaging using a golden angle approach, as is performed in the golden-angle radial
sparse parallel (GRASP) sequence, enables dynamic imaging using continuous data
acquisition and retrospective reconstruction of image series with an arbitrary tem-
poral resolution by grouping different numbers of consecutive radial lines into tem-
poral frames. This means that, with the use of GRASP, images of every temporal
resolution can be reconstructed, thus, both ultrafast and regular high spatial reso-
lution acquisitions can be obtained using the same sequence, as described for liver,
pediatrics, breast, and neck82. This approach can help to improve clinical work-
flow by enabling data acquisition without the need for synchronization with breath-
hold commands or for selection of predefined rigid temporal resolution. A recently
published study83 showed that the performance of the GRASP sequence in terms of
conspicuity of benign and malignant breast lesions is near-comparable to that of con-
ventional volumetric imaging breath-hold examination (VIBE) imaging. Thus, tech-
niques that employ compressed sensing might be used to further improve image
quality of ultrafast imaging. Table 2.5 lists multiparametric protocols that include
ultrafast MRI sequences recently described in literature.
2.9 Future perspectives: contrastless screening
As earlier discussed, one major disadvantage of breast MRI is the need for contrast
agent administration. This is not solved by either abbreviated, ultrafast, or hybrid
protocols. Since the recent observation of gadolinium deposition/retention in the
brain in a fraction of patients who underwent multiple injections of gadolinium-
based contrast agents84–86, this has become a debated subject, especially for breast
MRI screening, because healthy women at increased risk for breast cancer are annu-
ally exposed to gadolinium-based contrast agents.
Even though there are currently no clinical sequels associated with deposition/re-
tention and guidelines for the use of breast MRI have remained unchanged87, this is
an additional reason (next to the associated costs, need for intravenous cannulation,
and risks of already known adverse events such as allergic reactions) to investigate
alternative MRI screening strategies that do not rely on contrast administration. The
recent technological developments in cancer imaging have led to a shift towards
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Table 2.5: Multiparametric protocols containing ultrafast sequences
First authorref.# Protocol
Pineda77 1. Ultrafast sequence
2. High resolution sequences
Herrmann78 1. Pre-contrast 2D gradient-echo
2. Ultrafast sequence (TWIST)
Tudorica79 1. Ultrafast sequence (TWIST) with fat saturation
2. Axial T2-weighted sequence with fat saturation
3. 3D T1-weighted sequence without fat saturation
Le80 Healthy volunteers, no contrast administration
1. TWIST Dixon sequence
2. VIBE SPAIR
Mann55 1. DWI
2. VIBE (T1-weighted)
3. TWIST (T1-weighted)
4. T2-weighted
Feng82 1. GRASP
Heacock83 1. Sagittal T1-weighted gradient echo
2. Sagittal T2-weighted gradient echo
3. Sagittal T1-weighted gradient echo
When breast biopsy images were acquired; Sagittal GRASP
sequence continuously acquired before, during, and after contrast
injection
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functional assessment of tissue characteristics, possibly making contrast administra-
tion in the future unnecessary.
Of all techniques in use, DWI appears the strongest candidate for contrastless breast
MRI. Like T2-weighted imaging, DWI does not require contrast agent administra-
tion, however, its sensitivity is much higher. This makes that DWI can be used in
patients with a poor renal function or patients with an allergy to gadolinium-based
contrast agents. Although currently not as good as contrast-enhanced MRI, the sen-
sitivity of DWI is already competitive with that of mammography.
Sebastian Bickelhaupt and coworkers88 investigated the fusion of T2-weighted im-
ages and DWI for characterization of BI-RADS 4/5 mammographic findings. Com-
bining morphological information from the former with bio-physiological character-
istics from the latter allowed radiologists to get a high diagnostic accuracy for lesion
characterization (92%) comparable to that of the full DCE protocol (95%). Research
is needed to investigate whether this can be used for breast MRI screening.
Further diffusion-based approaches to contrastless breast MRI include diffusion ten-
sor imaging (DTI), that appears to improve the diagnostic capacity of DWI, and al-
lows imaging at a substantially higher resolution than that is common for DWI89
and intravoxel incoherent motion (IVIM), although the spatial resolution of the lat-
ter currently still precludes any screening90.
An approach to obtain vascular information without contrast administration is ar-
terial spin labeling (ASL). The arterial blood supplying the tissue of interest is la-
beled’ altering its longitudinal magnetization; perfusion quantification can be easily
performed as the signal changes are proportional to blood flow91,92. The technique
has already been successfully implemented to improve disease detection and char-
acterization in the brain, pancreas, and kidney91. Several ASL techniques exist, all
based on three different spin states (equilibrium, saturation, and inversion) and can
also be categorized as on- and off-slice tagging sequences. Pilot studies showed an
ASL potential for distinguishing malignant from benign breast tissues (as malignant
tumors had a higher water content than normal tissue and a higher perfusion than
both normal tissues and benign lesions)92 and a correlation between MRI perfusion
values of breast tissue by ASL as compared to CT perfusion93. Unfortunately, the
ASL sequences for breast are still under development and some cannot even cover
the whole breast. In addition, the obtained signals are still too weak and reconstruc-
tion artefacts too strong to use it as a screening tool. It is a matter of time to see
2.10 Conclusion 35
whether ASL can evolve into a technique that can replace contrast-enhanced breast
MRI.
Metabolic imaging, predominantly MRS, is another path for exploration. It is well
established that total choline, in particular phosphocholine, is elevated in breast can-
cer58,68–71,94. As spectroscopic techniques improve, quantification of in-vivo spec-
tra can be done more reliably. This replaces the criterion of seeing or not seeing
the choline peak with more sophisticated quantitative criteria for judging whether a
breast lesion might be malignant58. However, for future screening application, mul-
tivoxel techniques (2D, or better, 3D) are needed. Moreover, the SNR is so low that
voxels are in the size order of cubic centimeters, thus, still not suitable for screening.
Nevertheless, novel approaches to metabolic imaging, such as phosphorous spec-
troscopy and chemical saturation transfer imaging (CEST) may enable much higher
resolution levels in the near future that might give them access to a new platform for
screening research95.
2.10 Conclusion
Breast MRI is solidly established as the most accurate screening technique for breast
cancer available, even though currently mainly applied to women at increased risk
of breast cancer. Current state-of-the-art protocols are multiparametric in nature and
focus on achieving both a high sensitivity and a high specificity. As the added value
of additional sequences on top of simple T1-weighted acquisitions in a screening set-
ting appears questionable and is, likely, not cost-effective, current research focuses
on shortening of MRI protocols. Both abbreviated and ultrafast approaches to breast
MRI allow acquisition within minutes without losing in accuracy.
Future research focuses on the use of non-contrast techniques for screening. DWI
currently seems most suitable. However, so far this technique cannot deliver the
quality of screening obtained with contrast-enhanced techniques.
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Abstract
Purpose To evaluate the real-life performance of a breast cancer screening program
for women with different categories of increased breast cancer risk with multiple
follow-up rounds in an academic hospital with a large screening population.
Materials and Methods Screening examinations (magnetic resonance [MR] imaging
and mammography) for women at increased breast cancer risk (January 1, 2003, to
January 1, 2014) were evaluated. Risk category, age, recall for workup of screening-
detected abnormalities, biopsy, and histopathologic diagnosis were recorded. Re-
call rate, biopsy rate, positive predictive value of recall, positive predictive value of
biopsy, cancer detection rate, sensitivity, and specificity were calculated for first and
follow-up rounds.
Results There were 8818 MR and 6245 mammographic examinations performed in
2463 women. Documented were 170 cancers; of these, there were 129 screening-
detected cancers, 16 interval cancers, and 25 cancers discovered at prophylactic mas-
tectomy. Overall sensitivity was 75.9% including the cancers discovered at pro-
phylactic mastectomy (95% confidence interval: 69.5%, 82.4%) and 90.0% excluding
those cancers (95% confidence interval: 83.3%, 93.7%). Sensitivity was lowest for
carriers of the BRCA1 mutation (66.1% and 81.3% when including and not including
cancers in prophylactic mastectomy specimens, respectively). Specificity was higher
at follow-up (96.5%; 95% confidence interval: 96.0%, 96.9%) than in first rounds
(85.1%; 95% confidence interval: 83.4%, 86.5%) and was high for both MR imag-
ing (97.1%; 95% confidence interval: 96.7%, 97.5%) and mammography (98.7%; 95%
confidence interval: 98.3%, 99.0%). Positive predictive value of recall and positive
predictive value of biopsy were lowest in women who had only a family history of
breast cancer.
Conclusion Screening performance was dependent on risk category. Sensitivity was
lowest in carriers of the BRCA1 mutation. The specificity of high-risk breast screen-
ing improved at follow-up rounds.
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3.1 Introduction
Breast magnetic resonance imaging (MRI) is considered to be the most sensitive
imaging modality for early breast cancer detection and is recommended as a supple-
mental screening technique for women with a lifetime risk for the development of
breast cancer of 20 - 25% or higher11,12. This includes women with a BRCA germline
mutation, for whom the lifetime risk is as high as 56 - 84%, and women who under-
went radiation therapy to the chest wall at young age11,12,37,96. Furthermore, women
with a strong family history for breast cancer, women with a personal history of
breast cancer, and women with high-risk lesions such as atypical ductal hyperplasia
and lobular carcinoma in situ are at increased risk, though for the latter risk cate-
gories the indication for additional screening with MRI is less clear11,12,97. Nonethe-
less, supplemental screening may be indicated for all these women because the rate
of interval cancers is relatively high98–100.
Whereas the sensitivity of breast MR imaging has been reported101 to be as high as
95% in women with known breast cancer, the sensitivity of breast MRI in screening
is lower. Initially, the sensitivity was reported to be around 77% in the screening set-
ting, but more recent studies document a higher sensitivity of around 90%15,41,75,102.
Studies15,41,75 show a nearly doubled cancer detection of combined MR imaging and
mammography screening compared with mammography screening alone. Conse-
quently, high-risk screening programs with MR imaging and mammography have
been implemented in clinical practices worldwide, although there are national, re-
gional, and local differences regarding whom to screen with supplemental MR imag-
ing11,12,103. This is likely also because it is so far unknown whether the diagnostic
value of breast MR imaging screening is different for groups with a different under-
lying risk and whether the added value of MR imaging persists in follow-up evalu-
ations for all groups.
A major criticism regarding breast MR imaging screening, beyond availability and
cost, is that the specificity appears lower than generally accepted for mammogra-
phy screening. Reported specificities range from 81% to 95% and compare poorly
to a specificity of 99% for mammography screening14,15,37,38,75,102,104. However, to our
knowledge, hardly any data exist on the effect of routine use of breast MR imaging
and the availability of prior examinations on the diagnostic accuracy of breast MR
imaging. Only a few recent studies of breast MR imaging screening programs docu-
ment recall rates, false-positive findings, and interval cancers15,41.
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The purpose of this study is to evaluate the real-life performance of a breast cancer
screening program for women with different categories of increased breast cancer
risk with multiple follow-up rounds in an academic hospital with a large screening
population.
3.2 Materials and Methods
Screening program
The breast cancer screening program for women at increased breast cancer risk (≥ 20
- 25% lifetime risk) in carriers of the BRCA mutation. From the age of 30 or older, MR
imaging is combined with a yearly mammographic examination in BRCA mutation
carriers. In women at high familial risk, screening starts between 35 and 45 years
or 5 years before the age at which the youngest relative developed breast cancer20.
In women with a personal history of breast cancer, screening starts 1 year after the
diagnosis of breast cancer.
Case selection
This retrospective study was approved by our local institutional review board and
the requirement for informed consent was waived. The local database was searched
to identify all screening MR examinations and mammographies performed from Jan-
uary 1, 2003 to January 1, 2014. Women were included when MR examinations were
performed on the basis of a screening indication, mammograms were included if
the indication was screening and mammography was performed within 1 year after
the screening MR examination. We recorded risk category (BRCA1, BRCA2, family
history, personal history, and other women), age, screening tests performed, recall
for workup of screen-detected abnormalities, biopsies, and histopathologic diagno-
sis when available.
During the study period, 9571 screening breast MR examinations and 6553 screen-
ing mammographic examinations were performed in 2773 women. After exclud-
ing women not at increased risk, we evaluated 8818 screening breast MR exami-
nations and 6245 screening mammographic examinations that were performed in
2463 women at increased risk for breast cancer (mean age, 44 ± 12 [standard devi-
ation]; age range, 15 - 91). The population included 770 women who were BRCA
mutation carriers (471 carriers of BRCA1 and 299 carriers of BRCA2) and 26 untested
first-degree relatives (16 carriers of BRCA1 and 10 carriers of BRCA2). Furthermore,
women were included on the basis of a family history of breast cancer (lifetime risk,
> 20%); N = 748), a personal history of breast cancer (N = 836), or other reasons
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Table 3.1: Characteristics of the study population
BRCA1
(N=471)
Untested
first degree
relatives
BRCA1
(N=16)
BRCA2
(N=299)
Untested
first degree
relatives
BRCA2
(N=10)
Family
history
(N=748)
Personal
history
(N=836)
Others at
increased
risk
(N=83)
Age at start
mean (range)
39 (23-75) 31 (22-69) 41 (23-73) 29 (25-50) 42 (16-73) 52 (22-91) 38 (15-71)
Median no.
of screening
MRI exams
performed
(range)
3 (1-13) 2 (1-4) 3 (1-11) 1 (1-10) 2 (1-12) 2 (1-12) 3 (1-10)
Median no.
of screening
mammography
exams performed
(range)
2 (0-11) 1 (0-5) 3 (0-11) 1 (0-10) 1 (0-10) 1 (0-12) 1 (0-7)
VDG at start$ (%) 398
available
11
available
265
available
7
available
526
available
474
available
52
available
a 88 (22.1) 1 (9.1) 52 (19.6) 0 (0.0) 46 (8.7) 59 (12.4) 10 (19.2)
b 104 (26.1) 1 (9.1) 63 (23.8) 2 (28.6) 83 (15.8) 130 (27.4) 19 (19.2)
c 117 (29.4) 4 (36.4) 102 (38.5) 1 (14.3) 202 (38.4) 187 (39.5) 21 (40.4)
d 89 (22.4) 5 (45.5) 48 (18.1) 4 (57.1) 195 (37.1) 98 (20.7) 11 (21.2)
$ VDG: Volpara density grade. A volumetric and automatically assessed density score on the raw mammogra-
phy data. The classes are created in analogy to the BI-RADS lexicon.
(chest radiation and high-risk lesions, N = 83). The mean number of MR examina-
tions performed per woman was three (range, one to 13 examinations), and the mean
number of mammographic examinations was two (range, zero to 12 examinations).
Characteristics of the study population are presented in Table 3.1.
Image acquisition
MR imaging protocols varied over time. Examinations were performed on a 1.5- or
3-T imager (Magnetom Avanto, Magnetom Sonata, Magnetom Simphony, or Mag-
netom Trio; Siemens, Erlangen, Germany) by using a dedicated bilateral breast coil.
Women were imaged in the prone position. A transverse or coronal three-dimension-
al T1-weighted gradient-recalled echo dynamic sequence was performed before con-
trast agent administration followed by four or five postcontrast-administration se-
quences. Pixel spacing, section thickness, matrix, echo time, repetition time, and
flip angle differed among acquisitions as previously described by Dalmis et al.105.
Diffusion-weighted imaging and T2-weighted acquisitions were added from those
imaged in 2012. Various gadolinium chelates were used, administered at a dose of
0.1mmol/kg or 0.2mmol/kg by using a power-injector (Medrad, Warrendale, Pa)
at a flow rate of 2.5mL/s, followed by a saline flush. Premenopausal women were
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scheduled between the 6th and 12th day of their menstrual cycle.
Mammograms were obtained in two directions (mediolateral oblique and cranio-
caudal) with a full-field digital mammography imager (GE Senograph 2000 or GE
Senograph DS, GE, Fairfield, Conn). Additional views and spot-compression views
were performed at request of the evaluating radiologist.
Image interpretation
All examinations were evaluated by one of 8 breast radiologists (R.M.M. and other
radiologists) using the Breast Imaging Reporting and Data System (BI-RADS)19,106.
Experience in breast MR imaging ranged from 0.5 to 23 years. For MR imaging,
both morphologic and dynamic parameters were evaluated by using a dedicated
breast MR imaging workstation (versions of DynaCAD, Invivo, Gainesville, Fla; and
Philips, Best, the Netherlands). When available, mammograms, MR images, and
previous examinations were evaluated together. Final assessment categories were
given as specified in the American College of Radiology BI-RADS atlas19. Biopsies
were performed for lesions classified as BI-RADS category 4 and BI-RADS category
5, and a subset of lesions classified as BI-RADS category 3. The remaining BI-RADS
category 3 lesions underwent short-term follow-up.
Ground truth
Our database was linked to the nationwide population-based Netherlands Cancer
Registry. Normal or benign screening examinations were confirmed by at least 1
year of clinical follow-up and regarded to be true-negative when no cancer was de-
tected before the subsequent screening round. When no biopsy was indicated at
short-term follow-up, at least one year of clinical follow-up was required to con-
firm benignity. All lesions that underwent biopsy and prophylactic mastectomies
performed in-house were identified by a cross-computer search with our pathology
database. We subsequently recorded whether the biopsy was performed for screen-
ing findings or symptoms.
Data-analysis
To evaluate the performance, we defined performance metrics (per examination) in
analogy to those used for evaluation of mammography screening programs33.
Screening examination negative for cancer were defined as screening examinations
that were rated as BI-RADS category 1 or 2. True-negative screening examinations
were defined as screening examinations negative for cancer in women in whom no
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cancer was detected in the subsequent year.
Results of pathologic analysis were grouped into malignant (ie, ductal carcinoma in
situ, invasive, and metastatic cancer) and benign (all other findings) lesions. Screen-
detected cancers were defined as cancers diagnosed after diagnostic workup initi-
ated by screening findings. In the high-risk screening program, we defined two
groups of non-screening-detected cancers. The first group consisted of interval can-
cers that manifested in between screening rounds because of symptoms. The second
group consisted of cancers that were detected in asymptomatic women who under-
went prophylactic mastectomy. Prognostic differences between these groups were
investigated using χ2 tests for categorical variables or one-way analysis of variance
for continuous variables.
Consequently, two different groups of false-negative examinations (referred to here
as FN1 and FN2) were defined. FN1 consisted of screening examinations rated as
BI-RADS category 1 or BI-RADS category 2 in which any cancer was detected in
the following year or before the subsequent screening examination. FN2 consisted
of screening examinations rated as BI-RADS category 1 or BI-RADS category 2 in
which a true interval cancer was detected.
The recall rate was defined as the number of examinations that were classified as
BI-RADS category 0, BI-RADS category 3, BI-RADS category 4, or BI-RADS cate-
gory 5 per 1000 screening examinations performed. The biopsy rate was defined as
the number of examinations in which a biopsy was performed per 1000 screening
examinations performed. The cancer detection rate was defined as the number of
examinations that led to breast cancer detection per 1000 screening examinations.
Screening examinations positive for cancer were defined as screening examinations
that were rated as BI-RADS category 0, BI-RADS category 3, BI-RADS category 4,
or BI-RADS category 5, and true-positive examinations were defined as screening
examinations positive for cancer that led to cancer detection. False-positive exam-
inations were defined as examinations that led to a recall in women in whom no
breast cancer was detected. The positive predictive value of recall was defined as
the fraction of recalls that led to cancer detection. The positive predictive value of
biopsy was defined as the fraction of biopsies that led to cancer detection.
We calculated the sensitivity of the complete screening program and for both modal-
ities separately. Three different sensitivities were recognized: the sensitivity for all
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breast cancers detected, the sensitivity for screening-detected cancers and interval
cancers detected because of symptoms (excluding cancers detected in prophylactic
mastectomies), and the modality-specific sensitivity for screening-detected cancers.
For the latter category, lesions were considered visible with a modality when they
were mentioned in radiologic report of that modality (or report section when both
modalities were reported simultaneously). Cancers only reported in mammogra-
phy were considered to be false-negative findings in MR imaging and vice versa.
Specificity was determined using examinations of women that had at least 1 year of
follow-up without recall and calculated for complete screening and independently
for each modality.
We analyzed the overall screening results and separated results of the first screen-
ing round from follow-up rounds. The first screening round was defined as the first
time a woman with increased breast cancer risk underwent MR imaging. Follow-up
screening rounds were defined as screening examinations performed in a period be-
tween 10 and 24 months after a previous screening round.
To explore the influence of risk category on screening performance, the dataset was
divided into risk subgroups. To compare first screening rounds with follow-up
rounds, and analyze differences between subgroups, Fisher exact tests and one-way
analysis of variance were used and 95% confidence intervals were calculated107. Ad-
ditionally, the difference in tumor stage, nodal stage, and grade between cancers
detected in the first round and cancers detected in follow-up rounds were assessed
using χ2 statistics. Bonferroni correction was applied for performance measures,
and a two-sided P-value of ≤0.008 or less was considered to indicate statistical sig-
nificance. All statistics were performed by using statistical software (SPSS version
22; SPSS, Chicago, Ill).
3.3 Results
A total of 577 women (mean age, 44 ± 11; age range, 15 - 77 years) were recalled,
some more than once (505 women were recalled once, 60 women were recalled twice,
nine women were recalled three times, one woman was recalled four times, and
two women were recalled five times), which resulted in 666 recalls. This led to 424
women undergoing 475 biopsies (one biopsy, 383 women; two biopsies, 35 women;
three biopsies, three women; four biopsies, two women; five biopsies, one woman;
mean age, 44 years ± 11; age range, 15 - 77 years) as a consequence of screening.
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Cancers
In total, 170 newly diagnosed cancers in 156 women were documented. Of these,
129 (75.9%) cancers were screening-detected and 118 cancers were detected at MR
imaging (modality sensitivity, 91.5%; 47 cancers were detected at the first round and
71 cancers were detected at follow-up rounds). Mammography was available for 108
screening-detected cancers, and in 62 women a cancer was visible at mammography
(modality sensitivity, 57.4%). Eleven of these cancers were found at mammography
alone (all at follow-up; mean age, 52 years ± 8.8; age range, 35 - 69 years), of which
seven cancers (63.6%) were pure ductal carcinoma in situ. The incremental cancer
detection at mammography was stronger (although not significant) in women with-
out a BRCA mutation than in those with a BRCA mutation (sensitivity increase in
BRCA mutation carriers vs in women without a BRCA mutation who underwent
both examinations, 3.3% [from 64.1% to 67.4%] vs 10.3% [from 75.6% to 85.9%], re-
spectively; P = 0.11).
Forty-one interval cancers were detected outside screening, of which 16 were found
because of patient symptoms. Twenty-five cancers were found at prophylactic mas-
tectomy. Of these cancers, 21 were detected at our hospital among 421 prophylactic
mastectomies in 246 patients (cancer frequency per breast, 5.0%). The frequency of
prophylactic mastectomy varied among risk categories, and most were performed
in carriers of the BRCA1 mutation (265 mastectomies in BRCA1, 111 mastectomies in
BRCA2, 16 mastectomies in women with a family history, 27 mastectomies in women
with a personal history, and two mastectomies in the group with other reasons).
Eighteen of 25 (72.0%) cancers detected at prophylactic mastectomy were pure duc-
tal carcinoma in situ. Patient and tumor characteristics of screening-detected and
interval cancers are shown in Table 3.2. In general, symptomatic interval cancers
have a higher tumor stage, are of higher grade, and are more often invasive com-
pared with those found at prophylactic mastectomy (P ≤ 0.05).
Screening performance
Performance metrics are presented in Table 3.3 with individual risk category in Ta-
bles 3.5 - 3.11. The overall screening program had a sensitivity of 75.9% when all
recognized cancers were included and a sensitivity of 90.0% when prophylactic mas-
tectomy cancers were excluded. Whereas the sensitivity of MR imaging for invasive
disease was higher than that of mammography (78.7% vs 46.2%, respectively, with
inclusion of all cancers [P < 0.001]; 83.3% vs 48.0%, respectively, excluding cancers
in prophylactic mastectomies [P < 0.001]), the sensitivities of mammography and
MR imaging for ductal carcinoma in situ were not significantly different (45.2% vs
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41.9%, respectively, with the inclusion of all cancers [P = 0.82], and 70.0% vs 72.0%,
respectively, excluding cancers detected in prophylactic mastectomies [P = 0.99]; see
Table 3.4).
The sensitivity of the screening program appears to be higher in carriers of the
BRCA2 mutation (69.7% including cancers found at prophylactic mastectomy and
92.0% excluding cancers found at prophylactic mastectomy), women with a family
history positive for cancer (90.9% and 95.2% with and without cancers found at pro-
phylactic mastectomy, respectively), women with a personal history of breast cancer
(82.0% and 91.1% with and without cancers found at prophylactic mastectomy, re-
spectively), and other patients at an increased level (100% both with and without
cancers found at prophylactic mastectomy) compared with carriers of the BRCA1
mutation (66.1% and 81.3% with and without cancers found at prophylactic mastec-
tomy, respectively), though this did not reach statistical significance (P = 0.05 and P
= 0.25 with and without cancers found at prophylactic mastectomy, respectively).
Overall recall ranged from 5.8 to 10.3% (from 57.8/1000 to 103.2/1000) across sub-
populations and was substantially lower in follow-up examinations than in first
round examinations (P < 0.001, see Table 3.3). Positive predictive value of recall
was 0.19 and was lowest for women with a family history of breast cancer (posi-
tive predictive value of recall, 0.09) (see Table 3.9). At follow-up rounds, the overall
cancer detection rate was lower in all subgroups, which shows the large fraction of
prevalent cancers detected at the first screening round. The largest decrease in cancer
detection rate was found in carriers of the BRCA1 mutation and other at increased
breast cancer risk (a difference of 23.0 [P = 0.008] and 42.1 [P = 0.05], respectively).
Nonetheless, we did not detect a difference in pT stage (P = 0.12), pN stage (P = 0.63),
or tumor grade (P = 0.33) between cancers detected at the first round and follow-up
rounds. Despite the declining cancer detection rate in follow-up rounds because of a
lower prevalence of cancer, sensitivity of MR imaging (69.4%) was higher than that
of mammography (45.9%; P< 0.001). Recall rate and biopsy rate strongly declined in
follow-up rounds, whereas positive predictive value of recall and positive predictive
value of biopsy increased for the entire population at both MR imaging (P = 0.004
and P = 0.005, respectively) and mammography (P < 0.001 for both positive predic-
tive values) except for the subgroup of other patients at increased breast cancer risk
(see Table 3.11). For MR imaging, the availability of previous imaging examinations
(MR imaging and/or mammography) strongly improved the specificity to a level
that was just below the specificity of mammography (97.1% vs 98.7%; P < 0.001).
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We showed that the specificity of high-risk screening in real-life practice is excellent,
both for mammography and breast MR imaging, especially in follow-up rounds.
This is different than in previous clinical trials that reported variable and gener-
ally much lower specificity of breast MR imaging14,15,37,102. In follow-up rounds, the
specificity of MR imaging approached the specificity of mammography, which reaf-
firmed that new examinations must be evaluated together with previous studies. By
doing so, the number of recalls is reduced and the positive predictive value of both
recall and biopsy increases.
The positive predictive value is substantially lower in women with a family history
of breast cancer than in all other subgroups. This might be partly related to the much
lower breast cancer risk in this population. Our results thus still indicate that strict
evaluation of risk category for intensified screening is required.
In terms of sensitivity, excluding cancers detected in prophylactic mastectomy, the
overall performance of the screening regimen is 90.0% and varied little between sub-
groups, except for carriers of the BRCA1 mutation in whom the sensitivity (81.3%)
appeared to be lower. This is in line with earlier studies39 and implies that, for car-
riers of the BRCA1 mutation, an even more stringent screening regimen, or prophy-
lactic mastectomy108, may be indicated.
Despite the high accuracy of the screening program, it is evident that there is a reser-
voir of undetected cancers that are only found in prophylactic mastectomy speci-
mens. At our center, 5% of prophylactic mastectomies contained undetected can-
cers. Hence, the overall sensitivity of the screening program is heavily dependent
on the frequency of prophylactic mastectomies in the target population and the in-
dication for prophylactic mastectomy. However, our results showed that the cancers
found in prophylactic mastectomy specimens were in general small and usually non-
invasive, which is in line with findings of previous studies109,110. Consequently, the
importance of detecting these cancers is unknown, even though they are most often
detected in carriers of the BRCA germline mutation, which, in turn, can be partly
explained by the fact that more prophylactic surgical procedures are performed in
BRCA mutation carriers.
The addition of mammography to MR imaging increased the sensitivity of the screen-
ing program to 8.1% (from 71.9% with only MR imaging to 80.0% with both exam-
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inations) in women who underwent both examinations. These were 11 cancers, of
which seven were ductal carcinoma in situ. Whether the additional detection of
these cancers is beneficial to the patient is unknown. Kuhl et al18 noted that the
sensitivity of breast MR imaging for high-grade ductal carcinoma in situ is excel-
lent, whereas mammography preferentially depicts lower grade lesions18. In line
with other studies, our results show that the sensitivity of mammography was espe-
cially low in carriers of the BRCA mutation and in women with a personal history of
breast cancer102,111–113. Nevertheless, the age from which supplemental mammogra-
phy screening is recommended varies from country to country and may be as low as
30 years in carriers of the BRCA mutation11. This advice could be modified to reflect
the importance of MR screening in this population.
Our study has limitations. This was a single institutional study, which potentially
limits its ability to generalize. Because the study is longitudinal in nature, clinical
and imaging protocols evolved over time. Furthermore, 13 radiologists reported
the cases over the years. Unfortunately, because of the limited number of cancer
detections per year, the influence of changing protocols and different levels of expe-
rience cannot be assessed. Whereas we analyzed the performance of MR imaging
and mammography separately, in most women these examinations were simulta-
neously evaluated. Therefore, the performance of each of the modalities may have
been affected by the findings in the other modality. In addition, because we only
have information on the prophylactic mastectomies negative for cancer that were
performed at our hospital, the actual frequency of cancer in specimens from prophy-
lactic mastectomy might be slightly over- or understated because of selection bias.
Another limitation is the fact that young women who are BRCA mutation carriers
(< 30 years) are only screened with MR imaging, and hence the number of MR ex-
aminations was different from the number of mammographic examinations, which
could potentially skew accuracy values. Finally, the rate of prophylactic mastec-
tomy reduces the apparent sensitivity for all cancers, so any difference in sensitivity
in breast cancer patients may largely be because of the higher rate of such mastec-
tomies rather than an unique difficulty in detection.
From our results it is evident that the group of women who underwent intensified
screening because of a family history of breast cancer was at substantially lower risk
than the other subgroups. Because of the retrospective nature of the study, we were
unable to obtain the actual family history and hence could not further stratify these
women. Similarly, the subgroup with risk category ”other” remains heterogeneous,
but because of the low frequency of the specific risks within this group, further divi-
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sion was not possible. Finally, survival data were not available. Further studies need
to establish whether there is a survival benefit for women who participate in breast
cancer screening programs114,115.
In conclusion, this study shows that, in real-life practice, the performance of a high-
risk screening program is affected by risk category and the frequency of prophylac-
tic mastectomies. The specificity of the screening program is high and improves at
follow-up. Especially in women who are BRCA mutation carriers, the added value
of mammography is limited.
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Table 3.2: Patient and cancer characteristics of cancers detected in high-risk screening
patients
Screen-detected
cancers
Interval cancers
due to patient
symptoms
Cancers found at
prophylactic
mastectomy
P-value
Number of cancers (%) 129 (75.9) 16 (9.4) 25 (14.7) N/A
Median age at detection in years (range in years) 50 (24-77) 42 (27-55) 42 (27-70) <0.001*
Risk category 0.10
- BRCA1 mutation (%) 39 (66.1) 9 (15.3) 11 (18.6)
- Untested BRCA1∗ (%) 0 (0.0) 0 (0.0) 0 (0.0)
- BRCA2 mutation (%) 23 (69.7) 2 (6.1) 8 (24.2)
- Untested BRCA2∗ (%) 0 (0.0) 0 (0.0) 0 (0.0)
- Family history (%) 20 (90.9) 1 (4.5) 1 (4.5)
- Personal history (%) 41 (82.0) 8 (8.0) 5 (10.0)
- Others (%) 6 (100.0) 0 (0.0) 0 (0.0)
Invasive disease 104 (81.9) 16 (12.6) 7 (5.5) N/A
Mean pathological size# (range in mm) 14.2 (2-70) 15.5 (5-26) 5.8 (1-11) 0.24
T-stage 0.54
- pT1 (%) 78 (83.9) 8 (8.6) 7 (7.5)
- pT2 (%) 18 (85.7) 3 (14.3) 0 (0.0)
- pT3 (%) 1 (100.0) 0 (0.0) 0 (0.0)
- pT4D (%) 1 (100.0) 0 (0.0) 0 (0.0)
- Recurrence (%) 4 (66.7) 2 (33.3) 0 (0.0)
- Unknown (%) 2 (40.0) 3 (60.0) 0 (0.0)
Grade 0.17
- Grade 1 (%) 19 (90.5) 0 (0.0) 2 (9.5)
- Grade 2 (%) 31 (86.1) 4 (11.1) 1 (2.8)
- Grade 3 (%) 45 (80.4) 8 (14.3) 3 (5.4)
- Unknown (%) 9 (64.3) 4 (28.6) 1 (7.1)
Molecular subtype 0.01
- Luminal A (%) 32 (88.9) 3 (8.3) 1 (2.8)
- Luminal B (%) 20 (95.2) 0 (0.0) 1 (4.8)
- HER2-type (%) 9 (100.0) 0 (0.0) 0 (0.0)
- Triple negative (%) 18 (60.0) 8 (26.7) 4 (13.3)
- Unknown (%) 25 (80.6) 5 (16.1) 1 (3.2)
N-stage 0.15
- pN0 (%) 71 (80.7) 7 (8.0) 4 (4.5)
- pN+ (%) 24 (82.8) 5 (17.2) 0 (0.0)
- Unknown (%) 9 (56.3) 4 (25.0) 3 (18.8)
M-stage N/A
- pM0 (%) 52 (82.5) 5 (7.9) 6 (9.5)
- Unknown (%) 52 (81.3) 11 (17.2) 1 (1.6)
In situ disease (%) 25 (58.1) 0 (0.0) 18 (41.9) N/A
Grade 0.02
- Grade 1 (%) 1 (20.0) 0 (0.0) 4 (80.0)
- Grade 2 (%) 12 (52.2) 0 (0.0) 11 (47.8)
- Grade 3 (%) 9 (90.0) 0 (0.0) 1 (10.0)
- Unknown (%) 3 (60.0) 0 (0.0) 2 (40.0)
N-stage 0.40
- pN0 (%) 21 (61.8) 0 (0.0) 13 (38.2)
- pN+ (%) 0 (0.0) 0 (0.0) 1 (100.0)
- Unknown (%) 4 (50.0) 0 (0.0) 4 (50.0)
∗ Cancers detected in untested first degree relatives of BRCA mutation carriers
# Pathological tumor size is known for 88 screen-detected invasive lesions, for 8 interval cancers, and for 5 cancers
detected in prophylactic mastectomy specimen.
In situ disease; pure ductal carcinoma in situ
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Table 3.3: Performance measures for mammography and MRI screening in the
entire population
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=8818 N=2092 N=6726
RR (per 1000) 75.5 [71.5-82.2] 167.8 [152.6-183.0] 46.8 [42.1-52.0] <0.001*
BR (per 1000) 53.9 [50.2-59.4] 113.3 [100.2-126.0] 35.4 [31.6-40.3] <0.001*
PPV1 0.19 [0.16-0.22] 0.13 [0.10-0.16] 0.26 [0.21-0.31] <0.001*
PPV3 0.27 [0.23-0.30] 0.20 [0.14-0.24] 0.34 [0.28-0.40] <0.001*
CDR (per 1000) 14.6 [12.1-17.0] 22.5 [15.8-27.9] 12.2 [9.7-15.0] 0.001*
Sensitivity1 (%) 75.9 [69.5-82.4] 81.0 [69.6-90.2] 73.2 [64.7-81.2] 0.35
Sensitivity2 (%) 90.0 [83.3-93.7] 88.7 [77.4-95.6] 89.1 [81.4-94.7] 0.99
Specificity (%) 93.8 [93.3-94.3] 85.1 [83.4-86.5] 96.5 [96.0-96.9] <0.001*
Mammography N=6245 N=1645 N=4600
RR (per 1000) 38.1 [36.3-46.0] 82.1 [74.5-101.1] 22.4 [19.4-28.2] <0.001*
BR (per 1000) 24.7 [22.9-30.8] 46.2 [39.5-60.0] 17.0 [14.6-22.4] <0.001*
PPV1 0.26 [0.20-0.31] 0.14 [0.09-0.20] 0.42 [0.33-0.52] <0.001*
PPV3 0.40 [0.32-0.47] 0.25 [0.16-0.34] 0.55 [0.44-0.65] <0.001*
CDR (per 1000) 9.9 [8.1-13.2] 11.6 [7.4-18.0] 9.3 [7.4-13.3] 0.47
Sensitivity1 (%) 45.9 [35.5-51.4] 41.3 [27.3-54.9] 48.3 [35.2-54.8] 0.47
Sensitvity 2 (%) 51.7 [43.0-60.7] 45.2 [30.5-59.8] 55.1 [44.7-66.6] 0.34
Specificity (%) 97.1 [96.7-97.5] 92.7 [91.4-93.9] 98.7 [98.3-99.0] <0.001*
MRI N=8818 N=2092 N=6726
RR (per 1000) 61.6 [57.9-67.7] 134.3 [120.2-148.0] 39.0 [34.9-44.0] <0.001*
BR (per 1000) 48.1 [44.3-53.0] 103.7 [90.2-115.0] 30.8 [27.0-35.2] <0.001*
PPV1 0.22 [0.18-0.24] 0.17 [0.12-0.20] 0.27 [0.22-0.32] 0.004*
PPV3 0.28 [0.23-0.31] 0.22 [0.15-0.26] 0.34 [0.28-0.40] 0.005*
CDR (per 1000) 13.4 [10.8-15.5] 22.5 [15.5-27.4] 10.6 [8.3-13.1] <0.001*
Sensitivity1 (%) 69.4 [61.9-75.8] 81.0 [67.8-89.0] 63.4 [54.1-72.1] 0.02
Sensitivity2 (%) 81.4 [73.7-86.7] 88.7 [75.3-94.4] 77.2 [67.5-85.0] 0.12
Specificity (%) 95.1 [94.6-95.5] 88.5 [87.0-89.8] 97.1 [96.7-97.5] <0.001*
1 The complete regimen consist of a combination of MRI and mammography when available
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented
performance measures.
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Table 3.4: Sensitivity for invasive disease and
DCIS for mammography and MRI
Mammography MRI P-value
Invasive disease
- Sensitivity1 46.2 [36.8-55.7]
(48/104)
78.7 [70.8-85.0]
(100/127)
<0.001*
- Sensitivity2 48.0 [38.5-57.7]
(48/100)
83.3 [75.7-88.9]
(100/120)
<0.001*
DCIS∗
- Sensitivity1 45.2 [29.2-562.2]
(14/31)
41.9 [28.4-56.7]
(18/43)
<0.001*
- Sensitivity2 70.0 [48.1-85.5]
(14/20)
72.0 [52.4-85.7]
(18/25)
<0.001*
* DCIS; ductal carcinoma in situ
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophy-
lactic mastectomy specimen as false negatives
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Table 3.5: Performance measures for mammography and MRI screening in
BRCA1 mutation carriers (excluding untested first degree relatives)
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=1714 N=424 N=1290
RR (per 1000) 76.4 [64.8-89.9]) 155.7 [124.3-193.3] 50.4 [39.7-63.7] <0.001*
BR (per 1000) 58.3 [48.2-70.4]) 115.6 [88.6-149.5] 39.5 [30.2-51.6] <0.001*
PPV1 0.30 [0.23-0.38] 0.26 [0.17-0.37] 0.34 [0.24-0.46] 0.34
PPV3 0.39 [0.30-0.49] 0.35 [0.23-0.49] 0.43 [0.31-0.57] 0.42
CDR (per 1000) 22.8 [16.7-31.0] 40.1 [25.2-63.3] 17.1 [11.3-25.7] 0.008*
Sensitivity1 (%) 66.1 [53.4-76.9] 73.9 [53.5-87.5] 61.1 [44.9-75.2] 0.40
Sensitivity2 (%) 81.3 [68.1-89.8] 77.3 [56.6-89.9] 84.6 [66.5-93.9] 0.71
Specificity (%) 94.4 [93.2-95.4] 87.8 [84.2-90.6] 96.6 [95.4-97.4] <0.001*
Mammography N=1534 N=395 N=1139
RR (per 1000) 29.3 [22.0-39.0] 53.2 [35.1-79.9] 21.1 [14.2-31.2] 0.10
BR (per 1000) 21.5 [15.3-30.0] 32.9 [19.3-55.5] 17.6 [11.4-27.0] 0.11
PPV1 0.49 [0.35-0.63] 0.33 [0.17-0.55] 0.63 [0.43-0.79] 0.08
PPV3 0.67 [0.50-0.80] 0.54 [0.29-0.77] 0.75 [0.53-0.89] 0.27
CDR (per 1000) 14.3 [9.5-21.6] 17.7 [8.6-36.1] 13.2 [8.0-21.7] 0.47
Sensitivity1 (%) 44.9 [31.9-58.7] 36.8 [19.2-59.0] 50.0 [33.2-66.9] 0.40
Sensitvity 2 (%) 51.2 [36.8-65.4] 38.9 [20.3-61.4] 60.0 [40.7-76.6] 0.22
Specificity (%) 98.4 [97.7-99.0] 96.3 [93.8-97.8] 99.2 [98.5-99.6] <0.001*
MRI N=1714 N=424 N=1290
RR (per 1000) 66.5 [55.6-79.3] 136.8 [107.3-136.8] 43.4 [33.6-55.9] <0.001*
BR (per 1000) 53.1 [43.4-64.7] 108.5 [82.3-141.7] 34.9 [26.2-46.4] <0.001*
PPV1 0.32 [0.25-0.42] 0.29 [0.19-0.42] 0.36 [0.24-0.49] 0.55
PPV3 0.41 [0.31-0.51] 0.37 [0.25-0.51] 0.44 [0.31-0.59] 0.53
CDR (per 1000) 21.6 [15.7-29.6] 40.1 [25.2-63.3] 15.5 [10.1-23.8] 0.006*
Sensitivity1 (%) 62.7 [50.0-73.9] 73.9 [53.5-87.5] 55.6 [39.6-70.5] 0.18
Sensitivity2 (%) 77.1 [63.5-86.7] 77.3 [56.6-89.9] 76.9 [58.0-89.0] 0.99
Specificity (%) 95.3 [94.2-96.3] 89.8 [86.4-92.4] 97.1 [96.1-97.9] <0.001*
1 The complete regimen consist of a combination of MRI and mammography when available
RR: Recall Rate; BR: Biopsy Rate; PPV1: Positive Predictive Value1; PPV3: Positive Predictive Value3;
CDR: Cancer Detection Rate
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented
performance measures.
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Table 3.6: Performance measures for mammography and MRI screening in
BRCA1 mutation carriers (including untested first degree relatives)
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=1748 N=440 N=1308
RR (per 1000) 77.2 [65.6-90.7] 159.1 [127.9-196.2] 49.7 [39.2-62.9] <0.001*
BR (per 1000) 58.9 [48.8-70.9] 118.2 [91.3-151.7] 39.0 [29.8-50.9] <0.001*
PPV1 0.29 [0.22-0.37] 0.24 [0.16-0.36] 0.34 [0.24-0.46] 0.26
PPV3 0.38 [0.29-0.48] 0.33 [0.22-0.46] 0.43 [0.31-0.57] 0.31
CDR (per 1000) 22.3 [16.4-30.3] 38.6 [24.2-61.0] 16.8 [11.1-25.3] 0.01
Sensitivity1 (%) 66.1 [53.4-76.9] 73.9 [53.5-87.5] 61.1 [44.9-75.2] 0.40
Sensitivity2 (%) 81.3 [68.1-89.8] 77.3 [56.6-89.9] 84.6 [66.5-93.9] 0.71
Specificity (%) 94.3 [93.1-95.3] 87.3 [83.8-90.2] 96.6 [95.5-97.5] <0.001*
Mammography N=1552 N=405 N=1147
RR (per 1000) 29.6 [22.3-39.3] 54.3 [36.1-80.8] 20.9 [14.1-30.9] 0.002*
BR (per 1000) 21.3 [15.2-29.8] 32.1 [18.9-54.1] 17.4 [11.3-26.7] 0.11
PPV1 0.48 [0.34-0.62] 0.32 [0.16-0.53] 0.63 [0.43-0.79] 0.05
PPV3 0.67 [0.50-0.80] 0.54 [0.29-0.77] 0.75 [0.53-0.89] 0.27
CDR (per 1000) 14.2 [9.4-21.4] 17.3 [8.4-35.3] 13.1 [7.8-21.5] 0.62
Sensitivity1 (%) 44.9 [31.9-58.7] 36.8 [19.2-59.0] 50.0 [33.2-66.9] 0.40
Sensitvity 2 (%) 51.2 [36.8-65.4] 38.9 [20.3-61.4] 60.0 [40.7-76.6] 0.22
Specificity (%) 98.4 [97.6-98.9] 96.1 [93.7-97.6] 99.2 [98.5-99.6] <0.001*
MRI N=1748 N=440 N=1308
RR (per 1000) 66.9 [56.1-79.6] 138.6 [109.4-174.0] 42.8 [33.1-55.2] <0.001*
BR (per 1000) 53.8 [44.2-65.4] 111.4 [85.3-144.2] 34.4 [25.8-45.7] <0.001*
PPV1 0.32 [0.24-0.41] 0.28 [0.18-0.40] 0.36 [0.24-0.49] 0.43
PPV3 0.39 [0.30-0.49] 0.35 [0.23-0.49] 0.44 [0.31-0.59] 0.40
CDR (per 1000) 21.2 [15.4-29.1] 38.6 [24.2-61.0] 15.3 [9.9-23.5] 0.006*
Sensitivity1 (%) 62.7 [50.0-73.9] 73.9 [53.5-87.5] 55.6 [39.6-70.5] 0.18
Sensitivity2 (%) 77.1 [63.5-86.7] 77.3 [56.6-89.9] 76.9 [58.0-89.0] 0.99
Specificity (%) 95.3 [94.1-96.2] 89.4 [96.1-92.1] 97.2 [96.1-98.0] <0.001*
1 The complete regimen consist of a combination of MRI and mammography when available
RR: Recall Rate; BR: Biopsy Rate; PPV1: Positive Predictive Value1; PPV3: Positive Predictive Value3;
CDR: Cancer Detection Rate
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented
performance measures.
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Table 3.7: Performance measures for mammography and MRI screening in BRCA2
mutation carriers (excluding untested first degree relatives)
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=1123 N=278 N=845
RR (per 1000) 83.7 [68.9-101.4] 190.6 [148.8-240.9] 48.5 [35.9-65.1] <0.001*
BR (per 1000) 67.7 [54.4-83.9] 140.3 [104.4-186.0] 43.8 [31.9-59.8] <0.001*
PPV1 0.24 [0.17-0.34] 0.13 [0.07-0.25] 0.39 [0.26-0.54] 0.007*
PPV3 0.30 [0.21-0.41] 0.18 [0.09-0.33] 0.43 [0.29-0.59] 0.02
CDR (per 1000) 20.5 [13.7-30.6] 25.2 [12.3-51.1] 18.9 [11.7-30.5] 0.48
Sensitivity1 (%) 69.7 [52.7-82.6] 77.8 [45.3-93.7] 66.7 [46.7-82.0] 0.69
Sensitivity2 (%) 92.0 [75.0-97.8] 100.0 [64.6-100.0] 88.9 [67.2-96.9] 0.99
Specificity (%) 93.5 [91.9-94.8] 82.9 [78.0-86.9] 97.0 [95.0-97.9] <0.001*
Mammography N=1009 N=258 N=751
RR (per 1000) 33.7 [24.2-46.7] 65.9 [41.5-103.0] 22.6 [14.2-35.9] 0.002*
BR (per 1000) 26.8 [18.5-38.7] 46.5 [26.8-79.5] 21.3 [13.2-34.2] 0.05
PPV1 0.32 [0.19-0.49] 0.18 [0.06-0.41] 0.47 [0.26-0.69] 0.14
PPV3 0.41 [0.25-0.59] 0.27 [0.10-0.57] 0.50 [0.28-0.72] 0.43
CDR (per 1000) 10.9 [6.1-19.4] 11.6 [3.9-33.6] 10.7 [5.4-20.9] 0.99
Sensitivity1 (%) 35.5 [21.1-53.1] 33.3 [12.1-64.6] 36.4 [19.7-57.0] 0.99
Sensitvity 2 (%) 44.0 [26.7-62.9] 42.9 [15.8-75.0] 44.4 [24.6-66.3] 0.99
Specificity (%) 97.6 [96.5-98.4] 94.4 [90.8-96.6] 98.8 [97.7-99.4] <0.001*
MRI N=1123 N=278 N=845
RR (per 1000) 74.8 [60.8-91.7] 172.7 [132.8-221.5] 42.6 [30.9-58.4] <0.001*
BR (per 1000) 61.4 [48.8-77.0] 129.5 [95.0-174.1] 39.1 [28.0-54.4] <0.001*
PPV1 0.26 [0.18-0.36] 0.15 [0.07-0.27] 0.42 [0.27-0.58] 0.007*
PPV3 0.32 [0.22-0.44] 0.19 [0.10-0.35] 0.45 [0.30-0.62] 0.04
CDR (per 1000) 19.6 [13.0-29.5] 25.2 [12.3-51.1] 17.8 [10.8-29.1] 0.46
Sensitivity1 (%) 66.7 [49.6-80.3] 77.8 [45.3-93.7] 62.5 [42.7-78.8] 0.68
Sensitivity2 (%) 88.0 [70.0-95.8] 100.0 [64.6-100.0] 83.3 [60.8-94.2] 0.53
Specificity (%) 94.3 [92.8-95.5] 84.8 [80.0-88.6] 97.4 [96.1-98.3] <0.001*
1 The complete regimen consist of a combination of MRI and mammography when available
RR: Recall Rate; BR: Biopsy Rate; PPV1: Positive Predictive Value1; PPV3: Positive Predictive Value3; CDR:
Cancer Detection Rate
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented perfor-
mance measures.
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Table 3.8: Performance measures for mammography and MRI screening in BRCA2
mutation carriers (including untested first degree relatives)
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=1154 N=288 N=866
RR (per 1000) 85.8 [71.0-103.4] 194.4 [152.8-244.0] 49.7 [37.1-66.3] <0.001*
BR (per 1000) 67.6 [54.5-83.6] 138.9 [103.7-183.6] 43.9 [32.2-59.7] <0.001*
PPV1 0.23 [0.16-0.32] 0.13 [0.06-0.24] 0.37 [0.24-0.52] 0.007*
PPV3 0.29 [0.21-0.40] 0.18 [0.09-0.32] 0.42 [0.28-0.58] 0.03
CDR (per 1000) 19.9 [13.3-29.7] 24.3 [11.8-49.3] 18.5 [11.4-29.8] 0.63
Sensitivity1 (%) 69.7 [51.7-82.6] 77.8 [45.3-93.7] 66.7 [46.7-82.0] 0.69
Sensitivity2 (%) 92.0 [75.0-97.8] 100.0 [64.6-100.0] 88.9 [67.1-96.9] 0.99
Specificity (%) 93.2 [91.6-94.5] 82.4 [77.5-86.5] 96.8 [95.4-97.8] <0.001*
Mammography N=1031 N=265 N=766
RR (per 1000) 33.0 [23.7-45.8] 64.2 [40.5-100.4] 22.2 [13.9-35.3] 0.002*
BR (per 1000) 26.2 [18.1-37.8] 41.5 [23.3-72.8] 20.9 [12.9-33.7] 0.12
PPV1 0.32 [0.19-0.49] 0.18 [0.06-0.41] 0.47 [0.26-0.69] 0.14
PPV3 0.41 [0.25-0.59] 0.27 [0.10-0.57] 0.50 [0.28-0.72] 0.43
CDR (per 1000) 10.7 [6.0-19.0] 11.3 [3.8-32.7] 10.4 [5.3-20.4] 0.99
Sensitivity1 (%) 35.5 [21.1-53.1] 33.3 [12.1-64.6] 36.4 [19.7-57.0] 0.99
Sensitvity 2 (%) 44.0 [26.7-62.9] 42.9 [15.8-75.0] 44.4 [24.6-66.3] 0.99
Specificity (%) 97.7 [96.6-98.5] 94.5 [91.0-96.7] 98.8 [97.7-99.4] <0.001*
MRI N=1154 N=288 N=866
RR (per 1000) 77.1 [63.1-93.9] 177.1 [137.3-255.4] 43.9 [32.2-59.7] <0.001*
BR (per 1000) 61.5 [49.0-76.9] 128.5 [94.7-172.1] 39.3 [28.3-54.4] <0.001*
PPV1 0.25 [0.17-0.35] 0.14 [0.07-0.26] 0.39 [0.21-0.55] 0.007*
PPV3 0.31 [0.21-0.42] 0.19 [0.09-0.34] 0.44 [0.29-0.61] 0.04
CDR (per 1000) 19.1 [12.7-28.7] 24.3 [11.8-49.3] 17.3 [10.5-28.4] 0.46
Sensitivity1 (%) 66.7 [49.6-80.3] 77.8 [45.3-93.7] 62.5 [42.7-78.8] 0.68
Sensitivity2 (%) 88.0 [70.0-95.8] 100.0 [64.6-100.0] 83.3 [60.8-94.2] 0.53
Specificity (%) 94.0 [92.5-95.3] 84.2 [79.5-88.0] 97.3 [95.9-98.2] <0.001*
1 The complete regimen consist of a combination of MRI and mammography when available
RR: Recall Rate; BR: Biopsy Rate; PPV1: Positive Predictive Value1; PPV3: Positive Predictive Value3; CDR:
Cancer Detection Rate
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented perfor-
mance measures.
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Table 3.9: Performance measures for mammography and MRI screening in
women with a family history of breast cancer
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=2624 N=613 N=2011
RR (per 1000) 87.3 [76.9-98.9] 189.2 [159.4-223.0] 56.2 [46.7-67.4] <0.001*
BR (per 1000) 55.6 [47.3-65.3] 109.3 [86.3-137.4] 39.3 [30.2-47.1] <0.001
PPV1 0.09 [0.06-0.13] 0.05 [0.02-0.11] 0.12 [0.07-0.20] 0.06
PPV3 0.14 [0.09-0.21] 0.09 [0.04-0.19] 0.18 [0.10-0.28] 0.15
CDR (per 1000) 7.6 [4.8-12.0] 9.8 [4.0-22.3] 7.0 [4.0-12.0] 0.44
Sensitivity1 (%) 90.9 [69.4-98.4] 100.0 [51.7-100.0] 87.5 [60.4-97.8] 0.99
Sensitivity2 (%) 95.2 [74.1-99.8] 100.0 [51.7-100.0] 93.3 [66.0-99.7] 0.99
Specificity (%) 92.0 [90.9-93.0] 81.9 [78.6-84.7] 95.0 [94.0-95.9] <0.001*
Mammography N=1885 N=467 N=1418
RR (per 1000) 47.7 [38.8-58.6] 113.5 [86.9-146.6] 26.1 [18.7-36.2] <0.001*
BR (per 1000) 22.8 [16.8-30.9] 42.8 [27.0-66.5] 16.2 [10.6-24.6] 0.002*
PPV1 0.13 [0.07-0.23] 0.04 [0.01-0.14] 0.27 [0.14-0.44] 0.003*
PPV3 0.28 [0.16-0.44] 0.10 [0.02-0.33] 0.43 [0.24-0.65] 0.02
CDR (per 1000) 6.4 [3.5-11.4] 4.3 [0.7-17.1] 7.1 [3.6-13.4] 0.74
Sensitivity1 (%) 63.2 [38.6-82.8] 50.0 [9.0-90.8] 66.7 [38.7-87.0] 0.60
Sensitvity 2 (%) 66.7 [41.2-85.6] 50.0 [9.2-90.8] 71.4 [42.0-90.4] 0.56
Specificity (%) 95.8 [94.8-96.6] 90.0 [85.8-91.5] 98.1 [97.2-98.7] <0.001*
MRI N=2624 N=613 N=2011
RR (per 1000) 64.0 [55.1-74.2] 128.9 [103.9-158.6] 44.3 [35.9-54.4] <0.001*
BR (per 1000) 49.2 [41.4-58.3] 101.1 [79.0-128.4] 33.3 [26.1-42.4] <0.001*
PPV1 0.10 [0.06-0.15] 0.08 [0.03-0.16] 0.11 [0.06-0.20] 0.45
PPV3 0.12 [0.07-0.20] 0.10 [0.04-0.21] 0.15 [0.08-0.26] 0.43
CDR (per 1000) 6.1 [3.6-10.1] 9.8 [4.0-22.3] 5.0 [2.5-9.5] 0.23
Sensitivity1 (%) 72.7 [49.6-88.4] 100.0 [51.7-100.0] 62.5 [35.9-83.7] 0.13
Sensitivity2 (%) 76.2 [52.5-90.9] 100.0 [51.7-100.0] 66.7 [38.7-87.0] 0.26
Specificity (%) 94.2 [93.2-95.0] 88.0 [85.1-90.3] 96.0 [95.1-96.8] <0.001*
1 The complete regimen consist of a combination of MRI and mammography when available
RR: Recall Rate; BR: Biopsy Rate; PPV1: Positive Predictive Value1; PPV3: Positive Predictive Value3; CDR:
Cancer Detection Rate
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented perfor-
mance measures.
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Table 3.10: Performance measures for mammography and MRI screening in
women with a personal history of breast cancer
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=3011 N=674 N=2337
RR (per 1000) 57.8 [49.8-66.9] 135.0 [110.6-163.7] 35.5 [28.6-44.0] <0.001*
BR (per 1000) 40.5 [33.9-48.3] 90.5 [70.4-115.4] 26.1 [20.2-33.6] <0.001*
PPV1 0.24 [0.18-0.31] 0.14 [0.08-0.24] 0.34 [0.24-0.45] <0.001*
PPV3 0.34 [0.25-0.43] 0.21 [0.12-0.34] 0.46 [0.33-0.59] 0.001*
CDR (per 1000) 13.6 [9.9-18.6] 19.3 [10.8-33.6] 12.0 [8.1-17.5] 0.18
Sensitivity1 (%) 82.0 [68.1-91.0] 81.3 [53.7-95.0] 82.4 [64.8-92.6] 0.99
Sensitivity2 (%) 91.1 [77.9-97.1] 92.9 [64.1-99.6] 90.3 [73.1-97.5] 0.99
Specificity (%) 95.5 [94.7-96.2] 88.1 [85.5-90.4] 97.6 [96.9-98.2] <0.001*
Mammography N=1658 N=458 N=1200
RR (per 1000) 35.6 [27.4-46.0] 78.6 [56.4-108.1] 19.2 [12.5-29.1] <0.001*
BR (per 1000) 25.9 [19.1-35.1] 56.8 [38.1-83.1] 14.2 [8.5-23.1] <0.001*
PPV1 0.24 [0.14-0.37] 0.14 [0.05-0.30] 0.39 [0.20-0.61] 0.03
PPV3 0.33 [0.20-0.49] 0.19 [0.07-0.40] 0.53 [0.29-0.76] 0.04
CDR (per 1000) 8.4 [4.8-14.5] 10.9 [4.0-26.8] 7.5 [3.7-14.7] 0.55
Sensitivity1 (%) 40.0 [24.4-57.8] 45.5 [18.1-75.4] 37.5 [19.6-59.2] 0.72
Sensitvity 2 (%) 46.7 [28.8-65.4] 55.6 [22.7-84.7] 42.9 [22.6-65.6] 0.70
Specificity (%) 97.2 [96.3-97.9] 93.1 [90.4-95.1] 98.8 [98.0-99.3] <0.001*
MRI N=3011 N=674 N=2337
RR (per 1000) 47.2 [40.0-55.5] 108.3 [86.4-134.8] 29.5 [23.2-37.4] <0.001*
BR (per 1000) 34.2 [28.1-41.5] 75.7 [57.4-99.0] 22.3 [16.8-29.3] <0.001*
PPV1 0.26 [0.19-0.34] 0.16 [0.09-0.27] 0.36 [0.25-0.49] 0.008*
PPV3 0.36 [0.27-0.46] 0.24 [0.13-0.38] 0.48 [0.34-0.62] 0.01
CDR (per 1000) 12.3 [8.8-17.1] 17.8 [9.7-31.8] 10.7 [7.1-16.0] 0.16
Sensitivity1 (%) 74.0 [59.4-84.9] 75.0 [47.4-91.7] 73.5 [55.3-86.5] 0.99
Sensitivity2 (%) 82.2 [67.4-91.5] 85.7 [56.2-97.5] 80.7 [61.9-91.9] 0.99
Specificity (%) 96.5 [95.7-97.1] 90.7 [88.3-92.7] 98.1 [97.5-98.6] <0.001*
1 The complete regimen consist of a combination of MRI and mammography when available
RR: Recall Rate; BR: Biopsy Rate; PPV1: Positive Predictive Value1; PPV3: Positive Predictive Value3; CDR:
Cancer Detection Rate
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented perfor-
mance measures.
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Table 3.11: Performance measures for mammography and MRI screening in others
at increased risk
Overall
[95% CI]
First screening
round [95% CI]
Follow-up rounds
[95% CI]
P-value (comparison
first round vs. follow-
up rounds)
Complete regimen1 N=281 N=77 N=204
RR (per 1000) 103.2 [72.8-144.3] 233.8 [153.3-339.6] 53.9 [30.4-93.9] <0.001*
BR (per 1000) 92.5 [36.9-132.1] 220.8 [142.7-325.5] 44.1 [23.4-81.7] <0.001*
PPV1 0.21 [0.10-0.38] 0.22 [0.09-0.45] 0.18 [0.05-0.48] 0.99
PPV3 0.23 [0.11-0.42] 0.24 [0.10-0.47] 0.22 [0.06-0.55] 0.99
CDR (per 1000) 21.4 [9.9-45.9] 51.9 [20.4-126.0] 9.8 [2.7-35.0] 0.05
Sensitivity1 (%) 100.0 [61.0-100.0] 100.0 [51.0-100.0] 100.0 [34.2-100.0] N/A
Sensitivity2 (%) 100.0 [61.0-100.0] 100.0 [51.0-100.0] 100.0 [34.2-100.0] N/A
Specificity (%) 91.6 [87.8-94.4] 80.8 [70.3-88.2] 95.5 [91.7-97.6] <0.001*
Mammography N=119 N=50 N=69
RR (per 1000) 75.6 [40.3-137.5] 140.0 [69.5-261.9] 29.0 [8.0-99.7] 0.03
BR (per 1000) 67.2 [34.4-127.0] 120.0 [56.2-238.0] 29.0 [8.0-99.7] 0.07
PPV1 0.33 [0.12-0.65] 0.29 [0.08-0.64] 0.50 [0.09-0.91] 0.99
PPV3 0.38 [0.14-0.69] 0.33 [0.10-0.70] 0.50 [0.09-0.91] 0.99
CDR (per 1000) 25.2 [8.6-71.5] 40.0 [11.0-134.6] 14.5 [2.6-77.6] 0.57
Sensitivity1 (%) 60.0 [23.1-88.2] 50.0 [15.0-85.0] 100.0 [20.7-100.0] 0.99
Sensitvity 2 (%) 60.0 [23.1-88.2] 50.0 [15.0-85.0] 100.0 [20.7-100.0] 0.99
Specificity (%) 94.7 [89.0-79.6] 89.1 [77.0-95.3] 98.5 [92.1-99.7] 0.04
MRI N=281 N=77 N=204
RR (per 1000) 96.1 [66.9-136.2] 207.8 [132.2-311.2] 53.9 [30.4-93.9] <0.001*
BR (per 1000) 89.0 [61.0-128.1] 207.8 [132.2-311.2] 44.1 [23.4-81.7] <0.001*
PPV1 0.22 [0.11-0.41] 0.25 [0.10-0.50] 0.18 [0.05-0.48] 0.99
PPV3 0.24 [0.12-0.43] 0.25 [0.10-0.50] 0.22 [0.06-0.55] 0.99
CDR (per 1000) 21.4 [9.9-45.9] 51.9 [20.4-126.0] 9.8 [2.7-35.0] 0.05
Sensitivity1 (%) 100.0 [61.0-100.0] 100.0 [51.0-100.0] 100.0 [34.2-100.0] N/A
Sensitivity2 (%) 100.0 [61.0-100.0] 100.0 [51.0-100.0] 100.0 [34.2-100.0] N/A
Specificity (%) 92.4 [88.6-95.0] 83.6 [73.4-90.3] 95.5 [91.7-97.6] 0.003*
1 The complete regimen consist of a combination of MRI and mammography when available
RR: Recall Rate; BR: Biopsy Rate; PPV1: Positive Predictive Value1; PPV3: Positive Predictive Value3; CDR:
Cancer Detection Rate
Sensitivity1: Sensitivity including all cancers
Sensitivity2: Sensitivity excluding cancers detected in prophylactic mastectomies as false negatives
Specificity: Specificity including cancers detected in prophylactic mastectomies as false negatives
The 95% confidence intervals (95% CI) are presented between brackets behind each of the presented perfor-
mance measures.
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Abstract
Introduction Breast MRI is the most sensitive imaging method for breast cancer de-
tection and is therefore offered as a screening technique to women at increased risk
of developing breast cancer. However, mammography is currently still added from
the age of 30 without proven benefits. The purpose of this study is to investigate the
added value of mammography when breast MRI is available.
Materials and Methods This retrospective single-center study evaluated 6553 screen-
ing rounds for 2026 women at increased risk (01/01/2003 - 01/01/2014). Risk cate-
gory (BRCA mutation versus others at increased risk of breast cancer), age at exam,
recall, biopsy, and histopathological diagnosis were recorded. Cancer yield, false
positive recall rate (FPR), and false positive biopsy rate (FPB) were calculated us-
ing Generalized Estimating Equations for age-categories (< 40, 40 - 50, 50 - 60, ≥ 60
years) separately. Numbers of screens needed to detect an additional breast cancer
with mammography (NSN) were calculated for each of the subgroups.
Results Of a total of 125 screen-detected breast cancers, 112 were detected by MRI
and 66 by mammography. 13 cancers were solely detected by mammography, in-
cluding 8 ductal carcinoma in situ-cases, most in women≥ 50 years (77%). In higher
age groups, mammography added more to the FPR. Below 50 years the mean num-
ber of mammographic examinations needed to find an MR-occult cancer was 1427.
Conclusion Mammography is of limited added value when breast MRI is available
for women at increased risk of all ages. While in older women the additional cancer
detection increases, there is also an increase in false positive findings.
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4.1 Introduction
Mammography based screening for breast cancer reduces breast cancer-related mor-
tality in the general female population116. However, in women at increased risk
(e.g. those with a germline mutation in the BRCA1 or BRCA2 genes) biennial mam-
mographic screening is insufficient due to low sensitivity and high rates of interval
cancers14,117–119. Consequently, these women at a higher-than-average lifetime breast
cancer risk (approximately ≥ 20 - 25% lifetime risk (LTR)) are invited to intensified
screening programs11,12, consisting of dynamic contrast-enhanced MRI (DCE-MRI)
and mammography. The sensitivity and specificity of these screening programs have
been reported to be as high as 97% and 98%, respectively14,15,37,39,75,102.
Recent studies question the added value of mammography in this population, es-
pecially in BRCA mutation carriers113. In the study of Kuhl et al.75, MRI proved to be
the most important contributor to stage reduction. Although these results show the
superiority of breast MRI compared to mammography for the detection of cancers,
routine mammography is currently recommended for all women, even at a relatively
young age. Various authors have proposed to cancel mammographic screening in
young women also screened with breast MRI, especially in BRCA1 mutation carri-
ers. In these BRCA1 mutation carriers, the mammographic sensitivity is exceedingly
low, reported as low as 35%120. This is believed to be caused not only by the on
average dense breasts of these women, but also by the mammographic benign-like
features of BRCA1-associated cancers121,122. Berrington de Gonzalez et al. reported
that there is little to no benefit of mammographic screening under the age of 35123.
Additionally, concerns are raised for the risk of radiation-induced cancers in these
women, since an increased radiation susceptibility exists in BRCA mutation carri-
ers123,124.
Although guidelines may vary per country, mammographic screening in BRCA mu-
tation carriers is already advised from an age of 30 years11,12. However, the actual
benefits in terms of tumor detection of the addition of mammography at such a
young age are still unclear. In addition, additional findings on the mammogram
might lead to an increase in false-positive recalls of the screening program.
Hence, there is a clinical need to find an optimal regimen for intensified screening
programs to prevent unnecessary recalls, biopsies, and radiation exposure. The pur-
pose of this study is to evaluate the added value of mammography when breast MRI
is available in terms of cancer detection and false positive rates in a population of
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women at increased risk of developing breast cancer.
4.2 Materials and Methods
This retrospective study was approved by our local institutional review board and
the requirement for informed consent was waived.
Screening program
The increased risk screening program was evaluated for the period 01/01/2003 un-
til 01/01/2014. The program starts at age 25 years for BRCA mutation carriers with
yearly MRI. At the age of 30, a yearly mammography is added. Women with an LTR
of≥ 20 - 25% are from the start screened with mammography and MRI, starting ages
differ by the reason for screening20. Furthermore, women may have been enrolled in
the program at a later point in time, after detection of a specific factor that increases
their personal risk. We previously reported on the overall screening performance in
this cohort125.
Case selection
The local database was searched to identify all screening MRI and mammography
examinations. Women were included when an MRI examination was considered a
screening examination (inquiry at the radiology department was for screening pur-
poses in asymptomatic women). Women were excluded when no mammography
was performed within six months of the screening MRI. Risk category, age, screen-
ing tests performed, eventual recall for workup of screen-detected abnormalities and
histopathological diagnosis were recorded when available.
Image Acquisition
MRI acquisitions and protocols varied over time and were reported in detail in a pre-
vious report105. In short: examinations were performed on either a 1.5 or 3.0 Tesla
Siemens scanner (Magnetom Avanto, Magnetom Sonata, Magnetom symphony or
Magnetom Trio) using a dedicated bilateral breast coil. Patients were imaged in
prone position. A transverse or coronal three-dimensional T1-weighted gradient-
echo dynamic sequence was performed before contrast agent administration fol-
lowed by 4 or 5 post-contrast sequences. Various gadolinium chelates were used
as a contrast agent, administered at a dose of 0.1 mmol/kg or 0.2 mmol/kg using
a power injector (Medrad, Warrendale, PA) at a flow rate of 2.5 mL/s, followed by
a saline flush. Premenopausal women were scheduled in the 6 - 12th day of their
menstrual cycle.
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Mammograms were obtained in two directions (medio-lateral oblique and cranio-
caudal) with a full field digital mammography machine (GE Senograph 2000 or GE
Senograph DS, GE, Fairfield, Connecticut, USA). Additional views and spot com-
pression views were performed at the request of the evaluating radiologist.
Image Interpretation
The Breast Imaging Reporting and Data system (BI-RADS)19,126 was used for evalu-
ation. All exams were evaluated by one of eight breast radiologists with experience
ranging from 0.5 - 23 years after certification. Reporting was done using a dedicated
breast MRI workstation (versions of DynaCAD, Invivo, Philips, Best, the Nether-
lands). Mammograms were evaluated together with MRI examinations when these
examinations were acquired the same day. In general, biopsies were performed for
lesions classified as BI-RADS 4 and 5, and a subset of lesions classified as BI-RADS
3. The remainder of BI-RADS 3 lesions underwent short-term follow-up.
Ground truth
For BI-RADS 3 lesions with short-term follow-up recommendation, at least one year
of clinical follow-up was required to confirm benignity. A cross-computer search of
our pathology records was performed to identify all performed biopsies. We subse-
quently analyzed if the biopsy was triggered by screening findings or whether the
woman presented with symptoms. To ensure detection of all cancers, the database
was also linked to the nationwide population-based Netherlands Cancer Registry
(NCR).
Data-analysis
Pathology results were grouped into malignant (in situ, invasive and metastatic can-
cer) and benign lesions (all other findings). Only screen-detected cancers were in-
vestigated, which were defined as cancers diagnosed after diagnostic workup initi-
ated by screening findings. We separated screen-detected cancers by mammography,
MRI, or both based on radiological reports of the respective modalities (or report sec-
tions when mammogram and MRI were reported simultaneously).
Cancer yield, false positive recall rate (FPR) and false positive biopsy rate (FPB) for
mammography, MRI, and the combination were calculated. Cancer yield was de-
fined as the number of screen-detected cancers per 1000 screening rounds. An FPR
or FPB was defined as a recalled/biopsied woman who was considered disease-free
after work-up and/or after at least one year of clinical follow-up. The FPR/ FPB
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were defined as the number of FPRs/FPBs per 1000 screening rounds.
Two risk categories were evaluated (BRCA mutation carriers, and all others). The
BRCA mutation carriers group also included first-degree, untested relatives. Exami-
nations were grouped into four age categories to investigate the influence of age (<
40, 40 - 50, 50 - 60, ≥ 60 years).
Statistical analysis
Descriptive statistics were extracted. χ2 tests were applied to compare differences
between groups in proportion of ductal carcinoma in situ (DCIS) and tumor grade.
To investigate the distribution of parameters over age categories χ2 trend-tests were
performed. Repeated screening results were summarized to form binomial counts
for each woman to estimate cancer yield, FPR, and FPB. For each woman, the number
of true positive and true negative screens per modality, and the number of screening
visits with or without breast cancer detected were counted. In this way, binomial
counts per modality were calculated and analyzed. As the dependent variable was
assumed to follow a binomial distribution, Generalized Estimating Equations (GEE)
was applied. The binomial proportions were modeled and conducted separately for
cancer yield, FPR, and FPB, using a compound symmetry correlation structure. The
analysis was conducted separately for each age category, modality, and risk category.
After applying Bonferroni correction, a two-sided P-value of 0.013 was considered
statistically significant. The number of mammography screens needed (NSN) to de-
tect one breast cancer that was missed by MRI was calculated by dividing the num-
ber of mammography screens performed by the number of breast cancers detected
by mammography alone. All statistics were performed by SPSS (version 22, SPSS
Inc., Chicago, IL).
4.3 Results
Study population
Final analysis included 2026 women with 6553 screening rounds (see Table 4.1). 125
screen-detected cancers were identified of which 13 and 59 were only detected by
mammography or MRI, respectively (P < 0.001). In total, 112 cancers were seen on
MRI and 66 on mammography. Overall, no significant difference was found between
tumor grade of cancers detected by mammography or MRI (P = 0.193). Mammogra-
phy detected a significantly higher proportion of pure DCIS (16/66 (24%) and 15/112
(13%) for mammography or MRI, respectively, P < 0.001). We did not observe a dif-
ference in grade of DCIS detected with mammography or MRI (P = 0.436).
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Mammography detected breast cancers
The majority of cancers detected only with mammography consisted of pure DCIS
(pTis) (8/13, 62%, see Table 4.2). Most women who were diagnosed with pure DCIS
were ≥ 50 years of age (6/8, 75%, see Table 4.2). The remaining five women with
Table 4.1: Population and breast cancer characteristics in the cohort
<40 years 40 - 50 years 50 - 60 years ≥ 60 years Overall P-value∗
Women (N)
- BRCA
- Others
- Overall
388
329
717
258
504
762
182
482
664
75
273
348
903
1588
2491
<0.001
0.014
<0.001
Exams (N)
- BRCA
- Others
- Overall
1113
716
1829
737
1313
2050
568
1265
1833
190
651
841
2608
3945
6553
<0.001
0.046
<0.001
BC (N)
- Mammography
- Mammography only
- MRI
- MRI only
- Overall
13
1
25
13
26
13
2
30
19
32
25
8
37
20
45
15
2
20
7
22
66
13
112
59
125
0.253
0.202
0.697
0.254
0.963
Invasive tumor (N)
- Mammography
- Mammography only
- MRI
- MRI only
- Overall
13
1
24
12
25
9
0
25
16
25
16
4
30
18
34
12
0
18
6
18
50
5
97
52
102
0.771
0.822
0.496
0.253
0.540
DCIS (N)
- Mammography
- Mammography only
- MRI
- MRI only
- Overall
0
0
1
1
1
4
2
5
3
7
9
5
7
2
11
3
1
2
1
4
16
8
15
7
23
0.073
0.281
0.036
0.848
0.164
Tumor grade of
all cancers (N)
Grade 1
- Mammography
- Mammography only
- MRI
- MRI only
Grade 2
- Mammography
- Mammography only
- MRI
- MRI only
Grade 3
- Mammography
- Mammography only
- MRI
- MRI only
Missing
1
0
3
2
1
0
3
2
11
1
17
7
2
1
0
4
3
5
1
10
6
7
1
15
9
1
4
1
5
2
7
2
17
12
11
2
15
6
3
1
0
5
4
4
1
6
3
6
1
5
0
4
7
1
17
11
17
4
36
23
35
5
52
22
10
0.536
0.655
0.384
0.442
0.171
0.317
0.170
0.335
0.339
0.822
0.010
0.009
0.197
FPR (N)
- Mammography
- Mammography only
- MRI
- MRI only
- Overall
63
22
159
118
181
75
38
143
106
181
55
28
72
45
100
22
15
25
18
40
215
103
399
287
502
<0.001
0.115
<0.001
<0.001
<0.001
FPB (N)
- Mammography
- Mammography only
- MRI
- MRI only
- Overall
35
6
114
85
120
46
15
113
82
128
32
11
51
30
62
9
3
18
12
21
122
35
296
209
331
<0.001
0.258
<0.001
<0.001
<0.001
BC = breast cancer (invasive cancer and ductal carcinoma in situ (DCIS)); FPR = false positive recall; FPB = false
positive biopsy
* χ2 test for trend was performed for the fraction of the overall population
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an invasive cancer detected only at mammography were aged 35, 53, 54, 55 and 56.
All pure mammography-detected breast cancers were detected in follow-up rounds.
The NSN for the overall population and the defined subgroups are presented in Ta-
ble 4.3. There was no cancer that was not reported by MRI in the first rounds of
screening, making an estimate of NSN not applicable. Our results show that the
NSN was highest in the lowest age categories. Whether a difference exists between
women with a proven BRCA mutation and women without is difficult to make, since
we did not observe only mammographically detected breast cancers in BRCA muta-
tion carriers under 50 years of age.
Cancer yield
Cancer yield increased over time, with a peak at the 50 - 60 age category (see Figure
4.1). The difference between cancers detected by MRI and the combination (mam-
mography + MRI) seemed to increase with age (< 40 years: 0.47, 40 - 50 years: 0.93,
50 - 60 years: 4.26, ≥ 60 years: 2.93 per 1000 examinations), pointing to a possible
increased added value of mammography in higher age categories (see Figure 4.2),
which was the strongest in the 50 - 60 years categories for both BRCA mutation carri-
ers and others. The increase in breast cancer yield by the addition of mammography
was not significant in all risk categories (P ≥ 0.303). Tables 4.4 - 4.6 summarize can-
cer yield, FPR, and FPB.
False positives
For FPRs, mammography added 103 FPRs on top of 112 FPRs based on both mam-
mography and MRI, and 287 FPRs based on MRI alone. Overall, mammography sig-
nificantly added to the FPRs (P = 0.001), especially in the group of women without
a BRCA mutation (P = 0.001). The relative increase of the FPR due to mammogra-
phy was higher in higher age-groups (< 40 years: 14%, 40 - 50 years: 27%, 50 - 60
years: 44%, ≥ 60 years: 61%, see Figure 4.2). This was significant in women without
a BRCA mutation (P < 0.001). In total 35 FPBs were performed based on mammog-
raphy alone. This did not lead to a significant increase in the overall FPBs (P = 0.013),
or in any of the subcategories (P ≥ 0.323).
Completely omitting mammography from the screening regimen would have led
to a reduction of 21% (103/502) of FPRs and 11% (35/331) of FPBs.
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4.4 Discussion
This study evaluated the added value of mammography on top of MRI in a multi-
modal imaging screening program for women who are at intermediate or high risk
of developing breast cancer in a single academic institute. The addition of mammog-
raphy translated mostly to the detection of a small number of DCIS cases that were
occult on MRI. However, five additional invasive carcinomas were also detected.
The number of mammography screening exams needed to detect an MRI occult can-
cer depended on age and was very high in women under 40. In addition, adding
mammography led to a slight increase in false-positive recalls and biopsies.
Screening, with the aim of early detection of (pre-) malignant breast lesions to de-
crease breast cancer-related mortality, is a well-accepted risk-reducing strategy for
most women at increased risk of developing breast cancer127. MRI is considered the
most accurate imaging modality15,32,41,75. Mammography is currently added to most
screening regimens that include MRI to detect calcified breast lesions that may be
visualized with mammography but not with MRI128,129. In our study, eight out of 13
cancers (62%) were MRI occult ductal in situ cancers that were detected based on mi-
crocalcifications on the mammogram. The five invasive cancers that were detected
only with mammography, were also found because of microcalcifications. By mam-
mography alone, only 1 invasive cancer was detected in a BRCA mutation carrier,
at the age of 56. Our results are in line with the meta-analysis of Heijnsdijk et al.130,
who reported only one invasive cancer detected by mammography alone in BRCA1
mutation carriers across 4 breast cancer screening trials of women at high risk for de-
veloping breast cancer. Obdeijn et al.113 also reported little benefit of mammography
screening in younger women with a BRCA1 mutation. In their study, omitting mam-
mography from the screening regimen would have led to two missed DCIS cases
in women aged 50 and 67. Obdeijn et al. suggested to increase the starting age for
mammography screening in women with BRCA1 mutations to 40 years.
Our results suggest that the detection of MRI occult breast cancers is very rare in
all women younger than 40 years. Ten out of 13 MRI occult cancers (both DCIS
and invasive cancers) were observed in women ≥ 50 years in our population, which
is in line with the results reported by Narayan et al.131. In our study, raising the
starting age of mammography to 40 years would have led to missing one invasive
ductal cancer in a woman with a positive family history of breast cancer but without
a known BRCA mutation and no DCIS cases would have been missed. In retrospect,
this invasive cancer was visible on the MRI and was therefore not truly occult accord-
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ing to Gubern-Merida et al.132. Additionally, while in older women the additional
detection of breast cancer increases with the addition of mammography, this is coun-
terbalanced by an increase in false positive findings. These results are supported by
the data of Phi and coworkers111.
Other imaging modalities may be used to detect additional cancers on top of MRI.
Unfortunately, handheld ultrasound or even automated breast ultrasound has been
shown to be of limited value in a screening setting where MRI is available15,32,75,102,133.
Digital breast tomosynthesis (DBT) has also been shown to increase the cancer detec-
tion rate and decrease the number of FPRs when compared to mammography alone
in women at average risk25,134. However, there is no consensus on the added value
of DBT when breast MRI is available135. Therefore, current guidelines only include
mammography. The gain in sensitivity with mammography seems to come mostly
from the detection of lesions presenting with calcifications. DBT appears to be of rel-
atively equal value to mammography for this purpose, but at a higher dose27,30. Since
younger women at high risk and in particular BRCA mutation carriers have been
shown to be more susceptible to develop radiation-induced cancers123,124, replacing
mammography with DBT might not be beneficial for women screened with MRI.
Berrington de Gonzalez et al.123 reported no net benefit of mammography surveil-
lance before the age of 35 years in women with a BRCA mutation and recommended
to limit the radiation dose by raising the age of mammography. Our results indicate
that raising the age limit of supplemental mammography screening to the age of 40
years should be considered, not only for BRCA germline mutation carriers, but for
all women at increased risk of developing breast cancer.
A further reason for this recommendation is that population-based mammography
screening programs have been criticized because of overdiagnosis and overtreat-
ment of non-fatal breast disease detected during screening136. Overdiagnosis, de-
fined as the detection of a breast cancer at screening that would have never been
identified clinically in the lifetime of the woman, has been reported between 1 -
10%137. Our results suggest that adding mammography screening to breast MRI may
contribute to overdiagnosis because of the preferential detection of relatively indo-
lent (pre-) malignant subtypes such as low grade calcified ductal in situ carcinoma
as described in a previous study125. These cancers might be biologically irrelevant
compared to invasive and in situ cancers detected with MRI that tend to be of higher
grade and are usually detected at an earlier stage75,135. However, this is not evident
from our data.
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Our study has some limitations. It is a single center study in a tertiary referral center
with a large high-risk screening program that might not be fully generalizable to the
whole breast imaging community. In addition, due to the retrospective nature of the
study, some of the exams of MRI and mammography were evaluated simultaneously
which might affect the screening outcomes either positively or negatively. While the
study describes a long time span the absolute number of cancers detected is still low,
and more studies are required to confirm our findings.
In conclusion, mammography does not significantly add to cancer yield for all ages.
Especially in younger women the added value is very limited and the number of
mammography screens needed is very high. In higher age groups mammography
does add to the detection rates, but also leads to an increase in FPR and FPB.
Figure 4.1: Cancer yield in women with a BRCA mutation versus all others (family,
personal, and others). With the tag combination is meant the combination of mam-
mography + MRI
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Table 4.3: Number of screens needed (NSN) for one additional mammography-only
detected cancer
Age group
(years)
Number of
breast cancers
Number of
screens
Breast cancers
detected by
mammography
only
NSN for
mammography
to detect breast
cancer missed
by MRI
Overall <40 years 26 1829 1 1829
40-50 years 32 2050 2 1025
50-60 years 45 1833 8 229
≥60 years 22 841 2 421
BRCA <40 years 17 1113 0 N/A
40-50 years 14 737 0 N/A
50-60 years 26 568 3 189
≥60 years 4 190 0 N/A
No BRCA <40 years 9 716 1 716
40-50 years 18 1313 2 657
50-60 years 19 1265 5 253
≥60 years 18 651 2 326
Follow up <40 years 17 1112 1 1112
40-50 years 20 1447 2 724
50-60 years 28 1342 8 168
≥60 years 11 626 2 313
BRCA <40 years 12 725 0 N/A
40-50 years 9 554 0 N/A
50-60 years 18 433 3 144
≥60 years 0 152 0 N/A
No BRCA <40 years 5 387 1 387
40-50 years 11 893 2 447
50-60 years 10 909 5 182
≥60 years 11 474 2 237
N/A: not applicable, first round was not shown in the table since no mammography-only
cancers were detected in first round
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Table 4.4: Cancer yield, FPR and FPB results for mammography
Mammography
Age
category
Risk
category
Cancer yield* (95% CI) FPR* (95% CI) FPB* (95% CI)
<40
years
Overall 6.54 (3.73-11.46) 36.06 (27.57-47.03) 19.48 (13.73-27.58)
BRCA 7.17 (3.61-14.18) 26.96 (18.07-40.03) 15.52 (9.03-26.57)
no BRCA 5.61 (2.10-14.89) 49.62 (34.62-70.64) 24.94 (15.94-38.83)
40-50
years
Overall 6.35 (3.71-10.83) 40.44 (31.53-51.72) 24.23 (17.66-33.16)
BRCA 6.78 (2.85-16.02) 18.90 (11.26-31.56) 12.21 (6.37-23.30)
no BRCA 6.11 (3.08-12.06) 52.66 (39.80-69.38) 30.56 (21.36-43.55)
50-60
years
Overall 13.57 (9.21-19.94) 33.28 (24.94-44.29) 18.38 (12.60-26.75)
BRCA 26.10 (15.93-42.47) 10.56 (4.75-23.31) 8.85 (3.67-21.15)
no BRCA 7.89 (4.26-14.58) 43.06 (31.68-58.27) 22.16 (14.61-33.47)
≥60
years
Overall 17.72 (10.81-28.93) 25.82 (16.76-39.58) 10.88 (5.64-20.90)
BRCA 21.48 (7.99-56.49) 10.69 (2.64-42.22) 0.00 (N/A)
no BRCA 16.90 (9.54-29.77) 30.38 (19.27-47.57) 14.14 (7.31-27.15)
Overall
Overall 9.95 (7.80-12.69) 36.42 (31.42-42.19) 20.05 (16.49-24.37)
BRCA 12.44 (8.75-17.65) 20.65 (15.32-27.77) 12.56 (8.50-18.51)
no BRCA 8.33 (5.95-11.65) 47.08 (39.74-55.71) 24.95 (19.91-31.24)
* GEE used to calculate performance measures; correcting for multiple screening rounds
within the same patient. All measurements are per 1000 exams; 95% CI: Wald 95%
confidence intervals.
N/A: no cancers, recalls, or biopsies were found in this category and no 95% CI of this
measure could be calculated.
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Table 4.5: Cancer yield, FPR and FPB results for MRI
MRI
Age
category
Risk
category
Cancer yield* (95% CI) FPR* (95% CI) FPB* (95% CI)
<40
years
Overall 13.09 (8.80-19.44) 87.25 (74.68-101.71) 62.30 (51.89-74.63)
BRCA 14.31 (8.81-23.16) 75.49 (60.59-93.70) 56.72 (44.03-72.79)
no BRCA 11.22 (5.61-22.31) 104.96 (84.38-129.84) 70.70 (54.44-91.35)
40-50
years
Overall 14.06 (9.83-20.07) 70.45 (59.44-83.31) 55.95 (46.39-67.33)
BRCA 18.86 (11.26-31.42) 47.03 (34.06-64.61) 34.73 (23.93-50.15)
no BRCA 11.37 (6.91-18.66) 82.49 (67.63-100.27) 67.55 (54.44-83.53)
50-60
years
Overall 19.56 (14.16-26.96) 41.64 (32.53-53.16) 29.88 (22.29-39.94)
BRCA 40.37 (27.00-59.96) 44.36 (29.42-66.36) 30.66 (18.27-51.02)
no BRCA 10.25 (5.97-17.55) 40.08 (29.42-54.38) 29.41 (20.59-41.84)
≥60
years
Overall 23.56 (15.39-35.93) 29.04 (19.45-43.15) 20.49 (12.72-32.85)
BRCA 21.48 (7.99-56.49) 10.85 (2.66-43.12) 10.85 (2.66-43.12)
no BRCA 24.40 (15.23-38.87) 34.37 (22.63-51.89) 23.31 (14.04-38.45)
Overall
Overall 16.64 (13.81-20.04) 62.52 (56.37-69.29) 46.27 (41.11-52.06)
BRCA 22.08 (17.03-28.60) 56.98 (48.07-67.42) 41.81 (34.35-50.80)
no BRCA 13.10 (10.02-17.10) 66.13 (58.03-75.27) 49.21 (42.42-57.03)
* GEE used to calculate performance measures; correcting for multiple screening rounds
within the same patient. All measurements are per 1000 exams; 95% CI: Wald 95% confi-
dence intervals.
N/A: no cancers, recalls, or biopsies were found in this category and no 95% CI of this
measure could be calculated.
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Table 4.6: Cancer yield, FPR and FPB results for the combination
Combination
Age
category
Risk
category
Cancer yield* (95% CI) FPR* (95% CI) FPB* (95% CI)
<40
years
Overall 13.56 (9.24-20.10) 99.78 (86.35-115.04) 65.68 (54.96-78.31)
BRCA 14.31 (8.81-23.16) 85.01 (69.45-103.66) 60.34 (47.29-76.70)
no BRCA 12.65 (6.58-24.21) 121.64 (99.00-148.59) 73.85 (56.96-95.26)
40-50
years
Overall 15.02 (10.64-21.17) 89.74 (77.29-103.98) 63.26 (53.13-75.18)
BRCA 18.86 (11.26-31.42) 57.42 (42.61-76.97) 42.39 (29.86-59.85)
no BRCA 12.89 (8.10-20.48) 107.19 (90.27-126.84) 74.68 (61.11-90.97)
50-60
years
Overall 23.82 (17.82-31.76) 60.11 (48.79-73.85) 36.58 (28.05-47.59)
BRCA 45.29 (31.14-65.43) 47.62 (32.20-69.90) 33.91 (20.91-54.54)
no BRCA 14.16 (8.97-22.29) 65.53 (51.26-83.42) 37.51 (27.28-51.37)
≥60
years
Overall 26.49 (17.31-40.36) 46.86 (34.05-64.17) 24.16 (15.57-37.33)
BRCA 21.48 (7.99-56.49) 22.05 (8.12-58.46) 10.85 (2.66-43.12)
no BRCA 27.87 (17.39-44.38) 54.21 (38.71-75.43) 28.06 (17.67-44.30)
Overall
Overall 18.68 (15.65-22.27) 79.65 (72.70-87.21) 51.73 (46.28-57.78)
BRCA 23.17 (18.00-29.79) 65.59 (56.09-76.55) 46.14 (38.31-55.47)
no BRCA 15.74 (12.28-20.15) 89.14 (79.65-99.64) 55.39 (48.20-63.57)
* GEE used to calculate performance measures; correcting for multiple screening rounds
within the same patient. All measurements are per 1000 exams; 95% CI: Wald 95% confi-
dence intervals.
N/A: no cancers, recalls, or biopsies were found in this category and no 95% CI of this
measure could be calculated.
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(a) False positives for recall
(b) False positives for biopsy
Figure 4.2: False positive rates for women with a BRCA mutation versus all others
(family, personal, and others). With the tag combination is meant the combination of
mammography + MRI
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Abstract
Purpose To evaluate the frequency of missed cancers on breast MRI in women par-
ticipating in a high-risk screening program.
Methods Patient-files from women who participated in an increased risk mammog-
raphy and MRI screening program (2003 - 2014) were coupled to the Dutch National
Cancer Registry. For each cancer detected, we determined whether an MRI scan was
available (0 - 24 months before cancer detection), which was reported to be negative.
These negative MRI scans were in consensus re-evaluated by two dedicated breast
radiologists, with knowledge of the cancer location. Cancers were scored as invisi-
ble, minimal sign, or visible. Additionally, BI-RADS scores, background parenchy-
mal enhancement, and image quality (IQ; perfect, sufficient, bad) were determined.
Results were stratified by detection mode (mammography, MRI, interval cancers, or
cancers in prophylactic mastectomies), and patient characteristics (presence of BRCA
mutation, age, menopausal state).
Results Negative prior MRI scans were available for 131 breast cancers. Overall, 31%
of cancers were visible at the initially negative MRI scan and 34% of cancers showed
a minimal sign. Presence of a BRCA mutation strongly reduced the likelihood of
visible findings in the last negative MRI (19 vs 46%, P < 0.001). Less than perfect IQ
increased the likelihood of visible findings and minimal signs in the negative MRI (P
= 0.021).
Conclusion This study shows that almost one-third of cancers detected in a high-risk
screening program is already visible at the last negative MRI scan, and even more in
women without BRCA mutations. Regular auditing and double reading for breast
MRI screening are warranted.
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5.1 Introduction
Breast Magnetic Resonance Imaging (MRI) is recognized as the most sensitive imag-
ing method for the early detection of breast cancer15. Therefore, women at a life-
time risk for breast cancer development of ≥ 20% are invited for intensified screen-
ing programs including both mammography and breast MRI. Recent prospective
studies have reported a sensitivity of MRI of around 90% using these screening set-
tings15,41,75,102,138.
Studies investigating the performance of mammography screening programs have
consistently shown that between 31% and 50% of cancers detected in follow-up
could have been detected at an earlier screening round139–142. This is one reason
for the implementation of double reading in mammography screening143,144. Fur-
thermore, the frequency of these errors in mammography screening is nowadays
regularly audited.
Although recently auditing guidelines for breast MRI screening were published by
the American College of Radiology19, these do not include the evaluation of prior
screening rounds in women who present with breast cancer. A few studies that
focused on reasons and features of missed cancers in MRI screening showed that
between 47% and 56% of cancers could have been detected at an earlier MRI ex-
amination145,146. However, to our knowledge, no studies report on the visibility of
interval cancers, tumors detected on mammography or tumors in prophylactic mas-
tectomy specimen in prior MRI scans.
Therefore, the purpose is to evaluate the frequency of visible breast cancers detected
in women participating in a high-risk screening program, that were missed on a
prior MRI scan (screen-detected, interval, and cancers in prophylactic mastectomy
specimen), and to assess patient and imaging factors contributing to non-detection.
5.2 Materials and Methods
Ethics
The local institutional review board approved this study and the requirement for in-
formed consent was waived.
Breast cancer screening in women at intermediate to high risk for breast cancer
The breast cancer screening program for women at high or intermediate risk (≥ 20 -
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25% lifetime risk) at our institution consists of annual breast MRI and mammogra-
phy, usually at the same day, although some women opt for having the examinations
6 months apart. In women with germ-line BRCA mutations screening starts from the
age of 25 years, and the first 5 years no mammography is performed. In other women
at increased risk for breast cancer, screening starts from the age of 35 or 45.
All women underwent contrast-enhanced breast MRI in prone position using a ded-
icated breast coil on a 1.5T or 3T MRI scanner (Siemens, Erlangen, Germany). Con-
trast (Gd-DOTA, Guerbet, France) was administered through an iv-canula in the cu-
bital vein at a dose of 0.1 mmol/kg using a power injector (Warrendale, Medrad, PA).
Acquisition parameters changed over time, and are reported in detail elsewhere105.
All MRI scans contained a 3D T1-weighted sequence that was performed before and
4 to 5 times after contrast administration. Clinical reporting was done by one of
8 board certified breast radiologists with between 6 months and 23 years of experi-
ence in breast MRI using a dedicated breast MRI workstation (versions of DynaCAD,
Philips, Best, the Netherlands), that automatically yields subtraction images, maxi-
mum intensity projections (MIPs), and enhancement curves. All mammograms were
obtained on full-field digital mammography machines (Senograph DS, Senograph
2000, GE, USA) by dedicated mammography technicians. Mammography was al-
ways performed in 2 planes (medio-lateral oblique and cranio-caudal), with optional
further acquisitions. Clinical reporting using dedicated mammography monitors
was done by the radiologists who also reported the MRI scan.
Case selection
All screening breast MRI and mammography exams performed from 01/01/2003 to
01/01/2014 were identified by a cross-computer search. This yielded 9571 screening
MRI studies and 6553 mammograms obtained in 2773 women. This database was
linked to the nationwide population-based Netherlands Cancer Registry. In our co-
hort, 164 women presented with a total of 179 cancers. For these women, we noted
age, menopausal status, and the reason for intensified screening: BRCA1, BRCA2,
family history of breast cancer, personal history of breast cancer, or other (includ-
ing germline PTEN mutation, previous radiation to the chest, hormone replacement
therapy, and lobular carcinoma in situ in an earlier biopsy).
Cancers (invasive cancers or ductal carcinoma in situ (DCIS)) were subsequently
categorized into MRI-detected, mammography-detected, interval cancers, and can-
cers detected in prophylactic mastectomy specimen (further referred to as incidental
cancers). For each of these categories, we obtained the images acquired at the time of
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tumor detection and the last MRI reported to be negative. The time between cancer
diagnosis and the last negative MRI scan was recorded. When no prior negative MRI
was available, the case was excluded (N = 48).
MRI-detected cancers
Cancers were considered MRI-detected when they were screen-detected and men-
tioned in the MRI-report at the time of diagnosis (hereafter called the current MRI).
The most recent breast MRI scan reported to be negative between 6 and 24 months
before cancer diagnosis was selected for re-evaluation.
Mammography-detected cancers
Cancers were considered mammography-detected when they were screen-detected
and described in the mammography-report, but the MRI-report was negative. In this
case, the MRI performed within the same screening round as the mammogram was
re-evaluated, and therefore the time between detection and the last negative MRI
scan is negligible.
Interval cancers
Interval cancers were defined as cancers that were detected in between screening
rounds due to symptoms. The last MRI prior to the cancer detection was selected.
Incidental cancers
Incidental cancers were defined as cancers detected in prophylactic mastectomy spec-
imens with negative prior imaging. We selected the last MRI scan prior to the pro-
phylactic mastectomy for assessment.
Retrospective MRI interpretation
The last negative breast MR-images were re-evaluated in consensus by two breast
radiologists with respectively 8 and 12 years of experience in breast MRI. Readers
were informed of the cancer location on the positive MRI and/or the histopathology
results. In the case of mammography detected cancers, the location described in the
mammography-report and histopathology results were given.
The review was performed on an in-house developed dedicated breast MRI worksta-
tion147. The workstation performed motion correction148, and showed T1-weighted
images, subtraction images and MIPs for all time-points. The average contrast en-
hancement versus time curve was shown for the pointer location. For the MRI-
detected cases, the current MRI was displayed alongside the prior MRI.
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The readers, in consensus, scored whether the cancer was either invisible, if there
was a minimal sign, or the cancer was visible in the last negative MRI in analogy
to the Dutch auditing practice for mammography screening140. When the MRI was
truly negative, the cancer was rated as invisible. Minimal signs were visible lesions
at the site of the later detected cancer that, according to the consensus reading, would
not likely be recalled in screening practice. Visible lesions were lesions that were
present at the site of the later detected cancer and should have been recalled accord-
ing to the consensus reading. All lesions in the current MRI, as well as all lesions
visible or showing a minimal sign in the prior MRI, were assessed according to the
Breast Imaging Reporting and Data (BI-RADS) MR-lexicon and BI-RADS scores were
given accordingly19,149.
For each MRI scan, background parenchymal enhancement (BPE) was scored as min-
imal, mild, moderate, or marked. In addition, image quality (IQ) was subjectively
scored as perfect, sufficient, or bad.
Performance measures
We first assessed the frequency of visible findings and minimal signs in the negative
MRI scans, overall and in the subgroups (MRI-detected, mammography-detected,
interval cancers, and incidental cancers). Subsequently, we investigated whether pa-
tient factors (age at cancer detection, menopausal state, the presence of a BRCA mu-
tation) and imaging factors (field strength of MRI scanner, BPE, reported IQ) were
related to the likelihood of missed lesions in prior breast MRI scans. For statistical
analysis, we used Pearson’s χ2 tests for categorical variables and one-way ANOVA
for continuous variables. The Tukey post-hoc test was used to compare the differ-
ences between the groups in case of continuous variables. To assess correlations,
Spearman’s rho was computed for ordinal values and when data were not normally
distributed (time between scan and cancer detection). A two-sided P-value of≤ 0.05
was considered statistically significant. All statistics were performed in SPSS (v22,
SPSS Inc., Chicago, IL).
5.3 Results
Between 01/01/2003 and 01/01/2014, 131 breast cancers were detected in women
participating in the intermediate and high-risk screening program, for whom a prior
(or in case of mammography-detected cancers current) negative MRI scan was avail-
able (see Table 5.1). Of these cancers, 76 were MRI-detected, 13 mammography-
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detected, 16 were interval cancers, and 26 were incidental cancers.
In the 131 re-evaluated MRI scans, lesions were considered invisible in 45 cases
(34%). A minimal sign was present in 45 cases (34%) and lesions were visible in
41 cases (31%). Figure 8.1 presents examples of lesions in the three visibility cate-
Table 5.1: Time to negative MRI and time to cancer diagnosis (in months), stratified
by detection mode and BI-RADS scores of prior MRI scans
MRI-detect MG-detect Interval1 Incidental2 Overall
N (%) 76 (58) 13 (10) 16 (12) 26 (20) 131
Mean patient age
in years (sd)
49.5 (11.2) 53.4 (8.3) 41.3 (9.1) 42.5 (10.6) 47.5 (11.2)
Time to last negative
MRI in months (sd)
11.5 (3.0) 1.2 (3.4) 8.6 (3.1) 2.8 (3.1) 9.5 (4.5)
Histology
IDC 49 (70) 2 (3) 15 (21) 4 (6) 70
ILC 4 (67) 0 (0) 1 (17) 1 (17) 6
DCIS 13 (33) 8 (21) 0 (0) 18 (46) 39
Mixed IDC & ILC 7 (78) 0 (0) 0 (0) 2 (22) 9
Other 3 (43) 3 (43) 0 (0) 1 (14) 7
Tumor stage at
detection
pTis 13 (33) 8 (21) 0 (0) 18 (46) 39
pT1mic 0 (0) 0 (0) 0 (0) 1 (100) 1
pT1a/b/c 7/22/18 (72) 3/1/0 (6) 0/1/7 (12) 2/3/1 (9) 12/27/26
pT2 12 (71) 1 (6) 3 (18) 1 (6) 17
pT3 1 (100) 0 (0) 0 (0) 0 (0) 1
pT4D 1 (100) 0 (0) 0 (0) 0 (0) 1
Recurrence 1 (33) 0 (0) 2 (67) 0 (0) 3
Unknown 1 (25) 0 (0) 3 (75) 0 (0) 4
Nodal status at
detection
pN0 52 (60) 11 (13) 7 (8) 17 (20) 87
pN+ 16 (67) 1 (4) 5 (21) 1 (8) 24
Unknown 8 (40) 1 (1) 4 (20) 7 (35) 20
Visibility on prior
Invisible 21 (47) 6 (13) 8 (18) 10 (22) 45
Minimal sign 31 (69) 4 (9) 3 (7) 7 (16) 45
Visible 24 (59) 3 (7) 5 (12) 9 (22) 41
1 Interval cancers were defined as cancers detected in between screening rounds
2 Incidental cancers were defined as cancers detected in prophylactic mastectomy specimens
In between parenthesis the percentage of lesions in the specified category is given, except
when indicated otherwise.
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gories. Of all visible lesions, 2 (5%) were re-evaluated as BI-RADS 3, 35 (85%) as
BI-RADS 4, and 4 (10%) as BI-RADS 5. Lesions that showed a minimal sign were
scored as BI-RADS 2 in 22 cases (49%), and BI-RADS 3 in 23 cases (51%). Overall, 64
cases (49%) of prior negative MRI scans were scored as BI-RADS 3 or higher.
Table 5.2 shows the distribution of these findings in each subgroup. We did not
observe a significant difference based upon the mode of cancer detection (P = 0.447).
However, the frequency of visible findings in negative MRI scans of women with
mammography-detected cancers was somewhat lower than in other categories, which
is likely related to the simultaneous interpretation of mammograms and MRI scans
in these cases and the fact that 8 of 13 cancers in this category were pure DCIS. It
should be noted that 5 of 16 (31%) interval cancers were already visible at the last
scan, and were all scored as BI-RADS 4 or 5.
Table 5.2 also shows the impact of patient and imaging factors on the likelihood of
false negative MRI-reports. Overall, the frequency of missed findings is influenced
by age, the reason for screening and reported image quality. Especially the pres-
ence of a BRCA mutation strongly reduces the frequency of visible findings in prior
negative MRI scans.
5.4 Discussion
Our results show that, of 131 breast cancers with negative prior MRI exams retro-
spectively evaluated in this study, 31% were already visible on this negative exam.
In fact, 29% of the 131 lesions were rated as BI-RADS 4 or BI-RADS 5 and should thus
have been recalled based on these prior-exams. When including cancers presenting
with minimal signs, 65% of the lesions were already recognizable on the prior MRI
exam. Both from a learning perspective and in terms of liability it is essential that
these figures are available.
These results are in line with reports from Yamaguchi et al.145, and Pages et al.146
who, in smaller cohorts (15 and 58 patients), reported that 56% and 47% of breast can-
cers were already visible on prior MRI examinations and retrospectively assessed as
BI-RADS 3 or higher. Both studies, however, only included screen-detected cancers
on MRI. To our knowledge, this study is the first to show that also 31% of interval
cancers and even 35% of incidental cancers can be identified at the last negative MRI
scan.
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Table 5.2: Visibility of lesions on prior negative MRI scans, stratified by patient and
imaging factors.
N (%) Invisible1 (%) Minimal
sign1 (%)
Visible1 (%) P-value2
Overall 131 (100) 45 (34) 45 (34) 41 (31) N/A
Patient factors
Mean age at cancer
detection in years (sd)
47 (11.3) 44 (11.4) 46 (9.8) 52 (11.4) 0.003
Menopausal status 0.229
- Premenopausal 60 (46) 25 (42) 17 (28) 18 (30)
- Postmenopausal 71 (54) 20 (28) 28 (39) 23 (32)
Reason for screening 0.001
- BRCA3 70 (53) 34 (49) 23 (33) 13 (19)
- non-BRCA 61 (47) 11 (18) 22 (36) 28 (46)
Imaging factors
Field strength 0.895
- 1.5T 96 (73) 33 (34) 32 (33) 31 (32)
- 3T 35 (27) 12 (34) 13 (37) 10 (29)
BPE 0.570
- Minimal 83 (63) 30 (36) 27 (33) 26 (31)
- Mild 22 (17) 5 (23) 9 (41) 8 (36)
- Moderate 12 (9) 3 (25) 4 (33) 5 (42)
- Marked 14 (11) 7 (50) 5 (36) 2 (14)
Reported IQ 0.021
- Perfect 111 (85) 43 (39) 34 (31) 34 (31)
- Sufficient 18 (14) 1 (6) 10 (56) 7 (39)
- Bad 2 (2) 1 (50) 1 (50) 0 (0)
1 According to the two readers in consensus in the prior MRI scan
2 P-value is based on Pearson’s χ2 test evaluating the differences between the 3 visibility
categories (invisible, minimal sign, and visible)
3 The BRCA population included also untested first degree relatives
IQ=image quality
In between parenthesis the percentage of lesions in the specified category is given, except
when indicated otherwise.
The program sensitivity of our high-risk screening cohort was, as reported earlier,
89.7%125, which is comparable to recent prospective studies on MRI-screening in
women at increased risk such as the Italian Hibcrit trial (91%)41 and the German
EVA trial (93%)75. Therefore, it is likely that our findings are applicable to all breast
MRI screening settings. Our findings related to the visibility of cancers in prior-
examinations are also similar to those found in mammography screening. Previous
studies140 have reported that up to 50% of the cancers detected in mammography
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screening with double reading were already visible at earlier screening examinations
and approximately half of these were suspicious.
The clinical consequences of missing a cancer in an MRI scan obtained before pro-
phylactic mastectomy are relatively minor. Most of these cancers are DCIS only. This
is a relatively frequent finding in prophylactic mastectomy specimen (approximately
5% in our institution)110. Since the period between the MRI scan and the subsequent
prophylactic mastectomy is usually short, it is unlikely that missing these lesions
Figure 5.1: First row are the subtraction images of a breast cancer invasive ductal
carcinoma (IDC) grade 3 (a), which were rated as invisible in the prior MRI (b), second
row are the images (c) rated as minimal sign in the prior image (d) also showing an
IDC grade 3, and the last row are the images of the current MRI (e) and the visible
lesion in the prior MRI (f) an invasive lobular carcinoma grade 2.
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will alter the patients prognosis. Nonetheless, the psychological impact might be
substantial and should be taken into account150.
The consequences of missing breast cancers that present subsequently as interval
cancer, on the other hand, are dire. These cancers usually are invasive, poorly dif-
ferentiated and fast-growing151. Detection of these cancers at the MRI-examinations
could still have had a significant effect on subsequent prognosis and warrants inves-
tigation of methods to reduce false negative reporting of MRI scans.
In the group of mammography-detected cancers, the number of visible cancers is
somewhat lower than in the other groups, though this did not reach statistical sig-
nificance. This result was expected as the examinations are in practice often reported
simultaneously. The fact that we did find 4 cancers on the current MRI scan that were
re-evaluated as visible in retrospect can therefore only be explained by underreport-
ing of subtle findings on the MRI scan due to already significant findings on the
mammogram that would warrant a biopsy anyway. In addition, of note is that of 4
invasive cancers in this mammography category only one cancer was also regarded
as invisible in the consensus reading. The finding that the frequency of invisible in
situ cancers is substantial (50%) underlines that, although the sensitivity of breast
MRI is high, it is not 100%, as we are certain these cancers are present in the breast.
The fact that the frequency of visibility of late(r) detected cancers is virtually in-
dependent of the eventual mode of cancer detection implies that the problem should
be sought in the evaluation of MRI scans themselves. Radiologists, in general, may
make two types of mistakes. The first is known as overlook error. The abnormal-
ity is simply not seen, and therefore cannot be classified correctly. The second is
known as interpretation error. In this case, the lesion is seen but falsely interpreted
as benign finding, and might therefore not even be reported, although the most ev-
ident cases of interpretation errors obviously mention the lesion as benign in the
report145,146,152,153. In the evaluation of screening breast MRI, likely both processes
play a role. In retrospect, 4 cases were classified as BI-RADS 5. It is unlikely that
these lesions were seen but not recalled (see Figure 8.2). It is far more likely that
these cases were overlooked. However, the vast majority (N = 35) of visible cases
were classified in the prior-exam as BI-RADS 4. In these cases, interpretation errors
might have prevented recall in clinical practice. This is also supported by the fact
that the strongest modifier of the frequency of visible lesions is the presence of a
BRCA mutation (49% of the lesions were truly invisible in BRCA mutation carriers
compared to 18% in others). The much higher a priori chance of these women to
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Figure 5.2: An example of an interval cancer detected on ultrasound nine months
after prior MRI. This visible lesion was scored as BI-RADS 5 in re-evaluation; (a) sub-
traction image of an invasive ductal carcinoma grade 2 (pT1cN1mi (sn)) in transversal
plane and (b) in coronal plane.
develop breast cancer compared to other women at increased risk96, along with the
fast growth of cancers in these women154, leads to lowering the threshold for recall.
In other words, women with BRCA mutations are recalled for lesions that would
have been ignored in women without BRCA mutations. This might also explain the
slightly younger age of women with invisible lesions at the last negative MRI, as the
BRCA population, in general, is younger than the non-BRCA population.
We also observed that IQ was associated to the visibility score, with more frequent
visible findings in negative reported MRI scans of less than perfect quality. This im-
plies that striving for excellent image quality is important. When a scan is of inferior
quality, for example, due to motion artefacts, rescanning the patient should be con-
sidered. We did not detect an effect of field strength on the visibility of lesions in
prior negative MRI scans and, therefore, underline that adequate MRI scans can be
performed at both 1.5 and 3T systems. BPE was not statistically related to the like-
lihood of visibility of lesions in the last negative MRI scan. Nevertheless, in women
with marked BPE, the frequency of visible lesions was with 14% substantially lower
than in other groups. We assume that very strong BPE might in fact sometimes
obscure lesions that would otherwise be detected155, though larger numbers are re-
quired for statistical analyses.
While an obvious solution to reduce misinterpretation of eventual cancers would
be to lower the threshold for recall in non-BRCA mutation carriers, this cannot be
straightforwardly applied. We earlier analyzed the positive predictive value of biopsy
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(PPV3) in women in this cohort125, which were 0.38 and 0.29 for BRCA1 and BRCA2
carriers, respectively. However, in women with a positive family history but no
BRCA mutation PPV3 was only 0.14, which implies that lowering the threshold for
recall in these women might lead to unacceptable high biopsy rates for benign le-
sions, and might further jeopardize the cost-effectiveness of MRI screening. The
optimal balance between recall and cancer detection for women in different risk cat-
egories has yet to be determined.
We acknowledge that in the consensus read a bias was introduced by the non-blinded
fashion of the evaluation. Readers were aware of the breast cancer location on the
current MRI scan, mammography, or in the excised specimen. While this is common
practice in auditing, it has been postulated that this approach is too harsh and leads
to more lesions classified as visible than what would have been the case in a blinded
setting where cases are mixed with normal scans156. However, in a previous study
of Gubern-Merida et al.132 a CAD system was used for the detection of breast cancer
in a subset of 40 of the cancer cases that were used in the current evaluation, mixed
with 120 normal cases. At 4 false positives per normal scan, the sensitivity of the
CAD system was 0.71 and 0.31 for visible and minimally visible lesions in the prior
negative scans, respectively, whereas sensitivity was 0.82 for the respective current
scans in which the cancers were actually diagnosed. This implies that indeed a sub-
stantial subset of the cancers is at least detectable in the prior negative scans and
patients could therefore indeed benefit from CAD-assisted reading or a blinded sec-
ond read.
This study has some other limitations. It is a single center study based upon ret-
rospective analysis of screening data. However, the fact that the program sensitivity
is in line with published prospective trials implies that the findings are likely gen-
eralizable to similar bi-modal screening programs for women at increased risk. In
addition, the prospective reads of the scans were conducted by one of eight radi-
ologists with a strong variability (6 months to 23 years) in experience with breast
MRI, which also reflects clinical practice. The numbers of missed cancers are too
small to assess the effect of experience on false negative reporting. MRI protocols
changed over time. However, all examinations were performed with at the time
state-of-the-art equipment and imaging quality was in adherence with international
recommendations11,44. Our numbers are likewise too small to detect whether MRI-
protocol changes might have influenced the frequency of visible findings in negative
MRI scans over time.
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In conclusion, our results show that almost one-third of breast cancers can be de-
tected at the last reported negative MRI. Since this is true for both screen-detected
and interval cancers, it is essential to find methods to reduce reading errors. As a
first step, regular auditing of clinical practice seems to be indicated. In addition,
structural double reading of breast MRI-exams may be of value, although further
research on the added cancer detection yield is required. Computer-aided detection
tools for cancer detection in breast MRI might play a significant role in the preven-
tion of reading errors in the future.
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Abstract
Purpose Higher background parenchymal enhancement (BPE) could be used for
stratification of MRI screening programs since it might be related to a higher breast
cancer risk. Therefore, the purpose of this study is to correlate BPE to patient and
tumor characteristics in women with unilateral MRI-screen detected breast cancer
who participated in an intermediate and high-risk screening program. As BPE in the
affected breast may be difficult to discern from enhancing cancer, we assumed that
BPE in the contralateral breast is a representative measure for BPE in women with
unilateral breast cancer.
Materials and Methods This retrospective study was approved by our local insti-
tutional board and a waiver for consent was granted. MR examinations of women
with unilateral breast cancers screen-detected on breast MRI were evaluated by two
readers. BPE in the contralateral breast was rated according to BI-RADS. Univariate
analyses were performed to study associations. Observer variability was computed.
Results The analysis included 77 breast cancers in 76 patients (age: 48 ± 9.8 years),
including 62 invasive and 15 pure ductal carcinoma in situ cases. A negative asso-
ciation between BPE and tumor grade (P ≤ 0.016) and a positive association with
progesterone status (P ≤ 0.021) was found. The correlation was stronger when only
considering invasive disease. Interreader agreement was substantial.
Conclusion Lower BPE in the contralateral breast in women with unilateral breast
cancer might be associated with higher tumor grade and progesterone receptor neg-
ativity. Great care should be taken using BPE for stratification of patients to tailored
screening programs.
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6.1 Introduction
In dynamic contrast-enhanced breast magnetic resonance imaging (DCE-MRI), nor-
mal breast parenchyma may enhance after administration of a contrast agent. This
enhancement is known as background parenchymal enhancement (BPE). The level
of BPE after contrast administration is highly variable between women. Multiple
factors, including age, pre- or postmenopausal status, phase in the menstrual cycle,
and hormone usage can affect glandular tissue enhancement. Younger women have
more often higher BPE and the degree of BPE naturally decreases with age96.
Previous research showed that BPE may obscure or mimic lesion enhancement and
can decrease the accuracy of breast MRI157–161, even though contradictory results ex-
ist for its effect on sensitivity159,162. Nonetheless, lesion demarcation is impaired and
it was shown that high BPE increases the likelihood of positive resection margins163.
According to the newest BI-RADS MRI lexicon, BPE can be qualitatively evaluated
rating the degree of enhancement as minimal, mild, moderate, or marked19,164.
Recent literature focused more on the relationship between BPE and breast cancer
occurrence. A study examining the relationship between breast cancer and BPE con-
cluded that higher BPE is associated with a higher likelihood of breast cancer devel-
opment23. Odds ratios increased from minimal to marked BPE by a factor of three
to ten. This may have strong implications for personalized screening strategies, as
these may be adapted to the level of BPE observed. This would be similar to us-
ing breast density in mammography as a parameter for stratification of women into
more personalized screening programs. This is of particular interest in women at a
lifetime risk of 20 to 50% because cost-effectiveness of MRI screening in these women
is often doubted165,166.
This raises the question whether high BPE is associated with the occurrence of all
breast cancers or just a specific subset of cancer types, as this may affect the use-
fulness of BPE as a tool for stratification of women to more tailored screening pro-
grams. Since tumor size, tumor grade, hormone receptor status, and nodal status
are the most essential parameters for long-term outcome prediction167, it is essential
to understand the correlation between BPE and these factors. However, only a few
studies investigate the relationship between BPE in breast cancer patients and prog-
nostic factors168,169, and none evaluate cancers detected only through screening.
Therefore, the purpose of this study is to correlate BPE to patient and tumor char-
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acteristics in women with unilateral breast cancer detected by a screening MRI ex-
amination who participated in an intermediate and high-risk screening program. As
BPE in the affected breast may be difficult to discern from enhancing cancer, we as-
sumed that BPE in the contralateral breast is a representative measure for BPE in
women with unilateral breast cancer.
6.2 Materials and Methods
Screening program
This retrospective study was approved by our local institutional review board (CMO
Arnhem-Nijmegen) and the requirement for informed consent was waived. The
breast cancer screening program for women at increased breast cancer risk (≥ 20-
25% lifetime risk) at our institution consists of annual breast MRI in women aged
from 25 to 60 in BRCA mutation carriers. In women of 30 years or older MRI is com-
bined with mammography. In women at high familial risk, screening starts at 35
or 45 years combining MRI and mammography20. The examinations are generally
acquired on the same day, although some women prefer to undergo mammography
and breast MRI sequentially at six-month intervals.
Case selection
The local database of all breast MR imaging records was searched to identify all
screening MR examinations performed between January 2003 and January 2014.
Imaging data were cross-referenced with pathology records to identify all malignant
lesions in this population. The inclusion criterion was histopathologically proven
screen-detected breast cancer (invasive cancer or pure ductal carcinoma in situ).
Screen-detected cancers were defined as cancers diagnosed after diagnostic workup
initiated by screening findings. Women with a personal history of breast cancer,
women who received radiation to the chest at a young age, and women who received
hormone replacement therapy were excluded. Pathology records were reviewed to
determine tumor characteristics according to the Dutch Guidelines for breast can-
cer20. Tumor characteristics were: histological type, histological grade (according to
the modified Elston and Ellis criteria167), hormone receptor status (using immuno-
histochemistry for the estrogen receptor (ER) and progesterone receptor (PR) status
and fluorescence in situ hybridization (FISH) for the human epidermal growth fac-
tor receptor 2 (HER2) status170,171), molecular subtype, primary tumor size (pT-stage)
and lymph node status (pN-stage). Molecular subtype was defined based upon re-
ceptor status and proliferation markers, as described previously in more detail172.
One year of follow-up was available for all patients.
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Image acquisition
Breast DCE-MRI acquisitions were performed on either a 1.5 or 3 Tesla Siemens
scanner (Magnetom Avanto, Magnetom Sonata, Magnetom Simphony or Magnetom
Trio). All women were scanned in prone position using a dedicated bilateral breast
coil. A transverse or coronal three-dimensional T1-weighted gradient-echo (GRE)
dynamic sequence was performed before contrast agent administration followed by
4 or 5 post-contrast sequences. Subtraction series were created for all post-contrast
time points. Motion correction was applied148. Pixel spacing (from 0.664 mm to 1.5
mm), slice thickness (from 1 mm to 1.5 mm), matrix (256 x 128, 448 x 381 or 512 x
96 pixels), echo time (from 1.71 msec to 4.76 msec), repetition time (from 4.56 msec
to 8.41 msec) and flip angle (from 10◦ to 25◦) differed among acquisitions because
of the long time span of this study and the use of various scanners and protocols.
Gadolinium-based contrast agents were administered at doses of 0.1 mmol/kg or
0.2 mmol/kg using a power injector (Medrad, Warrendale, PA) at a flow rate of 2.5
ml/s, followed by a saline flush. Premenopausal women were scheduled between
the sixth and twelfth day of their menstrual cycle.
MR interpretation
All MR examinations of women with histopathologically proven unilateral breast
cancer were reviewed by two experienced readers (a fifth year resident with experi-
ence in breast imaging (C.B.) and an experienced radiologist with nine years expe-
rience in breast MR imaging (R.M.M.)). The readers were informed of the location
of the cancer but they were blinded to all other information. The two readers inde-
pendently evaluated both the level of BPE in the contralateral breast and the level of
motion for the complete volume, since motion might result in subtraction artefacts
that might be mistaken for BPE. BPE was visually assessed according to the BI-RADS
MRI lexicon as minimal, mild, moderate, or marked on the first post-contrast sub-
traction series obtained at approximately 90 seconds after contrast administration19.
Motion was rated likewise on the same volumes as minimal, mild, moderate or se-
vere.
Statistical analyses
We performed univariate analysis (χ2 tests for categorical variables, Students T-test
and one-way ANOVA for continuous variables) to investigate whether BPE was as-
sociated with certain patient and tumor characteristics (age, menopausal state, in-
vasive versus in-situ disease, cancer type, tumor grade, ER status, PR status, HER2
status, molecular subtype, size of the primary tumor (pT-stage) and nodal status
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(pN-stage)). In addition, we investigated the relation between BPE and scored mo-
tion in the same manner. To assess inter-reader variability, linear weighted kappa
statistics (κ) were calculated. The strength of the kappa agreement was defined as
<0.000 = poor, 0.000 - 0.200 = slight, 0.201 - 0.400 = fair, 0.401 - 0.600 = moderate,
0.601 - 0.800 = substantial and 0.801 - 1.000 = almost perfect.
Because the difference between minimal and mild, and moderate and marked is
in clinical practice difficult to make, we chose to dichotomize BPE values in a sec-
ond step. BPE was dichotomized into low BPE (original scores: minimal and mild)
and high BPE (original scores: moderate and marked) to obtain more stable results.
Separate analyses were performed for all included cancers and for invasive cancers
only separately, and for cancers detected in BRCA patients and non-BRCA patients.
A two-sided P-value of ≤ 0.05 was considered statistically significant. All statistics
were performed in SPSS (version 22, SPSS Inc., Chicago, IL).
6.3 Results
In the period from January 2003 to January 2014, 10122 screening MR scans were
performed in 2798 women. The cohort consisted of BRCA mutation carriers, women
with a (strong) family history of breast cancer, women with a personal history of
breast cancer, and women with other reasons for inclusion (including women with a
germline PTEN mutation, women who had previous radiation to the chest at young
age, and women who were diagnosed with lobular carcinoma in-situ in a previous
biopsy). In total, 92 breast cancers (in 91 women) were screen-detected. Fifteen can-
cers in twelve women were excluded since these women had a personal history of
breast cancer (N = 12), radiation to the chest (N = 2) or received hormone replace-
ment therapy (N = 1). The final analysis included 77 cancers in 76 patients (median
age of 48 years, range: 24 - 76 years). One woman had two primary breast cancers in
the same breast (an invasive lobular cancer and an invasive ductal cancer).
Cancers
Patient and tumor characteristics are given in Table 6.1. The significant results of
univariate analysis of patient and tumor characteristics in relation to BPE are pre-
sented in Table 6.2. BPE seems to be associated with tumor grade, scored motion,
and to the PR status of the cancer. A substantial agreement in the assessment of BPE
was found between R1 and R2 for all the cancers (κ = 0.719 (95% CI: 0.615 - 0.824))
and for invasive cancers only (κ = 0.750 (95% CI: 0.640 - 0.861)) using the original 4
categories. When using 2 categories the agreement was still substantial (κ = 0.633
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(95% CI: 0.449 - 0.819)) for all cancers and for invasive cancers only (κ = 0.677 (95%
CI: 0.488 - 0.865)). Figures 6.1 to 6.4 show examples of the four BPE categories.
Associations
For both readers there was a significant negative association between BPE and patho-
logical tumor grade (R1; P = 0.016 and R2; P = 0.003 for all cancers, R1; P = 0.031 and
R2; P = 0.007 for invasive cancers only, using dichotomized BPE scores, see Figure
6.5).
We investigated the association in BRCA mutation carriers and non-BRCA patients
separately. The results show that there was no association between BPE and tumor
grade in BRCA mutation carriers (P = 0.175 for both readers), however, there was a
significant negative association in non-BRCA patients for reader 2 (P = 0.001).
We did also observe a significant positive association between BPE and motion in
one reader (R1; P = 0.009), and a significant association between BPE and PR status
for both the readers (R1; P = 0.018 and R2; P = 0.021, see Figure 6.6).
Figure 6.1: Maximum Intensity Projection (MIP, top image) and subtraction image
(bottom image) of woman with unilateral cancer (59 years old, breast tumor in the
left breast, IDC grade 2) with BPE rated as minimal by both readers.
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Figure 6.2: Maximum Intensity Projection (MIP, top image) and subtraction image
(bottom image) of woman with unilateral cancer (61 years old, breast tumor in the
right breast, DCIS grade 2) with BPE rated as mild by both readers.
Figure 6.3: Maximum Intensity Projection (MIP, top image) and subtraction image
(bottom image) of woman with unilateral cancer (70 years old, breast tumor in the
right breast, IDC grade 2) with BPE rated as moderate by both readers.
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Figure 6.4: Maximum Intensity Projection (MIP, top image) and subtraction image
(bottom image) of woman with unilateral cancer (60 years old, breast tumor in the
left breast, IDC grade 1) with BPE rated as marked by both readers.
Figure 6.5: The association between BPE and tumor grade for Reader 1 and Reader 2.
6.4 Discussion
In this study, we investigated the association between BPE and patient and tumor
characteristics in women at increased risk with screen-detected unilateral breast can-
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Figure 6.6: The association between BPE and PR status for Reader 1 and Reader 2
cer. Our results show that there is a negative association between BPE and tumor
grade. Furthermore, a positive association between BPE and PR status is observed.
There is a worldwide intention to shift current research of breast cancer screening
from population-based screening towards personalized screening. Based upon the
results of King et al.23 and the study of Telegrafo et al.173, who detected a strong
positive correlation between BPE and breast cancer risk, BPE has the potential to be
used as a stratification factor for personalized breast screening, although this was not
evident in all studies159,174. Considering the negative association between BPE and
grade in our study, this would, however, mean that women who tend to develop low
grade tumors might be more intensively screened than women who tend to develop
high grade tumors. Similarly, the possible association between BPE and PR status
should be taken into account.
The association between BPE and grade might be biologically explained by the fact
that low grade cancers are in general also hormone receptor positive, whereas more
aggressive cancers may be hormone receptor negative175. This might also explain the
positive association observed between tumor PR status and BPE. It has been shown
that increased estrogen and progesterone levels are related to an increased BPE176,177,
but also to increased breast cancer risk178–183, especially for hormone receptor-positive
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cancers184, consequently relating high BPE to hormone receptor-positive cancers.
However, we did not observe a correlation between ER status and BPE for any of
the readers.
Our study also hints at a different pathogenesis for high grade tumors, in which
hormonal stimulation is less important. This supports the theory that breast cancer
development for high grade tumors is vastly different from low grade tumors185,186.
This can also explain the difference between BRCA and non-BRCA patients (fre-
quently sporadic tumors), as hormonal stimulation pathways might be different in
BRCA tumor development, as described for the BRCA1 gene by Hu et al.187. Our
results may also partly explain the findings of van der Velden et al.168. The au-
thors showed that parenchymal enhancement in the contralateral breast of women
with invasive breast cancer is correlated with long-term outcome. Lower values of
parenchymal enhancement showed potential as a predictive biomarker for relatively
poor outcome in women who received endocrine therapy. This might be due to dif-
ferences in tumor grade, but it could also be explained by the lower importance of the
hormonal stimulation pathway for breast cancer growth in women with relatively
low contralateral BPE. However, it must be taken into account that the definition of
parenchymal enhancement of van der Velden et al. is different from the definition
described in the BI-RADS MRI lexicon. In their study, automatically calculated late
enhancement of the parenchyma (percentage of parenchymal enhancement over the
whole post-contrast period) was used.
We found an association between BPE and increased motion scores in one reader
(R1), which may be explained by the fact that motion can be misleading and might
be incorrectly considered as BPE in subtraction images and vice versa188,189. How-
ever, further research is needed to investigate whether this holds true in a larger
dataset and with more experienced readers.
Our findings are in contrast to the, to our knowledge, only study that so far investi-
gated the relation between BPE and tumor characteristics169. Kim et al. reported that
BPE of the contralateral breast is independent of tumor characteristics. Likely, this
difference can be explained by the differences in patient cohorts. We only included
women participating in an intermediate and high-risk screening program, whereas
Kim et al.169 included all patients with invasive ductal cancers who underwent pre-
operative MRI. The patients in our study had a different risk profile, although age
(age under 50 years: 53.8% in current study versus 51.7% in the study of Kim et al.)
and menopausal status (pre-menopausal: 45.0% in current study versus 47.9% in the
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study of Kim et al.) between groups were comparable. We chose to study this pop-
ulation because these women are regularly screened using MRI and might benefit
from personalized screening programs.
We calculated χ2 tests to study associations between BPE and tumor characteristics.
This was chosen over performing an analysis calculating odds ratios (including more
variables as age and menopausal state) because tumor grade was the only prognos-
tic factor that showed a significant relation to BPE in both of the readers, and the
limited number of cases.
Our study has some limitations. Despite the fact that the number of cancers re-
ported on in a high-risk screening program is relatively large, the absolute number
of cancers included to study the correlations is relatively low. This holds particularly
true for the number of pure DCIS cases (N = 15), although 19% pure DCIS (15/77) is
a realistic representation of screening practice190. Furthermore, we suspect that the
relatively low number of cancers might be one of the main reasons for not finding a
significant association between BPE and age. Other studies showed a strong nega-
tive correlation of age with BPE159,176. This small sample size is also the main reason
why no multivariable statistical methods are used in the current study. Future re-
search is needed to test for possible confounders and interaction terms. In addition,
continuous values of BPE could be used in future research to be able to define clear
cut-offs.
Lastly, because of the long time span of this study, there is a large variability of
MRI acquisitions in this dataset. Different MRI field strengths (1.5T and 3T), breast
coils (4-channel, 7-channel, and 16-channel) and MRI protocols were used, and dif-
ferent types and amounts of contrast agents were injected. This may have strongly
affected the amount of enhancement seen in the scans. However, the rating of BPE
according to the BI-RADS MRI lexicon only considers the visual assessment of the
fraction of fibroglandular tissue that enhances at 90 seconds after contrast adminis-
tration and does not change based on differences in peak enhancement or wash-out
pattern, which are more likely to be affected by the variability in scanning parame-
ters. To our knowledge, only the study of Uematsu et al.191 directly compared BPE
in breast cancer patients at 1.5T and 3T and found no differences in the assessment
between field strengths. The large variability, on the other hand, has the advantage
that it reflects many of the breast MRI protocols currently in use and our findings,
therefore, seem extendable to breast MRI screening in general.
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In conclusion, BPE in the contralateral breast of patients with unilateral breast can-
cer in an intermediate and high-risk population might be negatively related to tumor
grade and positively related to progesterone receptor status. Based on this finding,
great care must be taken before using BPE as a method to stratify women at increased
risk to more personalized MRI screening strategies. These results should, however,
be validated in a larger study.
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Table 6.1: Patient and cancer characteristics
Age
48 years +/- 9.9 years
(range: 24 - 76 years)
Menopausal state
premenopausal: 36 (47%)
postmenopausal: 41: (53%)
Cancer types
DCIS 15 (19%)
Grade 1 0 (0%)
Grade 2 9 (60%)
Grade 3 6 (40%)
Invasive 62 (81%)
IDC 51 (82%)
ILC 10 (16%)
Other 1 (2%)
Grade 1 11 (18%)
Grade 2 22 (36%)
Grade 3 29 (47%)
ER status Positive: 41 (66%)
Negative: 20 (32%)
Unknown: 1 (2%)
PR status Positive: 30 (48%)
Negative: 31 (50%)
Unknown: 1 (2%)
HER2 status Positive: 10 (16%)
Negative: 50 (81%)
Unknown: 2 (3%)
Molecular subtypes Luminal A: 37 (60%)
Luminal B: 3 (5%)
HER2 type: 7 (11%)
Basal-like: 13 (21%)
Unknown: 2 (3%)
T-stage (invasive)
Stage 1 42 (68%)
Stage 2 17 (27%)
Stage 3 1 (2%)
Unknown 2 (3%)
N-stage (invasive)
Stage 0 38 (61%)
Stage 1 20 (32%)
Stage 2 1 (2%)
Stage 3 1 (2%)
Unknown 2 (3%)
DCIS: Ductal carcinoma in-situ, IDC: Invasive
ductal carcinoma, ILC: Invasive lobular carci-
noma, ER: Estrogen receptor, PR: Progesterone
receptor, HER2: Human epidermal growth fac-
tor receptor 2
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Abstract
Background The amount of fibroglandular tissue (FGT) is known to be associated
with an increased breast cancer risk. In recent case-control studies background paren-
chymal enhancement (BPE) on breast MRI was also proposed as a feature correlating
to the development of breast cancer. In this study the predictive value of FGT and
BPE for breast cancer development and risk of false positive findings, as measured
at baseline, is investigated in women at increased risk for breast cancer.
Methods Negative baseline MRI scans of 1533 women participating in a screening
program for women at increased risk for breast cancer between 01/01/2003 and
01/01/2014 were selected. Automated tools based on deep-learning were used to
obtain quantitative measures of FGT and BPE. Logistic regression using forward se-
lection was used to assess relationships between FGT, BPE, cancer detection, false
positive recall and false positive biopsy.
Results Sixty cancers were detected in follow-up. FGT and BPE were not associated
with breast cancer risk (P = 0.540 and P = 0.112, respectively). High FGT and BPE
did lead to more false positive recalls at baseline (OR: 1.259, P = 0.050 and OR: 1.475,
P = 0.003) and to more frequent false positive biopsies at baseline (OR: 1.315, P =
0.049 and OR: 1.807, P = 0.002), but were not predictive for false positive findings in
subsequent screening rounds.
Conclusion FGT and BPE, measured on baseline MRI, are not predictive for breast
cancer development in women at increased risk. High FGT and BPE lead to more
false positive findings at baseline.
Impact FGT and BPE cannot be implemented in risk prediction models.
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7.1 Introduction
Women at increased risk of breast cancer (≥ 20 - 25% lifetime risk) are eligible for
intensified screening programs, including a yearly breast Magnetic Resonance Imag-
ing (MRI) study. Depending on the underlying risk factors, MRIs may be performed
on an annual basis from the age of 25 (in BRCA mutation carriers)11,12. Women with
a hereditary germline mutation and women with a history of radiation therapy to
the chest at a young age are eligible for these programs. For other women, risk pre-
diction tools are used to determine whether women are at increased risk and thus
eligible for MRI screening. The current risk prediction tools rely mainly on personal
factors, such as family history, age, race, etc.192,193. However, recent studies show
that additional independent risk factors, including imaging biomarkers, might in-
crease the predictive power of risk prediction.
Mammographic breast density (BD), for example, correlates to breast cancer risk in
the general female population and in BRCA mutation carriers194,195. Consequently, a
number of studies recommend adding BD to the available risk prediction tools196–199.
The increased use of breast MRI allows for evaluation of additional risk factors to
improve current risk prediction tools. Recent publications indicate that the amount
of fibroglandular tissue (FGT) and/ or background parenchymal enhancement (BPE)
measured on breast MRI may be useful to predict breast cancer risk in women un-
dergoing breast MRI23,24,162.
While in breast MRI all normal FGT enhances after contrast injection, the strength
and speed of enhancement is dependent on variations in hormone levels, as deter-
mined by menstrual cycle phase, menopausal status, tamoxifen therapy, and hor-
mone replacement therapy158,200,201. Studies of King et al. and Dontchos et al.23,24
showed that higher amounts of BPE in the contralateral breast increase the risk of a
breast cancer diagnosis. Their results thus suggest that BPE might be used for the
prediction of breast cancer risk. Unfortunately, both studies evaluated BPE at time
of breast cancer detection, and are therefore unable to document its predictive value
for future breast cancer occurrence.
A further problem is that visual rating of BPE on a four-point scale (minimal: <
25%, mild: 25 - 50%, moderate: 50 - 75%, and marked: 75 - 100%), as used in studies
so far, suffers from high interrater variability53. This limits its value for risk pre-
diction. Analogue to the systems currently in use to automatically estimate BD on
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digital mammograms, automated tools to assess FGT and BPE may reduce interrater
variability and possibly provide more robust parameters for risk stratification.
The purpose of the current study is, therefore, to study whether FGT and BPE, as
computed on a cancer-free baseline MRI-scan using an automated tool, are predic-
tors of future breast cancer in an intermediate and high-risk breast cancer screening
program. Furthermore, we evaluate whether FGT and BPE predict false positive
findings.
7.2 Materials and Methods
This retrospective cohort study was approved by our local institutional review board
and the requirement for informed consent was waived.
Screening program
The breast cancer screening program for women with a lifetime risk of ≥ 20% - 25%
at our institution consists of annual breast MRI and mammography11,20. In BRCA
mutation carriers, the screening regimen starts with breast MRI only at the age of 25.
Mammography is added from age 30. Others start screening with both modalities at
age 35 or 40, depending on the age at which relatives developed breast cancer. The
first MRI scan performed for screening is hereafter referred to as the baseline MRI.
Case selection
The local database was searched to identify all patients who underwent breast MRI
screening between 01/01/2003 - 01/01/2014. The case selection process is presented
in Figure 7.1. Women of any age were included when they underwent at least two
breast MRI examinations for screening in this period. We recorded for each pa-
tient whether a BRCA mutation was present and whether and when a risk-reducing
salphingo-oophorectomy (RRSO) was performed. Women in whom a cancer was de-
tected at the baseline MRI or within 6 months thereafter, women with a prior history
of breast cancer, and women in whom the automated assessment of BPE failed were
excluded. We did not exclude women who had a false positive finding in the first
round of screening.
Ground truth
Normal or benign screening examinations were confirmed by at least one year of
clinical follow-up and regarded as true negative when no cancer was detected be-
fore the subsequent screening examination. When no biopsy was indicated at short-
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2645 eligable women
1112 women excluded
Final analysis included 1533 women
Exclusion:
- Only one MRI scan (N = 386)
- Previous breast cancer (N = 654)
- Cancer detection first round (N = 28)
- No BPE score (N = 44)
Figure 7.1: Flow diagram of the selection procedure.
BPE: background parenchymal enhancement
term follow-up, at least one year of clinical follow-up was required to confirm benig-
nity. Biopsied lesions were identified by a cross-computer search with our pathology
records. We subsequently analyzed if the biopsy was performed based on screening
findings or for other reasons (e.g. symptoms).
Image acquisition
MRI Protocols varied over time105. Dynamic contrast-enhanced breast MRI acqui-
sitions were performed on either a 1.5 or 3 Tesla Siemens scanner using a dedi-
cated bilateral breast coil. Patients were placed in prone position. A transverse or
coronal three-dimensional T1-weighted gradient-echo (GRE) dynamic sequence was
performed before contrast agent administration followed by 4 or 5 post-contrast se-
quences. The first time point was acquired before intravenous agent injection and the
following time points after injection of the contrast agent. The gadolinium chelates
were administered at a dose of 0.1 mmol/kg or 0.2 mmol/kg using a power injector
(Medrad, Warrendale, PA), followed by a saline flush.
Imaging interpretation
Automatic tools were used to objectively calculate percentages of FGT and BPE on
breast MRI volumes. Breast and FGT were segmented on the native T1-weighted
pre-contrast acquisitions using a deep-learning based method as described by Dalmis
et al.105. The fraction of FGT was calculated as the segmented volume of FGT divided
by the total breast volume. BPE relative enhancement values were computed using
the pre-contrast and the first post-contrast T1-weighted acquisition after motion cor-
rection148, according to the ACR guidelines19,126. The fraction of BPE is expressed
relative to the volume of the FGT, where an FGT voxel is considered to enhance if
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it has a relative enhancement value higher than 10%. According to Dalmis et al.202,
who correlated BPE as scored by the automated tool to BPE as rated by radiologists,
10% relative enhancement correlates best. Figure 8.2 shows an example of auto-
mated computations of FGT and BPE. Final FGT and BPE measurements were the
result of averaging over the two breasts of each woman. To verify whether corre-
lations change when investigating different cut-off values, we performed the same
analyses on 20%, 30%, 40% and 50% relative enhancement values (see Table 7.6).
Data-analysis
Women who developed cancer were identified by linkage of our data to the Nether-
lands Comprehensive Cancer Organisation. False positive MRI examinations were
defined as examinations that led to recall in women in whom no breast cancer was
detected. False positive recalls (FPR) include all women who were recalled (with or
without the performance of biopsy). False positive biopsies (FPB) only include the
women for whom the recall led to biopsy. We separated FPR and FPB in the first
round from those that occurred in subsequent screening rounds.
Statistical analysis
Incomplete data was assumed to be missing at random and was excluded. Descrip-
tive statistics were prepared with the use of contingency-table analyses for categori-
cal data and Fisher’s exact tests. The 95% confidence intervals (95% CI) for propor-
tions were estimated using the Z-test for single proportions. Continuous data were
compared with the Student’s t-test or Pearson correlation coefficient (r) when nor-
mally distributed, otherwise, Mann-Whitney U tests were used. Bootstrapping (N =
1000) was used to calculate 95% CI. To increase statistical power, FGT and BPE were
dichotomized into two categories based on the optimal categories in ROC-analysis
(0 - 50th percentile and 50 - 100th percentile). A binary logistic regression model
was constructed to find independent predictors for breast cancer or false positives.
Separate and combined models were performed for FGT and BPE. The inclusion of
variables in the model was based on existing knowledge of risk factors for breast
cancer and/or false positives (covariates: age and BRCA status). Non-linear effects
were evaluated using Box-Tidwell tests and when needed transformations were per-
formed. The value of predictors was assessed by using forward feature selection (us-
ing a liberal probability-to-enter of 0.1). Interactions between predictors were eval-
uated in the final models by including interaction terms along with the main-effect
terms. The final model was bootstrapped (N = 1000). Shrinkage using the heuristic
method was applied to account for over-optimism203. Odds ratios (OR) were used to
report on the relative odds of the occurrence of the outcome (future cancer, or false
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positive result), where OR = 1 means that the predictor does not affect odds of out-
come; OR > 1 means that the predictor is associated with higher odds of outcome;
and OR < 1 means that the predictor is associated with lower odds of outcome. All
statistical tests were two-sided. P ≤ 0.05 was considered significant. All statistics
were performed in SPSS (version 22, SPSS Inc., Chicago, IL).
Table 7.1: Baseline patient characteristics
Total cohort Developed cancer
(N=1533) Yes (N=60) No (N=1473)
Age in years (median$, IQR) 41 (17.0) 40 (13.0) 42 (17.0)
BRCA mutation carriers (N, fraction*) 573, 0.37 41, 0.68 532, 0.36
FGT in percentage (median$, IQR) 12.7 (18.9) 11.6 (19.8) 12.7 (18.7)
BPE in percentage (median$, IQR) 67.7 (27.6) 71.3 (30.4) 67.6 (27.6)
Cancer (N, fraction*) 60, 0.04 60 (N/A) N/A
- Age at cancer detection (median$, IQR) 42 (15.0) 42 (15.0) N/A
False positive recall overall (N, fraction*) 337, 0.22 19, 0.32 318, 0.22
- Age at recall (median$, IQR) 42 (15.0) 40 (18.0) 42 (15.0)
False positive recall MRI (N, fraction*) 264, 0.17 16, 0.27 248, 0.17
- Age at recall (median$, IQR) 40 (15.0) 39 (16.8) 40 (15.0)
False positive biopsy overall (N, fraction*) 221, 0.14 12, 0.20 209, 0.14
- Age at biopsy (median$, IQR) 41 (14.5) 39 (16.5) 41 (14.5)
False positive biopsy MRI (N, fraction*) 203, 0.13 11, 0.18 192, 0.13
- Age at biopsy (median$, IQR) 40 (15.0) 38 (18.0) 40 (15.0)
RRSO (N, fraction*) 103, 0.07 5, 0.08 98, 0.07
N/A: not applicable, BPE: background parenchymal enhancement, FGT: amount
of fibroglandular tissue, IQR: the difference between the 75th and 25th percentiles,
RRSO: risk-reducing salpingo-oophorectomy
* fraction: fraction of positive cases
$ Tested on normality using the Kolgomorov-Smirnov test
7.3 Results
Population
The final analysis evaluated baseline breast MRI scans of 1533 women, including 573
(37.4%) BRCA mutation carriers. Patient selection and exclusion is shown in Figure
7.1. The median age at baseline was 41 years (37 years for BRCA mutation carriers,
and 44 years for others). In 60 (3.9%) women, cancer was identified after a negative
baseline scan. 45 (75%) cancers were screen-detected cancers, 6 (10%) were interval
cancers, and 9 (15%) cancers were detected in prophylactic mastectomies. 43 (71.7%)
cancers were invasive and 17 (28.3%) were ductal carcinoma in situ (DCIS) only. The
median time between the negative baseline scan and cancer detection was 3 years (2
in BRCA patients, 3 in others). Of the 573 BRCA mutation carriers 103 (18%) women
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Table 7.2: Baseline characteristics of BRCA mutation carriers
Total cohort Developed cancer
(N=573) Yes (N=41) No (N=532)
Age in years (median$, IQR) 37 (17.0) 41 (14.5) 37 (18.0)
FGT in percentage (median$, IQR) 9.3 (14.5) 10.7 (16.7) 9.3 (14.5)
BPE in percentage (median$, IQR) 65.6 (26.7) 71.2 (33.3) 65.1 (26.1)
Cancer (N, fraction*) 41, 0.07 41, 1.00 0, 0.00
- Age at cancer detection (median$, IQR) 42 (14.5) 42 (14.5) N/A
False positive recall overall (N, fraction*) 118, 0.21 12, 0.29 106, 0.20
- Age at recall (median$, IQR) 38.5 (15.0) 38 (19.5) 39 (14.3)
False positive recall MRI (N, fraction*) 97, 0.17 10, 0.24 87, 0.16
- Age at recall (median$, IQR) 38 (14.5) 38 (18.75) 39 (14.0)
False positive biopsy overall (N, fraction*) 80, 0.14 7, 0.17 73, 0.14
- Age at biopsy (median$, IQR) 38 (14.0) 34 (11.0) 39 (14.5)
False positive biopsy MRI (N, fraction*) 72, 0.13 7, 0.17 65, 0.12
- Age at biopsy (median$, IQR) 38 (15.3) 34 (11.0) 38 (15.5)
RRSO (N, fraction*) 103, 0.18 5, 0.12 98, 0.18
N/A: not applicable, BPE: background parenchymal enhancement, FGT: amount
of fibroglandular tissue, IQR: the difference between the 75th and 25th percentiles,
RRSO: risk-reducing salpingo-oophorectomy
* fraction: fraction of positive cases
$ Tested on normality using the Kolgomorov-Smirnov test
Table 7.3: Baseline characteristics of others at increased risk
Total cohort Developed cancer
(N=960) Yes (N=19) No (N=941)
Age in years (median$, IQR) 44 (15.0) 40 (11.0) 44 (15.0)
FGT in percentage (median$, IQR) 14.9 (20.7) 20.8 (20.5) 14.8 (20.6)
BPE in percentage (median$, IQR) 69.0 (27.6) 73.4 (29.1) 69.0 (27.6)
Cancer (N, fraction*) 19, 0.02 19, 1.00 N/A
- Age at cancer detection (median$, IQR) 43 (16.0) 43 (16.0) N/A
False positive recall overall (N, fraction*) 219, 0.23 7, 0.37 212, 0.23
- Age at recall (median$, IQR) 43 (14.0) 46 (15.0) 43 (14.0)
False positive recall MRI (N, fraction*) 167, 0.23 6, 0.32 161, 0.17
- Age at recall (median$, IQR) 42 (15.0) 47.5 (17.8) 42 (14.0)
False positive biopsy overall (N, fraction*) 141, 0.15 5, 0.26 136, 0.14
- Age at biopsy (median$, IQR) 43 (14.0) 46 (10.0) 43 (14.0)
False positive biopsy MRI (N, fraction*) 131, 0.14 4, 0.21 127, 0.13
- Age at biopsy (median$, IQR) 42 (14.0) 47.5 (12.5) 42 (14.0)
RRSO (N, fraction*) 0, 0.00 0, 0.00 0, 0.00
N/A: not applicable, BPE: background parenchymal enhancement, FGT: amount
of fibroglandular tissue, IQR: the difference between the 75th and 25th percentiles,
RRSO: risk-reducing salpingo-oophorectomy
* fraction: fraction of positive cases
$ Tested on normality using the Kolgomorov-Smirnov test
had a RRSO prior to the first screening round.
337 (22.0%) women had a false positive recall. Seventy-three (21.7%) of these women
were recalled based upon mammography findings. 264 (78.3%) women had at least
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one false positive recall based on the MRI exam (total: 286 recalls on MRI), and 203
(13.2%) women had at least one false positive biopsy due to MRI findings (total: 217
biopsies). Median FGT measured on MRI was 12.7% (IQR: 18.9%), and median BPE
was 67.7% (interquartile range (IQR): 27.6%). A more detailed presentation of the
population characteristics is presented in Tables 7.1 - 7.3.
In univariate analysis, a significant association between FGT and BRCA status was
found in both percentages (P = 0.001) and the dichotomous scores (P < 0.001). BRCA
mutation carriers had lower FGT scores than others. Interestingly, the BRCA muta-
tion carriers had a lower age at the baseline scan (median age of 37 for BRCA mu-
tation carriers versus 44 for others, P < 0.001). A similar association was found
between the percentage of BPE and BRCA status (P = 0.005), as BRCA mutation car-
riers had significantly lower BPE scores. When dichotomizing BPE, this remained
significant (P = 0.020). FGT and BPE were negatively correlated to age (r = -0.289
and r = -0.129, P < 0.001), also when using dichotomous values (P≤ 0.007). In BRCA
mutation carriers coefficients were r = -0.418 (P < 0.001) and r = -0.132 (P = 0.002),
respectively, and in women without a BRCA mutation r = -0.307 (P < 0.001) and r =
-0.152 (P < 0.001). FGT and BPE were not correlated (P = 0.879). Plots of the univari-
ate analysis are presented in Figures 7.3 - 7.10. In BRCA mutation carriers, BPE was
not associated with a history of RRSO (P = 0.886, Table 7.2).
Cancer prediction models
In univariate analysis, FGT was not associated with breast cancer for both discrete
(P = 0.768) and dichotomous values (P = 0.511). In regression analysis, FGT was not
considered an independent risk factor for breast cancer, only BRCA status was (OR:
3.615, P = 0.001). Likewise, percentages and dichotomized BPE scores of the baseline
MRI scan were not associated with breast cancer (P = 0.625 and P = 0.236, respec-
tively). In regression analysis, adjusting for the only significant risk factor (BRCA
status), BPE was also no significant predictor of cancer (P = 0.112). When evaluating
both FGT and BPE, both were not significantly associated with breast cancer risk (P
= 0.824 and P = 0.112). Also in the subgroup of the BRCA and non-BRCA mutation
carriers only, BPE and FGT were not associated to breast cancer. Details of predictors
can be found in Table 7.4.
False positive recall (FPR) models
When investigating the first round results alone (diagnostic model), both FGT and
BPE were correlated to higher FPR rates (OR: 1.259; P = 0.050, and OR: 1.475; P
= 0.003, respectively). For subsequent rounds (prognostic model), higher FGT at
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baseline was still significantly related to higher FPR in both continuous and di-
chotomized values (P ≤ 0.029). BPE, however, was not related to FPR (P ≥ 0.818)
in univariate analysis. In regression analysis only age remained as related factor to
FPR in follow-up (OR: 0.955, P = 0.001, Table 7.5).
False positive biopsy (FPB) models
When only investigating the first round (diagnostic model), both FGT and BPE were
correlated to higher FPB (OR: 1.315 (P = 0.049) and OR: 1.807 (P = 0.002), respec-
tively).When excluding the FPB in the first round (prognostic model), FGT and BPE
were both not related to false positive biopsies (P≥ 0.066) in univariate analysis. Re-
gression analysis showed that age was negatively related to FPB in follow-up (P =
0.001, Table 7.5).
No interaction terms were found to be significant in none of the prediction models.
In addition, changing levels of BPE cut-offs did not change any of the conclusions
for both the cancer- and false positive prediction models (Table 7.6 and 7.7).
Table 7.4: Regression coefficients and odds ratios for the prognostic cancer prediction
model
Model Predictor P-value
Included in
final model
β
(95% CI)
OR
(95% CI)
Shrinkage
factor
Overall population
Cancer-FGT BRCA* <0.001 x 1.285 (0.762 - 1.872) 3.615 (2.143 - 6.501) 0.96
Age 0.930 -
FGT 0.511 -
Cancer-BPE BRCA* <0.001 x 1.285 (0.769 - 1.875) 3.615 (2.158 - 6.521) 0.96
Age 0.930 -
BPE 0.236 -
Subgroup BRCA
Cancer-FGT Age 0.330 - N/A
FGT 0.936 - N/A
Cancer-BPE Age 0.330 - N/A
BPE 0.106 - N/A
Subgroup non-BRCA
Cancer-FGT Age 0.126 - N/A
FGT 0.621 - N/A
Cancer-BPE Age 0.126 - N/A
BPE 0.641 - N/A
For every model different shrinkage factors were used, shrunk β and OR are presented.
β: standardized coefficients, OR: odds ratio, CI: confidence interval, FGT: amount of fibroglandular tissue, BPE:
background parenchymal enhancement, N/A: not applicable
* BRCA = 0 is reference category
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7.4 Discussion
The purpose of this study was to investigate the predictive value of FGT and BPE in
predicting breast cancer risk in a population at increased risk of developing breast
cancer. Additionally, the effect of FGT and BPE on false positive recalls and biopsies
was investigated. Our results show that neither FGT nor BPE at baseline was associ-
ated with the risk of developing breast cancer. Both higher FGT and BPE did lead to
Table 7.5: Regression coefficients and odds ratios for the effect on current and subse-
quent MRI scans on false positive findings
Model Predictor P-value
Included in
final model
β
(95% CI)
OR
(95% CI)
Shrinkage
factor
Diagnostic model for false positive findings (current MRI scans)
FP Recall-FGT BRCA 0.771 -
Age 0.167 -
FGT* 0.050 x 0.230 (0.012 - 0.451) 1.259 (1.012 - 1.569) 0.74
FP Recall-BPE BRCA 0.612 -
Age 0.102 -
BPE* 0.003 x 0.389 (0.120 - 0.666) 1.475 (1.128 - 1.946) 0.87
FP Recall-FGT BRCA 0.894 -
and BPE Age 0.229 -
FGT* 0.072 x 0.251 (-0.013 - 0.535) 1.285 (0.987 - 1.707) 0.83
BPE* 0.005 x 0.366 (0.111 - 0.625) 1.442 (1.118 - 1.868)
FP Biopsy-FGT BRCA 0.350 -
Age 0.496 -
FGT* 0.049 x 0.274 (0.022 - 0.568) 1.315 (1.022 - 1.765) 0.74
FP Biopsy-BPE BRCA 0.269 -
Age 0.362 -
BPE* 0.002 x 0.592 (0.253 - 0.957) 1.807 (1.288 - 2.605) 0.91
FP Biopsy-FGT BRCA 0.453 -
and BPE Age 0.651 -
FGT* 0.064 x 0.312 (-0.012 - 0.677) 1.367 (0.988 - 1.968) 0.87
BPE* 0.002 x 0.559 (0.218 - 0.911) 1.750 (1.243 - 2.487)
Prognostic model for false positive findings
FP Recall-FGT BRCA 0.773 -
Age 0.001 x -0.047 (-0.069 - -0.026) 0.955 (0.933 0.975) 0.95
FGT* 0.224 -
FP Recall-BPE BRCA 0.773 -
Age 0.001 x -0.047 (-0.069 - -0.026) 0.955 (0.933 0.975) 0.95
BPE* 0.932 -
FP Biopsy-FGT BRCA 0.892 -
Age 0.001 x -0.051 (-0.081 - -0.026) 0.951 (0.922 0.974) 0.94
FGT* 0.557 -
FP Biopsy-BPE BRCA 0.892 -
Age 0.001 x -0.051 (-0.081 - -0.026) 0.951 (0.922 0.974) 0.94
BPE* 0.572 -
For every model different shrinkage factors were used, shrunk β and OR are presented. β: standardized coeffi-
cients, OR: odds ratio, CI: confidence interval, FGT: amount of fibroglandular tissue, BPE: background parenchymal
enhancement
* FGT and BPE = low is reference category
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higher odds ratios for false positive findings in the baseline examination. We did not
observe any predictive value of FGT or BPE for FPR or FPB in subsequent screening
rounds.
It has already been well established that mammographic BD impairs mammographic
sensitivity204. In an average risk population, BD is also known to correlate with
breast cancer risk194. In line with the studies from Dontchos et al.24 and Passape-
ruma et al.205 who reported that neither mammographic BD nor FGT on MR images
was predictive of breast cancer risk in women at increased risk, we did not observe
a correlation between the fraction of FGT and the development of breast cancer in
our high risk cohort. However, Mitchell et al.195 reported contradictory results. In
their study it was suggested that high BD in BRCA mutation carriers increased the
risk of breast cancer, with a relative risk similar to that observed in the general pop-
ulation. The discordance between this report and our findings may at least partly be
explained by the automated volumetric FGT estimation in our study, which provides
a different representation of the FGT than visually inspected BD in mammography,
albeit previous studies showed a clear correlation between these measurements206.
It may also be related to the limited sample size in our study and other studies pub-
lished thus far.
Current clinical practice is shifting towards personalized screening, making risk pre-
diction tools increasingly important. Recent case-control studies have shown that
BPE might be predictive of breast cancer risk23,24, although contradictory results ex-
ist for non-high risk women207. However, in these studies the BPE scores of the
healthy breast (partly for Dontchos et al.24) in breast cancer patients were compared
to BPE scores in healthy controls. The current study, in which the BPE before cancer
development is evaluated in actual patients, suggests that BPE is not predictive for
breast cancer in women at increased risk. A possible explanation for this is that in
case-control studies BPE in cancer patients might have been affected by the presence
of breast cancer. Consequently, further research into the biological basis and modi-
fying factors of BPE is needed. Alternatively, our results might point to a different
carcinogenesis in women at increased risk.
Evidence suggests that BPE correlates negatively with age and increases with hor-
monal activity176,208,209. Interestingly, our results showed that BRCA mutation car-
riers had significantly lower FGT and BPE values compared to women without a
BRCA mutation, while the age of BRCA mutation carriers was significantly lower
than that of women without BRCA mutation. This counterintuitive result may be
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due to differences in the effect of hormones on FGT in women with and without
BRCA mutation210. The fact that we did not observe a difference in BPE between the
BRCA mutation carriers who did and did-not undergo a RRSO before the baseline
MRI (P = 0.886) also points in this direction. Nevertheless, prior research showed
that RRSO may still reduce both BPE and FGT values211, and therefore our results
need to be interpreted with caution as they might also be explained by the relatively
low number of women who underwent RRSO in our study.
Women with high BPE scores had a 1.5 times higher chance to get a FPR, and 1.8
times higher chance to get a FPB in the first screening round. This is in line with
previous studies, describing that more focal, regional, or asymmetric BPE was asso-
ciated with a higher likelihood of BI-RADS 3 assessment in the screening setting174.
Giess et al. stated that, in the latter case, it may be hard to distinguish BPE from
non-mass enhancement (NME)212. Consequently, when the enhancement pattern is
interpreted as NME, the reporting radiologist has to consider the possibility of ma-
lignancy, thus chances on false positives increase. DeMartini et al.159 also reported
that higher amounts of BPE were associated with higher rates of abnormal interpre-
tation. Brennan et al. reported that moderate and marked BPE are associated with
significantly higher MR imaging-guided core biopsy cancellation rates compared to
minimal or mild BPE213. However, the even stronger correlation between BPE and
FPB in our study unfortunately suggests that many biopsies are still performed due
to BPE. Nevertheless, neither BPE nor FGT is predictive of false positive recalls or
biopsies in subsequent screening rounds, which could mean that BPE and FGT are
only affecting false positives when no prior exams are available.
The automated algorithm for BPE estimation eliminates intra- and interrater vari-
ability. This is relevant as previous studies reported only a fair interrater variability
for BPE when using observer scores according to the BI-RADS lexicon53. The auto-
mated method provides quantitative measurements and therefore creates an oppor-
tunity to define more precise cut-off points. The chosen cut-off was selected based
upon previous research, but it is possible that different cut-off points might lead to
different results, but did not lead to different conclusions. This is in line with a recent
study on the prognostic value of BPE in the contralateral breast of women with uni-
lateral breast cancer, where the effect of different cut-offs appeared to be minimal214.
Nevertheless, it should be noted that the different methods to assess BPE may also
lead to different outcomes in the risk model.
Our study has some limitations. Due to the retrospective nature of our data, it was
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not always possible to retrieve data on the menstrual cycle or menopausal status.
Therefore, we could not correct for these factors. In addition, this was a single insti-
tutional study, which potentially limits its generalizability. During the study period,
we changed from a 1.5 T scanner to a 3 T scanner, and also adapted the scanning
protocol several times which could potentially influence the results of the BPE cal-
culation algorithm. Another possible limitation of the study was that, only in the
case of false positive findings, we did not exclude women who had a false positive
finding directly after the first screening round. In theory this could alter FGT and
BPE scores, although we minimized this effect by averaging scores over two breasts.
In conclusion, automatically computed FGT and BPE measures at baseline were not
associated with subsequent breast cancer occurrence in a cohort of women at high
risk for breast cancer. This has implications for personalized screening, as FGT and
BPE cannot be implemented in risk prediction models. Higher FGT and BPE were,
however, associated with higher rates of false positive findings at baseline, patient
counseling should therefore include these outcomes before starting MRI screening.
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Figure 7.2: An example of the steps of the automated tool. First, the original image
(a), then the breasts and parenchymal tissue are segmented (b), and finally, relative en-
hancement values are computed for the segmented FGT volumes (c). BPE values are
extracted from the enhancing voxels within the parenchymal tissue, based on these
relative enhancement values.
Table 7.6: BPE values for different cut-off values of the deep-learning system
Total cohort Developed cancer
Yes No
BPE in percentage (median, IQR) (10%) 67.7 (27.6) 71.3 (30.4) 67.6 (27.6)
BPE in percentage (median, IQR) (20%) 50.4 (32.5) 52.6 (38.8) 49.8 (32.0)
BPE in percentage (median, IQR) (30%) 38.0 (32.4) 38.6 (39.7) 35.3 (31.9)
BPE in percentage (median, IQR) (40%) 29.1 (28.4) 26.9 (36.1) 25.6 (28.3)
BPE in percentage (median, IQR) (50%) 22.7 (24.2) 18.8 (30.4) 18.6 (23.9)
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Figure 7.3: Distribution of the amount of fibroglandular tissue (FGT) for women with
a BRCA mutation and women without a BRCA mutation. The box plots show lowest
and highest FGT values (outermost horizontal lines), median FGT (central horizontal
line), and interquartile range (top and bottom borders of the box) for breast cancer
(no/yes).
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Figure 7.4: Distribution of the amount of fibroglandular tissue (FGT) for women with
a BRCA mutation and women without a BRCA mutation. Scatter plots showing asso-
ciation of FGT to breast cancer occurrence (no/yes) and age at baseline MRI.
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Figure 7.5: Distribution of the amount of fibroglandular tissue (FGT) for women with
a BRCA mutation and women without a BRCA mutation. The boxplots are shown for
false positive recall occurrence (no/yes).
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Figure 7.6: Distribution of the amount of fibroglandular tissue (FGT) for women with
a BRCA mutation and women without a BRCA mutation. The scatterplots show the
association of FGT to false positive recall occurrence.
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Figure 7.7: Distribution of the background parenchymal enhancement (BPE) for
women with a BRCA mutation and women without a BRCA mutation. The box plots
show lowest and highest BPE values (outermost horizontal lines), median BPE (cen-
tral horizontal line), and interquartile range (top and bottom borders of the box) for
breast cancer (no/yes).
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Figure 7.8: Distribution of the background parenchymal enhancement (BPE) for
women with a BRCA mutation and women without a BRCA mutation. Scatter plots
showing association of BPE to breast cancer occurrence (no/yes) and age at baseline
MRI.
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Figure 7.9: Distribution of the background parenchymal enhancement (BPE) for
women with a BRCA mutation and women without a BRCA mutation. The boxplots
are shown for false positive recall occurrence (no/yes).
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Figure 7.10: Distribution of the background parenchymal enhancement (BPE) for
women with a BRCA mutation and women without a BRCA mutation. The scatter-
plots show the association of BPE to false positive recall occurrence.
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Table 7.7: Regression coefficients and odds ratios for the different BPE cut-offs (20%,
30%, 40%, 50%) for the effect on current and subsequent MRI scans on cancer false
positive findings
Model Predictor P-value
Included in
final model
β
(95% CI)
OR
(95% CI)
Shrinkage
factor
Prognostic cancer model
Cancer-BPE BRCA 0.001 x 1.285 (0.747 - 1.908) 3.616 (2.110 - 6.743) 0.96
20%-50% Age 0.930 -
BPE* ≤ 0.761 -
Current false positive recall model
FPR-BPE BRCA 0.623 -
20% Age 0.120 -
BPE* 0.005 x 0.404 (0.133 - 0.704) 1.498 (1.142 - 2.022) 0.88
FPR-BPE BRCA 0.605 -
30% Age 0.144 -
BPE* 0.005 x 0.379 (0.098 - 0.665) 1.461 (1.105 - 1.944) 0.87
FPR-BPE BRCA 0.299 -
40% Age 0.046 x -0.009 (-0.018 - 0.000) 0.991 (0.982 - 1.000) 0.70
BPE* 0.299 -
FPR-BPE BRCA 0.299 -
50% Age 0.045 x -0.009 (-0.018 - -0.001) 0.991 (0.982 - 0.999) 0.70
BPE* 0.424 -
Prognostic false positive recall model
FPR-BPE BRCA 0.773 -
20%-50% Age 0.001 x -0.047 (-0.070 - 0.027) 0.954 (0.932 - 0.973) 0.95
BPE* ≤ 0.839 -
For every model different shrinkage factors were used, shrunk β and OR are presented. β: standardized coeffi-
cients, OR: odds ratio, CI: confidence interval, FGT: amount of fibroglandular tissue, BPE: background parenchy-
mal enhancement
* BPE = low is reference category
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Abstract
Purpose of review Breast MRI has been recognized as the most sensitive modality
for breast cancer screening. Its use is, however, restricted due to the high costs of the
MRI scan itself, the limited availability of MRI scanners and the long reading times.
In this review, the use of shorter MRI protocols for screening is discussed.
Recent findings Shortened scan-protocols have been proposed to reduce both the
actual patient handling time and the time to evaluate the scan. So far, these ’ab-
breviated’ scan protocols have shown similar sensitivity and only marginally lower
specificity as the common scan protocols, while largely reducing scan time and time
required for evaluation. To retain the dynamic information, ultrafast dynamic breast
MRI was introduced, capturing the inflow of contrast in a lesion. This comes for free
in terms of scan-time. The diagnostic information from this dynamic evaluation is
even stronger than the conventional curve types and can be exceptionally helpful in
the evaluation of small lesions. Since abbreviated and ultrafast MRI are not mutu-
ally exclusive, both techniques can be combined, yielding a screening protocol with
a scan-time below five minutes. However, only very few studies evaluated these
protocols in a true screening setting, and the number of detected cancers is likewise
very low.
Summary Abbreviated protocols with ultrafast MRI allow shortening of breast MRI
for screening while retaining excellent sensitivity and specificity. Prospective study
data are, however, limited and must be further substantiated.
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8.1 Introduction
Worldwide the incidence of breast cancer is growing. Depending on the country, the
risk of an average woman to develop breast cancer is up to 15%1. Treatment options
are simpler, less mutilating and better tolerated when cancers are detected at an early
stage; moreover, early detection is still very important for eventual disease-free and
overall survival, despite the improvement in systemic therapies215. Consequently,
screening for breast cancer is employed worldwide, mainly using mammography,
although in some Asian countries ultrasound screening is preferred mainly due to
the relatively small and dense breasts of women in these countries.
The mammographic screening programs have been highly successful in reducing
breast cancer-related mortality, with reported breast cancer-related mortality reduc-
tions up to 58% for women who actually attended216. Nevertheless, mammographic
screening still fails to detect breast cancers early enough for curative treatment in up
to 30% of women. These women eventually develop distant metastasis and may die
from the disease. Mammography functions especially poor in women at increased
risk for the development of breast cancer, with a reported sensitivity well below
50%14,37. After the discovery of the high sensitivity of contrast-enhanced breast MRI
in the mid-eighties35,217, it was soon recognized that breast MRI may have a consid-
erable advantage over mammography for early breast cancer detection. Studies fo-
cused on the detection of breast cancer in women at increased risk, not only because
the performance of mammography in these women was poor, but also due to the fact
that the higher incidence of breast cancer in these women required fewer patients to
be included in the trials to yield significant results. The results of these initial breast
MRI screening trials in many countries were unequivocal, despite the variation in
patient populations; the sensitivity of breast MRI is roughly double that of mam-
mography14,37,41,75,102. In addition, breast MRI triples the additional yield of breast
US as a supplementary screening test for women at increased risk133. Finally, the use
of breast MRI as a screening tool induces a stage shift in these women and a substan-
tially lower risk for distant metastasis and death (0 - 16% and 0 - 7%, respectively),
when compared to historical cohorts (27 - 30% and 17 - 25%, respectively)39,218.
Based upon the initial MRI screening studies, the American Cancer Society pub-
lished its recommendation to screen women with a lifetime risk of 20 - 25% or higher
annually with breast MRI in 2007. This advice was subsequently also adopted by
the European Society for Breast Imaging (EUSOBI), as it was mainly based upon Eu-
ropean trials11,12. Nonetheless, many national organizations do not adhere to this
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advice due to issues with cost-effectiveness. Whereas in women with a BRCA mu-
tation MRI screening is undoubtedly cost-effective219, this is questioned for women
at lower risk, due to the higher amount of women that need to be scanned to find
one additional cancer. Unfortunately, the cost-effectiveness is most influenced by the
price of a single MRI scan220.
Meanwhile, further evaluation of MRI as a screening tool in populations at lower
risk is ongoing. In a recently published study with very liberal inclusion criteria the
supplemental cancer detection using breast MRI in women at average risk, with a
negative screening mammogram was 15.5 per thousand in the first round, which re-
duced to 6.9 per thousand in incidence rounds (nearly all only detected with MRI),
fairly equal to the mammographic detection rates in Europe, and, therefore, once
again showing the potential of breast MRI to induce a stage shift in breast cancer
detection221. Further prospective randomized trials in women with extremely dense
breasts and women with an increased risk based upon family history alone are ongo-
ing9,222. Despite the very likely highly positive results of these trials in terms of early
cancer detection and reduction of interval cancers, it can be anticipated that cost-
effectiveness analysis will once again show that breast MRI in these populations is in
general not affordable, thus limiting the use of an otherwise highly effective screen-
ing tool.
For the further implementation of breast MRI as a screening tool it is thus mandatory
to reduce the costs of the examination itself, which can be most easily achieved by
increasing the throughput of patients in the MRI scanner.
8.2 Abbreviated breast MRI
Abbreviated MRI aims to reduce breast MRI to a minimum length in both acquisition
and interpretation time. Nonetheless, most research focuses on reducing the acqui-
sition time of sometimes lengthy breast MRI protocols (reported scan-times of up to
45 minutes). It is, therefore, necessary to define a maximum scan-time for an MRI
protocol to be called ”abbreviated”. In this paper, we will assume that a truly abbre-
viated breast MRI protocol has a scan-time of less than 5 minutes. Since patient han-
dling times vary between 5 and 10 minutes, this allows the performance of between
4 and 6 breast MRI scans per hour on an average MRI scanner. Virtually all abbrevi-
ated protocols use a subset of the sequences employed in current state-of-art multi-
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parametric protocols that consist usually of at least a dynamic contrast-enhanced se-
ries of about 7 minutes, a T2-weighted acquisition, and possibly a diffusion-weighted
series. Such a protocol lasts between 15 and 20 minutes, lengthier protocols are out-
side of research situations usually not needed and discouraged11,44. The studies on
abbreviated MRI so far usually acquired a whole multi-parametric protocol and an-
alyzed subsets of sequences blinded to the rest of the protocol. There are hardly any
studies that used abbreviated MRI alone for screening of women.
Kuhl et al., who also coined the term, presented the simplest form of abbreviated
MRI. In their protocol, a standard T1-weighted sequence was performed before and
after administration of a contrast agent76. This protocol takes 3 minutes of scan time
as each of the T1-weighted acquisitions lasts approximately 60 seconds and a 60-
second pause from the start of contrast injection is observed to allow the contrast
agent to flow into eventual lesions. Image evaluation was performed by generating
maximum intensity projections (MIP) from the post-contrast subtraction images (see
Figure 8.1). Reading these is extremely fast (reported to be below 2 seconds), and
allows quick dismissal of normal cases when the quality of the MIP images is high.
Using this approach an overall sensitivity of 91% using only the MIP images and
100% when also evaluating the complete subtraction series was achieved (compared
to the normal multiparametric protocol). The specificity was 94.3%, with a negative
predictive value of 99.8%. The main advantage of the full diagnostic protocol was a
better characterization of lesions classified as probably benign (i.e. BI-RADS 3, which
constituted 9% of abbreviated protocol readings). While the entire study included
606 screens, it only detected 11 cancers, therefore solid conclusions about sensitivity
and specificity cannot be drawn. In a study by Mango et al. evaluating cancers only
the sensitivity of evaluating the MIP images alone was also substantially lower than
when evaluating the actual subtraction images (84 - 96%, vs 93 - 98%, over different
readers)52, and it must be stressed that dismissing studies as normal based upon the
MIP images alone requires very good quality MIP images without motion artefacts.
Subsequent studies evaluated different variations of abbreviated protocols. Results
are listed in Table 8.1. Of note is that several abbreviated protocols do not conform
to the definition of a true abbreviated protocol given above, as the scan time is far
longer than would be acceptable for high throughput screening.
Almost all authors reported that sensitivity of abbreviated MRI is virtually equal to
the sensitivity of a full diagnostic protocol. However, results on specificity are more
heterogeneous. While several authors did not report any deviation, many authors re-
port a small to substantial decrease in specificity when evaluating abbreviated breast
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Figure 8.1: Maximum intensity projection of subtracted post contrast acquisition,
clearly showing a multifocal invasive lobular cancer in the left breast
MRI16,17,223–225. This is in fact also in line with the initial study of Kuhl et al. and
seems to be related to the evaluation of the more difficult ”probably benign” and
relatively small lesions. Heacock et al. reported that lesion conspicuity in malignant
breast lesions could be increased by adding a T2-weighted sequence to the abbrevi-
ated protocol54, whereas Chen et al. improved specificity substantially by adding a
diffusion-weighted sequence224. Several authors reduce the number of post-contrast
T1-weighted acquisitions to more than one, thus still enabling dynamic evaluation
of breast lesions in the abbreviated protocol, which is likewise aimed at preserving
the specificity as it does not seem to have an effect on sensitivity. Recently Strahle et
al. tried to define an optimal abbreviated protocol by assessing the diagnostic value
of each of the sequences. They obtained the best results by reducing the full protocol
to a shortened, but still dynamic T1-weighted series, interleaved with a normal T2-
weighted sequence for a total acquisition time of 7.5 minutes, underlining the added
discriminatory value of dynamics and to lesser extent T2226. It should be noted that
their full protocol, however, did not include DWI. In conclusion, it is evident that
abbreviated MRI allows shortening of the full diagnostic breast MRI protocol, with-
out a significant reduction in sensitivity. Effects on specificity are mainly limited to
patients with lesions of low suspicion for malignancy and can be improved by ei-
ther preserving dynamic evaluation, or adding T2 and DWI. However, whether the
extension in acquisition time required for improved lesion classification is economi-
cally viable in a situation where most scans are completely negative (i.e. in screening,
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especially non-high-risk) remains debatable.
8.3 Ultrafast breast MRI
Ultrafast breast MRI is developed to capture the inflow of contrast in breast lesions
and hence enable dynamic analysis of contrast wash-in rather than contrast wash-
out. The technique builds largely on earlier attempts to analyze the pharmacoki-
netic characteristics of breast cancer vasculature, which were shown to allow good
separation between benign and malignant breast lesions227,228. The main difference
Figure 8.2: Maximum intensity projections from an ultrafast dynamic series with a
temporal resolution of 4.3 seconds. TTE is relative to the enhancement of the de-
scending aorta, the first volume that shows this vessel is designated t0 (A). In (B) the
first volume where the lesion is visible is shown, the very early enhancement (only
4.3 seconds after the aorta) make it very likely that this lesion is malignant. In later
time points, morphology becomes clear and can be easily appreciated (C). In (D) the
time versus signal intensity curve for the inflow period is presented. The very steep
upslope is indicative of malignancy.
140 Ultrafast and abbreviated breast MRI
between these techniques, however, is that ultrafast breast MRI is performed with a
spatial resolution that enables morphological assessment of eventual breast lesions
as it meets the international standards for diagnostic breast MRI, and can therefore
also be used for lesion detection. Like abbreviated MRI the term ”ultrafast” is not
clearly defined and sometimes used for MRI techniques that are not exceptionally
fast. In this paper, ultrafast breast MRI is defined as T1-weighted imaging with a
temporal resolution below 6 seconds, and a spatial resolution of at least 1x1x2.5 mm.
Herrmann et al. were in 2011 the first to publish that, view-sharing, a then novel
approach to k-space filling, allowed construction of high-resolution breast MRI ac-
quisitions at a temporal resolution of 5.7 seconds78. The commercial name of the
used sequence is time-resolved angiography with stochastic trajectories (TWIST),
and hence TWIST has become sort of synonymous with ultrafast breast MRI. Le et
al. and Saranathan et al. subsequently showed that similar results were also possible
using fat-saturated and even Dixon techniques, although these are (still) computa-
tionally heavy and, therefore, require long reconstruction times229,230.
In 2014, we proposed the use of ultrafast breast MRI alone as a new screening tech-
nique for breast cancer, based upon a study of 199 abnormalities where the wash-in
characteristics obtained with TWIST were compared to the wash-out characteristics
from the same lesions obtained from regular T1-weighted series. The ultrafast pro-
tocol obtained 20 T1-weighted volumes at a temporal resolution of 4.3 seconds, for
a total duration of 102 seconds, therefore being faster than any of the abbreviated
protocols discussed above. The study unequivocally showed that maximum slope
(MS), a heuristic dynamic parameter obtained from the TWIST images largely out-
performed the conventional curve types (area under the curve 0.81 vs 0.69), while
still allowing imaging at diagnostic spatial resolution. MS can be assessed in a simi-
lar way as the curve types, where a steep slope is indicative of malignancy, a shallow
slope of a likely benign lesion and an intermediate curve is indeterminate55. In fur-
ther studies, it was subsequently shown that also the time to enhancement relative
to aortic enhancement (TTE) is a highly discriminative and very reproducible pa-
rameter for breast lesion characterization231. In simple words, lesions that enhance
within 10 seconds after the aorta are likely malignant, lesions that enhance between
10 and 15 seconds after the aorta are indeterminate, and lesions that enhance more
than 15 seconds after the aorta are likely benign. As ultrafast breast MRI allows the
generation of a series of MIP images (one for each post-contrast timepoint acquired),
it is possible to evaluate these dynamic MIPS as a movie of contrast inflow. Based
upon the above, the first enhancing lesion is usually the one that deserves the most
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attention. In patients with cancer, you may observe a ”lightbulb” effect, as you see
the cancer enhancing in an otherwise completely black breast (see Figure 8.2). This
effect is also very valuable for the evaluation of breasts with nodular background
enhancement, to differentiate true lesions from focal areas of adenosis77. Another
approach is the assessment of the time between arterial supply and venous drainage
in breast lesions. Overall, when arterial supply is observed, the lesion already has
a very high likelihood of being malignant, which further increases when the time
from arterial supply to venous drainage is short, a parameter that is highly related
to the TTE described above232. It is, nonetheless, suggested to start with the evalu-
ation of the MIP generated from the last time point obtained. When this MIP is of
good quality and truly negative there is no need for evaluation of the other phases
(which is comparable to the MIP reading proposed by Kuhl et al. and Mango et
al.). Of note is that the excellent discriminating capacity of MS and TTE are also
valid for computer-aided diagnosis233, and remain valid over various types of breast
cancer, including invasive lobular cancers and ductal carcinoma in situ234. It is still
essential to realize that, even though with TWIST a spatial resolution is obtained of
1x1x2.5 mm, this is still lower than in most high-resolution T1-weighted protocols
where voxels usually are below 1mm isotropic. Consequently, multi-plane recon-
struction is somewhat limited and therefore morphological evaluation is not as good
as with conventional protocols in all directions. However, recent studies employing
compressed sensing with iterative reconstruction rather than view-sharing allow a
substantial further reduction of the spatial resolution, down to 0.8x0.8x1.6 mm, in
the same time frame235,236.
Whether ultrafast MRI alone is good enough for breast screening remains to be
evaluated, as published studies so far mainly looked at lesion classification capac-
ity. However, Van Zelst et al. presented at RSNA 2016 preliminary results of a
reader study with TWIST only versus a full diagnostic protocol on 85 biopsied le-
sions, including 31 malignancies, obtained from over 3000 screening examinations,
and complemented with 115 normal cases. Based upon the first 4 readers the av-
erage sensitivity of TWIST only evaluation was 80%, compared to 85% for the full
diagnostic protocol, without statistical significance. However, the relative low sen-
sitivities show the difficulty of the comprised case set consisting of only screening
cases. Typically the average specificity of TWIST only reading was, at 81%, signifi-
cantly higher than with the full diagnostic protocol at 77%, while the average area
under the curve for the two reading modes was virtually identical81. Nevertheless,
the final results of that study, including more readers must be awaited.
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8.4 Hybrid imaging
It is important to realize that the definitions of abbreviated and ultrafast MRI are not
mutually exclusive. In fact, ultrafast MRI alone is a form of an abbreviated protocol
with a very short acquisition time (less than 2 minutes). However, for the perfor-
mance of ultrafast breast MRI as a stand-alone technique, specific sequences are re-
quired that are not uniformly available. With classic, and far more commonly avail-
able, keyhole techniques (i.e. turboFLASH, eThrive etc.), it is, unfortunately, not pos-
sible to obtain the required temporal resolution at a diagnostically acceptable spatial
resolution. Nevertheless, even in the most basic form of an abbreviated protocol, the
period of contrast inflow must be observed. Kuhl et al. solved this by simply wait-
ing 60 seconds before acquiring the post-contrast acquisition. Obviously, ultrafast
acquisitions (even of lower spatial resolution) can be inserted in this waiting period
without any penalty in overall scanning time. This still allows very fast evaluation
of the entire protocol by evaluating the MIP image and high-resolution subtraction
series, but in the presence of lesions substantial additional dynamic information is
present for lesion classification (it should be noted that when the last post-contrast
scan is negative, it is not needed to evaluate all the previous phases). The superior
performance of wash-in characteristics from ultrafast imaging compared to standard
wash-out evaluation truly makes late phase acquisitions obsolete and enables a huge
shortening of the protocol without losing any information. Whether or not the addi-
tion of T2 or DWI is beneficial in the screening setting remains to be seen.
8.5 Conclusion
The further expansion of breast MRI as a screening tool is limited by the high cost
of the examination itself. To enable a more widespread use of this highly effective
screening technique, it is important to reduce the price of an actual MRI scan. The
most practical approach to that is shortening the actual acquisition protocol, as only
an increase in throughput can reduce the price of a single breast MRI to a more
acceptable level. This is particularly important when screening women at an inter-
mediate risk for the development of breast cancer, such as those with a positive fam-
ily history without hereditary genetic mutations, and women with extremely dense
breasts. Abbreviated protocols, particularly those employing (also) ultrafast breast
MRI, may offer the required efficiency. However, although in recent years many
studies have investigated such protocols, the actual amount of screening-detected
cancers in these studies is still very low. This makes a true assessment of the value
of either abbreviated or ultrafast MRI as a screening technique still somewhat lim-
8.5 Conclusion 143
Table 8.1: Studies comparing abbreviated protocols to full diagnostic protocols; effects on sensi-
tivity and specificity
Author (year) Abbreviated
protocol (duration)
Number of
cancers/total
cases
Sensitivity
Abbreviated
protocol
Specificity
Abbreviated
protocol
Sensitivity
Full diagnostic
protocol
Specificity
Full diagnostic
protocol
Kuhl 2014 76 T1 pre & post
contrast (3 min)
11/606
(screening
population)
100% 94.3% 100% 93.4%
Mango 2015 52 Sag T1 pre
& post contrast
(10-15 min)*
100
(cancers only)
93-98% NA 95-98% NA
Grimm 2015a 53 T2 FS, T1 pre
& post contrast
(21 min)*
12/48
(enriched)
86% 52% 95% 52%
Grimm 2015a 53 T2 FS, T1 pre
& post contrast +
second post
contrast
(23 min)*
12/48
(enriched)
89% 45% 95% 52%
Harvey 2016 16 T1 pre & post
contrast
(4.4 min)
7/568
(screening
population)
100% 94% 100% 96%
Heacock 2016a 54 T1 pre & post
contrast
(7min)
107
(cancers only)
97.8% NA 99.4% NA
Heacock 2016a 54 T2 FS, T1 pre &
post contrast
(12 min)
107
(cancers only)
99.4% NA 99.4% NA
Moschetta 2016 17 T2 STIR, T2, T1
pre & postcontrast
(10 min)
75/470
(clinical
population)
89% 91% 92% 92%
Chen 2017 223 T1 pre & post
contrast
(3 min)
16/478
(dense breast
screening)
93.8% 88.3% 100% 94.6%
Petrillo 2017 237 T1 pre & post
contrast
(3 min)
207/508
(clinical
population)
99.5% 75.4% 99.5% 77.1%
Chen 2017a 224 T1 pre & post
contrast
(3 min)
14/356
(dense breast
screening)
92.9% 86.5% 100% 96.8%
Chen 2017a 224 T1 pre & post
contrast +DWI
(6 min)
14/356
(dense breast
screening)
100% 95% 100% 96.8%
Romeo 2017 225 T1 pre & 3 *
post contrast
(7 min)
110/180
(lesions only)
99% 93% 97% 95%
Panigrahi 2017 238 T1 pre & post
contrast
(3 min)
11/678
(high risk
screening)
81.8% 97.2% 81.8% 97.4%
* scan time reported included patient positioning
a reported 2 different abbreviated protocols in one study
ited. Considering the current results, it is nevertheless unlikely that the sensitivity
of abbreviated MRI is much lower than that of a full diagnostic protocol and defini-
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tively much higher than either mammography, tomosynthesis, or ultrasound. This
already underlines its potential value for supplemental evaluation of women with
very dense breasts, even when it is still somewhat unsure whether it can completely
replace the full diagnostic protocol in women currently already screened with MRI.
It is, in fact, likely that the specificity of abbreviated breast MRI is somewhat lower
than that of a full diagnostic protocol, which in the screening setting might be a
large issue, leading to a substantially higher number of recalls and additional eval-
uations. Still, this may already be largely compensated by incorporation of ultrafast
breast MRI in the abbreviated protocol (if not used as stand-alone technique). Con-
sequently, ultrafast abbreviated MRI will likely become the MRI screening technique
of the near future.
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Abstract
Objective Ultrafast dynamic contrast-enhanced magnetic resonance imaging of the
breast enables assessment of the contrast inflow dynamics while providing images
with diagnostic spatial resolution. However, the slice thickness of common ultra-
fast techniques still prevents multiplanar reconstruction. In addition, some temporal
blurring of the enhancement characteristics occurs in case view-sharing is used. We
evaluate a prototype compressed-sensing volume-interpolated breath-hold exami-
nation (CS-VIBE) sequence for ultrafast breast MRI that improves through plane spa-
tial resolution and avoids temporal blurring while maintaining an ultrafast temporal
resolution (less than 5 seconds per volume). Image quality (IQ) of the new sequence
is compared with an ultrafast view-sharing sequence (time-resolved angiography
with interleaved stochastic trajectories [TWIST]), and assessment of lesion morphol-
ogy is compared with a regular T1-weighted 3D Dixon sequence (VIBE-DIXON) with
an acquisition time of 91 seconds.
Materials and Methods From April 2016 to October 2016, 30 women were scanned
with the CS-VIBE sequence, replacing the routine ultrafast TWIST sequence in a hy-
brid breast MRI protocol. The need for informed consent was waived. All MRI
scans were performed on a 3T MAGNETOM Skyra system (Siemens Healthcare, Er-
langen, Germany) using a 16-channel bilateral breast coil. Two reader studies were
conducted involving 5 readers. In the first study, overall IQ of CS-VIBE and TWIST
in the axial plane was independently rated for 23 women for whom prior MRI ex-
aminations with TWIST were available. In addition, the presence of several types of
artefacts was rated on a 5-point scale. The second study was conducted in women (N
= 16) with lesions. In total, characteristics of 31 lesions (5 malignant and 26 benign)
were described independently for CS-VIBE and VIBE-DIXON, according to the BI-
RADS MRI lexicon. In addition, a lesion conspicuity score was given.
Results Using CS-VIBE, a much higher through-plane spatial resolution was achieved
in the same acquisition time as with TWIST, without affecting in-plane IQ (P = 0.260).
Time-resolved angiography with interleaved stochastic trajectories showed slightly
more motion artefacts and infolding and ghosting artefacts compared with CS-VIBE,
whereas CS-VIBE showed more breathing and pulsation artefacts. For morphologic
assessment, intrareader agreement between CS-VIBE and the more time-consuming
VIBE-DIXON was slight to almost perfect and generally higher than interreader
agreement. Mean sensitivity (84.0% and 92.0% for CS-VIBE and VIBE-DIXON, P
= 0.500) and specificity (60.0% and 55.4% for CS-VIBE and VIBE-DIXON, P = 0.327)
were comparable for both sequences.
Conclusions Compressed-sensing volume-interpolated breath-hold examination al-
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lows an increase of the through-plane spatial resolution of ultrafast dynamic contrast-
enhanced magnetic resonance imaging compared with TWIST at a comparable in-
plane IQ. Morphological assessment of lesions using CS-VIBE is comparable to VIBE-
DIXON, which takes 18 times longer. Consequently, CS-VIBE enables 3D evaluation
of breast lesions in ultrafast breast MRI.
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9.1 Introduction
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the breasts
is considered to be the most sensitive method for early breast cancer detection. In a
meta-analysis, an overall sensitivity of 90% was reported, and also in recent screen-
ing studies in high-risk patients, a sensitivity of over 90% was achieved41,75,239. None-
theless, breast MRI is currently only used for screening purposes in women at in-
creased risk for developing breast cancer (> 20% of lifetime risk)166. In the early
years of breast MRI, a lower specificity of DCE-MRI in comparison to mammogra-
phy240 was repeatedly reported. This led to the development of dedicated protocols
for breast MRI that incorporated, for example, contrast-wash-out evaluation, late
high-resolution T1 acquisitions, T2, and diffusion sequences. Although several au-
thors showed that each of these techniques has the ability to improve the specificity
of breast MRI without lowering its sensitivity57,158,241, their added value in a screen-
ing setting where most scans are normal is debatable. In fact, screening women at
lower risk is only cost-effective if the costs of breast MRI itself can be reduced, and
thus any sequence that lengthens the protocol should be critically evaluated.
Current research hence focuses on shortening breast MRI protocols without decreas-
ing sensitivity or specificity. For this purpose, abbreviated protocols were created
and investigated52–54,76. In the most basic form, an abbreviated MRI protocol con-
sists of T1 acquisitions before and after contrast administration (typically around
90 seconds per acquisition), subtraction, and the formation of maximum intensity
projections. This allows morphologic evaluation of possible breast lesions but dis-
cards most other information, including the dynamic contrast characteristics that
have long been regarded as a hallmark of breast MRI.
Ultrafast MRI protocols re-enable dynamic analysis during contrast inflow and there-
fore do not lengthen the protocol (temporal resolution of 5 seconds). In fact, ultrafast
breast MRI can be performed within 2 minutes and thus even shortens the protocol
further. Mann et al55 showed that the dynamic parameters obtained can be used to
characterize lesions as benign or malignant, which is particularly useful in the evalu-
ation of small breast lesions typically found in screening, as these often do not show
the classical morphologic features of malignancy55.
Although the ultrafast sequences used today can achieve a diagnostic spatial resolu-
tion (under 1 x 1 x 2.5 mm) according to international standards, the through-plane
resolution is not sufficient for multiplanar reconstruction. In addition, the view-
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sharing used may give rise to temporal blurring.
With the recent advances in MRI and computational power, a new technique called
compressed sensing (CS) has become available. Compressed-sensing accelerates
imaging by acquiring a subset of the full k-space. Random subsampling of data and
constraining the reconstruction for certain properties allow for obtaining artefact-
free images242. Using CS, an image with a high spatial resolution can be computed
at a temporal resolution of less than 5 seconds.
In this study, we evaluate whether a prototype sequence for ultrafast dynamic breast
MRI based on a gradient-echo sequence with compressed sensing (compressed-sens-
ing volume-interpolated breath-hold examination [CS-VIBE])243 could replace the
DCE series currently in use in clinical practice. This requires both a very high tem-
poral resolution to document the wash-in phase and high 3-dimensional spatial res-
olution to allow for multiplanar assessment of morphology. We compare CS-VIBE to
a commercially available technique based on view-sharing (time-resolved angiogra-
phy with interleaved stochastic trajectories [TWIST]), evaluating image quality (IQ)
and the presence of artefacts, to assess whether the compressed sensing approach can
overcome the limitations that are still present with the view-sharing technique. In
patients with abnormalities, we also compare the CS-VIBE sequence for morphologic
evaluation and lesion conspicuity assessment to a regular T1-weighted gradient-
echo Dixon sequence (VIBE-DIXON) with an acquisition time of 91 seconds.
9.2 Materials and Methods
Patients
From April 2016 until October 2016, 30 women with a breast MRI indication were
scanned with a hybrid protocol that included the prototype ultrafast CS-VIBE se-
quence during contrast inflow. The institutional review board waived the need for
informed consent.
Imaging
All women were scanned on a 3T MAGNETOM Skyra system (Siemens Healthcare,
Erlangen, Germany) using a 16-channel bilateral breast coil. In our previously pub-
lished hybrid protocol,13 the regular ultrafast view-sharing acquisition (TWIST) is
interleaved in between the initial phases of a high-resolution T1-weighted 3D gra-
dient echo Dixon sequence (VIBE-DIXON). In this study, the TWIST sequence was
replaced with the prototype CS-VIBE sequence243. The CS-VIBE sequence incoher-
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Table 9.1: Sequence parameters
CS-VIBE TWIST VIBE-DIXON
TR (ms) 4.47 3.96 5.97
TE (ms) 2.06 2.02
1: 2.46
2: 3.69
FA (◦) 15 20 15
Field of View (mm2) 358.4x358.4 345.6x345.6 332.8x332.8
Matrix size 448x381 384x346 416x358
In-plane resolution (mm) 0.8x0.8 0.9x0.9 0.9x0.9
TWIST central region A (%) /
Sampling density B (%)
-
A: 15
B: 10
-
Slice thickness (mm) 1.6 2.5 1.0
Voxel volume (mm3) 1.02 2.03 0.81
Phase resolution (%) 85 90 86
Slice resolution (%) 70 77 80
Acceleration factor 20 3 3
Acceleration mode CS GRAPPA GRAPPA
Time resolution per volume (s) 1.55 4.57 91
Total acquisition time (min) 1:40 2:03 1:31
ently subsamples the phase-encoding plane in a variable-density manner with a se-
lectable overall acceleration factor. Specifically, the sampling is designed to obey a
Gaussian distribution for which the density drops from center to border of acquired
k-space and can be adjusted in both phase-encoding directions. Furthermore, it is
also guaranteed that the accumulated sampling up to any time point does not devi-
ate from its expectation value by more than one. Image reconstruction is performed
by optimizing a cost function of the form
min
I
(
1
2
||AI−D||22 + ||WI||I) (9.1)
where I is the reconstructed 3D + time image series; D is the acquired MRI k-space
data; and A is the system operator consisting of multiplication with coil sensitivi-
ties, Fourier transformation, and masking. Finally, W is the redundant Haar wavelet
transformation that was applied in the phase-encoding directions and the time di-
rection. Parameters of the prototype CS-VIBE, the TWIST, and the VIBE-DIXON are
presented in Table 9.1.
In addition, to enable comparison of CS-VIBE to TWIST, we collected all previous
MRI acquisitions of these women that contain TWIST from the picture archiving and
communication system, when available. Images were obtained before, during, and
after contrast administration (0.1 mmol/kg Dotarem [gadoteric acid 0.5 mmol/mL];
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Guerbet, Villepinte, France) through an intravenous cannula placed in the cubital
vein. A power injector (Medrad, Warrendale, PA) was started immediately after
completion of the first population in k-space in case of the TWIST sequence or after
the first acquisition in case of the CS-VIBE sequence at a rate of 2.5 mL/s. The con-
trast bolus was followed by a saline flush of 20 mL.
Reader studies
Two separate reader studies were conducted, using an in-house developed platform
for diagnostic studies244. This platform showed original and subtracted images for
all available time points and provided reformatted images in the coronal and sagittal
planes, along with the originally obtained axial acquisitions. Five readers with var-
ious levels of experience read both studies (1 radiologist with 9 years of experience
in breast MRI, 1 radiologist with 7 years of experience in breast MRI, 1 radiologist
with 3 years of experience in breast MRI, 1 radiologist with less than 1 year of expe-
rience in breast MRI, and 1 radiologist in training with less than 1 year experience in
breast MRI). For both studies, readers were blinded to all clinical information, and
the cases were presented to the readers in random order. In the first study, image
quality of CS-VIBE was compared with TWIST. In the second study, lesion conspicu-
ity and morphological assessment was compared with VIBE-DIXON.
Reader Study 1: Image Quality of CS-VIBE Compared with TWIST
This study was conducted in 23 women for whom prior MRI examinations with
TWIST were available. Overall image quality (IQ) of the CS-VIBE and TWIST im-
ages was independently rated on a discrete scale from 1 to 100. In addition, the
effect of several types of artefacts (motion, breathing and pulsation, ghosting and
infolding, external influences [susceptibility]) on image evaluation was rated on a
5-point scale (1 = heavily disturbing to 5 = not present).
Reader Study 2: Lesion Appearance on CS-VIBE Compared with VIBE-DIXON
The second study was conducted using all lesions described in the clinical evaluation
of the breast MRI scans. Motion correction was applied for VIBE-DIXON images148.
In total, 31 lesions were described in 16 patients. Five lesions were proven to be
malignant, 26 lesions were benign (either based upon histology [N = 13] or clinical
follow-up of at least 1 year [N = 13]). Patients were presented in random order to
the readers. Either the CS-VIBE images or the VIBE-DIXON water images were pre-
sented. Each case was thus read twice. Readers were informed about the location
of the lesions in the breast(s) (quadrant and clockface); no further information was
provided.
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The lesions were independently evaluated on the CS-VIBE images and the VIBE-
DIXON water images. Each lesion was described according to the BI-RADS MRI
lexicon19,126. A BI-RADS score (1 to 5) was provided. In addition, a lesion conspicu-
ity score on a 5-point scale (1 = not visible to 5 = very clear) was provided for each
lesion.
Dynamic Analysis
To investigate whether the dynamic parameters obtained with the CS-VIBE sequence
were in line with those obtained with TWIST, the time to enhancement (TTE) was
measured and maximum slope type of the inflow curve was scored by 1 reader for
all lesions in which a prior MRI scan with TWIST was available (N = 24; all benign).
Time to enhancement was defined as the time to enhancement measured from the
moment the aorta starts to enhance245. Slope types were scored according to Mann
et al55.
Statistical Analysis
To assess the IQ of CS-VIBE compared with TWIST, we averaged all IQ scores per
reader. To account for multiple independent readers and for repeated measures, a
linear mixed model approach was used. The sequence (CS-VIBE, TWIST) was used
as a fixed classification score. Interreader agreement was assessed using the intra-
class correlation coefficient (ICC). To assess the impact of artefacts, we dichotomized
the results per reader, based upon the assumption that scores 1 and 2 might impair
the evaluation, whereas 3 to 5 are given in cases where the artefacts might be present
but will not impact the evaluation. We, subsequently, evaluated whether the pres-
ence of severe artefacts (rated 1 or 2) in each of the 4 defined artefact categories was
more prevalent in CS-VIBE or TWIST using McNemar tests per-reader. Interreader
agreement was assessed using Fleiss kappa for the dichotomized artefact values.
To assess the quality of lesion characterization, we compared lesion conspicuity
scores between CS-VIBE and VIBE-DIXON using the Wilcoxon signed ranks test. To
assess whether lesion characteristics were comparable for the 2 sequences, we calcu-
lated intrareader agreement using weighted kappa statistics. Interreader agreement
was assessed using Fleiss kappa statistics. The strength of the agreement was defined
as poor for less than 0.000, slight for 0.000 to 0.200, fair for 0.201 to 0.400, moderate
for 0.401 to 0.600, substantial for 0.601 to 0.800, and almost perfect for 0.801 to 1.000.
Sensitivity and specificity of both sequences based on morphologic evaluation were
calculated using the BI-RADS scores, where BI-RADS 3, 4, and 5 were considered
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positive. Sensitivities and specificities were calculated using the pooled scores for all
readers and compared using McNemar tests. All statistical analyses were performed
using SPSS (version 22, SPSS Inc, Chicago, IL). Results with 2-sided P-values of 0.05
or less were considered statistically significant.
9.3 Results
Subjects
The 30 women included in this study were on average 46 years of age (range: 28
- 72). Breast MRI scans were performed for screening in women with a BRCA gene
mutation (N = 15), family history of breast cancer without a known mutation (N = 3),
personal history of breast cancer (N = 3), dense breasts (N = 1), ataxia telangiectasia
(N = 1), and previous radiation to the chest (N = 1); problem solving in 1 woman
with duct ectasia and 1 woman referred from the screening program; and staging of
known breast cancer (N = 4).
Reader Study 1: Image Quality of CS-VIBE Compared with TWIST
Using the CS-VIBE sequence, images could be obtained with a comparable temporal
resolution as that of TWIST (see Table 9.1). The advantage of CS-VIBE over TWIST
is the possibility of achieving a much higher spatial resolution (0.8 x 0.8 x 1.6 mm
vs 0.9 x 0.9 x 2.5 mm) and therefore enabling better multiplanar reconstructions (see
Figure 9.1). The average IQ scores per reader were 75, 66, 70, 69, and 56 for CS-VIBE,
and 70, 63, 76, 71, and 45 for TWIST (see Table 9.2), and statistical analysis showed
that IQ was comparable between CS-VIBE and TWIST (P = 0.260). Table 9.2 also lists
the artefact scores per reader. Overall, artefacts that disturbed image interpretation
were relatively rare. According to the 5 readers, motion artefacts severely impacted
image quality appeared more in TWIST compared with CS-VIBE (0 to 3 cases and
0 to 9 cases for CS-VIBE and TWIST, respectively); in 1 reader (R3, P = 0.031), this
difference was significant. Severe breathing and pulsation artefacts were reported 0
to 11 cases for CS-VIBE and 0 to 10 cases for TWIST. In the CS-VIBE cases, pulsation
artefacts were seen only in the axilla. In 1 reader, these artefacts were significantly
higher in CS-VIBE images (R3, P = 0.004, see Figure 9.2). Ghosting and infolding
artefacts were reported in 0 to 6 cases for CS-VIBE and 0 to 13 cases in TWIST. In 1
reader, TWIST (R5, see Figure 9.3) significantly showed more of these artefacts (P =
0.039). One reader reported severe susceptibility artefacts in 4 cases for CS-VIBE and
6 for TWIST.
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Reader Study 2: Lesion Appearance on CS-VIBE Compared with VIBE-DIXON
For this analysis, 31 lesions were re-evaluated (see Figure 9.4). Although lesion con-
spicuity scores were slightly lower for CS-VIBE (average CS-VIBE = 3.3, average
VIBE-DIXON = 3.6, P = 0.004, see Table 9.3), sensitivity and specificity did not sig-
nificantly differ (P = 0.500 and P = 0.327 for sensitivity and specificity, respectively).
Pooled sensitivity and specificity were 84.0% and 60.0% for CS-VIBE and 92.0% and
55.4% for VIBE-DIXON. Intrareader agreement for BI-RADS descriptors was slight
to almost perfect depending on the descriptor tested and ranged from 0.145 to 0.937
between sequences, as shown in Table 9.4. Overall intrareader variability was struc-
turally less than interreader variability, hence showing more effect from readers than
from the sequences used.
Table 9.3: Lesion assessment of lesion appearance reader study
CS-VIBE VIBE-DIXON
R1 R2 R3 R4 R5 R1 R2 R3 R4 R5
Assessment
category
- BI-RADS 1 1 10 1 0 4 0 1 0 0 1
- BI-RADS 2 20 11 10 14 11 20 11 5 23 13
- BI-RADS 3 4 8 5 11 2 5 14 8 6 3
- BI-RADS 4 2 2 11 6 14 2 2 14 1 12
- BI-RADS 5 4 0 4 0 0 4 3 4 1 2
Lesion conspicuity
score ∗
1 0 12 1 0 4 0 7 0 0 1
2 3 10 6 0 2 2 7 2 1 2
3 7 9 11 14 8 12 10 8 9 6
4 17 0 9 7 7 14 7 13 12 5
5 4 0 4 10 10 3 0 8 9 17
* Lesion conspicuity is scored from 1: not visible to 5: very clear
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Figure 9.1: An example of the described sequences in a 28 years old woman. An ex-
ample of TWIST of approximately one year earlier (a), CS-VIBE (b), and VIBE-DIXON
(c) in axial (top), coronal (middle), and sagittal reconstruction (bottom).
Dynamic Analysis
Dynamic analysis (TTE and inflow curve type) was compared using 24 benign le-
sions in 11 women for which both CS-VIBE and TWIST acquisitions were available.
The mean TTE was 16 seconds for the CS-VIBE and 22 seconds for TWIST (P = 0.448,
sdCS-VIBE = 12.7 seconds, and sdTWIST = 9.2 seconds). Also, curve types were com-
parable between the CS-VIBE sequence and TWIST (P = 0.242). Most lesions showed
a relatively slow wash-in of contrast (curve type 1), as is expected in benign lesions.
9.4 Discussion
In this study, we show that the use of compressed sensing allows strong improve-
ment of the spatial resolution of ultrafast breast MRI. A reduction of more than 50%
of the voxel size compared with a view-sharing approach is possible at comparable
in-plane image quality. This allows multiplanar reformatting of axial acquisitions
and thus morphological assessment of eventual lesions in 3 perpendicular planes.
In fact, we found that morphologic assessment of specified lesions was not signifi-
cantly different between CS-VIBE and the 18 times lengthier T1-weighted 3D Dixon
sequence, and we also did not observe significant differences in sensitivity or speci-
ficity between these sequences, thus showing the potential of using ultrafast acqui-
sitions alone for both morphologic and dynamic analysis.
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Figure 9.2: Example of a typical pulsation artefact in CS-VIBE; best seen in the left
axillary region.
Figure 9.3: Example of a typical ghosting artefact in TWIST
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Figure 9.4: Lesion morphology in CS-VIBE (a, latest time-point (20)) and VIBE-
DIXON (b, first time point) in a 53-year-old woman with an invasive ductal carci-
noma in the right breast is virtually identical in all planes. Left column: original
images; right column subtraction images.
Compressed-sensing volume-interpolated breath-hold examination seems to reduce
ghosting and infolding artefacts compared with TWIST, although the results of the
current study are not significant. This is important as Le et al229 also noted that these
artefacts were common in TWIST, and may impair image quality in the breasts.
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In CS-VIBE, a specific pulsation artefact was commonly seen in the axillary region,
where propagation of heartbeats sometimes distorts the image. Whether this is im-
portant when screening for breast cancer is an area of debate. Less than 1% of all
breast cancers are detected by axillary metastasis alone246, and the specificity of
breast MRI for the detection of abnormal lymph nodes is only moderate at best247.
Even in ultrasound screening, it was recently shown that assessment of the axilla
mainly leads to more false-positive findings and is thus discouraged248. Conse-
quently, in a screening setting, the assessment of the axilla seems to be of limited
relevance, and artefacts in this region are therefore relatively acceptable.
Initially, ultrafast DCE-MRI acquisitions of breast lesions were developed to capture
the inflow of contrast in breast lesions. The information obtained could be quanti-
fied using pharmacokinetic models that yielded the contrast transfer coefficient, the
rate constant, and the relative fraction of the extravascular extracellular space. It was
shown in several studies that this information could be used to improve the discrim-
ination between benign and malignant lesions249. In terms of spatial resolution, the
sequences used for this purpose were poor, and therefore morphologic evaluation
of lesions using these images alone was long deemed impossible. Only with the de-
velopment of faster view-sharing sequences such as TWIST, 4d TRAK, and DISCO,
it became possible to obtain inflow information at a spatial resolution that was con-
sidered diagnostically adequate55,230. Simultaneously, alternative approaches for in-
terpretation of the dynamic data, such as maximum slope and time to enhancement,
that abandoned the quantitative calculations, improved the usability of inflow dy-
namics for clinical practice. It was, thus, postulated that using TWIST alone, breast
screening with MRI could be performed in less than 2 minutes55. Nonetheless, pro-
tocols now in use and under development for abbreviated breast MRI still use a hy-
brid approach9, where the ultrafast series is interleaved between 2 high-resolution
acquisitions during inflow of contrast. In practice, this adds about a minute of scan
time to the dynamic protocol, which may not seem much but is an increase in over-
all scan time of approximately 150% and likely also adds to the interpretation time.
Further improvement of ultrafast acquisitions that completely resolve the need for
additional high-resolution acquisitions is thus warranted, and CS-VIBE seems an im-
portant step in this process.
In addition to the limited through-plane resolution of TWIST, all view-sharing se-
quences also suffer from temporal blurring. This may cause a delay in the visualiza-
tion of small vessels and reduce the discriminative power of enhancement charac-
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teristics. Rapacchi et al250 combined compressed sensing with TWIST to reduce the
temporal footprint. This reduced blurring due to motion in thoracic MRA and in-
creased overall vessel sharpness. In our study, we showed that dynamic parameters
obtained with TWIST and CS-VIBE were comparable for benign lesions. However,
due to the low number of malignant cases in our dataset (N = 5), we were unable to
determine the discriminating capacity between benign and malignant breast lesions
of the dynamic parameters obtained from the CS-VIBE. The reduction in temporal
blurring might imply that cutoffs determined for view-sharing approaches should
be slightly adjusted for the compressed sensing approach. Future research should
determine whether there is a significant difference in time to enhancement and max-
imum slope for TWIST and CS-VIBE and whether this may have a clinical impact on
lesion management.
There are some limitations to our study. In the current study, apart from the pres-
ence of artefacts, we did not quantify other image quality aspects such as sharpness
of contours or image homogeneity but rather focused on the subjective reader as-
sessment of image quality for diagnosis. For quality comparison, we used TWIST
images that were obtained approximately 1 year before the CS-VIBE acquisitions,
rather than performing both sequences in succession in the same patient. This may
have increased the presence of positioning differences and associated motion arte-
facts251. However, we thought this was appropriate due to the fact that the value of
ultrafast acquisitions can only be appreciated during contrast administration. Per-
forming the 2 acquisitions in succession would require a contrast wash-out period
in between and thus patients would anyway be taken out of the scanner and repo-
sitioned for the next acquisition. Differences in positioning and movement artefacts
would therefore likely have occurred in a similar fashion using this approach. This
would, however, have prevented eventual differences in breast shape and volume
caused by weight gain or loss of our patients. Nonetheless, giving contrast twice to
the same patient only for comparison of 2 sequences might be regarded as less ac-
ceptable in light of the current discussion on the safety of gadolinium-based contrast
agents86. This holds also true for the comparison of CS-VIBE versus VIBE-DIXON, in
which, due to the structural differences in timing (the VIBE-DIXON was always ac-
quired after the CS-VIBE) different levels of background parenchymal enhancement
were observed. In theory, this may slightly affect the morphological description of
the lesions.
Furthermore, we investigated multiple lesions within the same patient, thus assum-
ing that all lesions can be considered as independent primary lesions. Although this
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assumption likely holds true for benign lesions, it may not be completely valid in
malignant lesions as multicentric or multifocal disease is present in 20% to 25% of
the malignant cases11. To overcome this issue, we only evaluated lesions that were
reported as independent abnormalities in clinical evaluation. This implied that, only
in 1 patient with a malignancy, 2 malignant lesions were scored, as these were highly
different in their morphological appearance.
As commonly reported252, interreader variability of morphological BI-RADS descrip-
tors was large. In this specific study, it might have even been larger than usually
reported due to the different clinical background and experience of our readers.
However, because we mainly focused on the effects of the different sequences on
intrareader variability, this is of less concern.
A current limitation for implementation of the CS-VIBE is that, on the standard scan-
ner hardware, reconstruction of the complete time series per subject still takes 45
minutes (depending on breast size). Currently, this is impairing clinical workflow.
However, future optimization of the reconstruction process will probably render the
technique clinically viable. In addition, it is possible to perform the reconstructions
offline, which now already allows a clinically viable pipeline, considering that it
seems acceptable that scans are read a day after acquisition.
In conclusion, the IQ of CS-VIBE was comparable to TWIST while a much higher
spatial resolution can be achieved. In addition, CS-VIBE reduces temporal blurring
in the evaluation of inflow dynamics and enables multiplanar assessment of lesion
morphology. Compressed-sensing volume-interpolated breath-hold examination is
a promising technique for ultrafast breast MRI with high spatiotemporal resolution.
General discussion
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The early detection of breast cancer has proven to increase survival253–255. Mainly
because of this finding, many countries have introduced population-based mammo-
graphic screening programs. However, mammography has its limitations. These
limitations make mammography less suitable as a stand-alone technique for screen-
ing of women at high risk of developing breast cancer. Women at increased risk for
breast cancer are, therefore, invited for intensified screening programs composed of
a yearly breast MRI in addition to a yearly mammography exam.
Prospective trials14,15,37–42 have evaluated the performance of these breast MRI screen-
ing programs. In these trials, the screening performance was measured by several
performance measures that are regularly used for auditing purposes. In accordance
with the terminology used for mammographic screening: recall rate, biopsy rate,
positive predictive value of recall, positive predictive value of biopsy, cancer detec-
tion rate, sensitivity, and specificity are the usually reported metrics. Sensitivity and
specificity numbers of breast MRI reported by prospective trials are in the range of
71% to 91% and 89% to 97%, respectively14,15,37–42.
The detection and appearance of most breast cancers on breast MRI are relatively
straightforward. Cancers can be recognized by their fast and strong enhancement
as they typically light up within a minute after the contrast agent is injected. How-
ever, not only cancers light up with breast MRI, benign lesions or even normal breast
parenchyma can also have a relatively fast enhancement with wash-out. This is the
reason why breast MRI has a lower specificity compared to mammography15.
Before the publication of several articles in this thesis, only data on prospective clin-
ical trials in sharply defined population-groups were reported. Data on the real-
world performance of breast MRI screening programs for women at increased risk
in clinical practice was lacking.
10.1 Screening performance of breast MRI and mam-
mography
In the first chapters of this thesis (Chapter 3 - Chapter 5), the current breast MRI
screening program at our institution was analyzed. It was shown that the overall
program has a relatively good performance. Nevertheless, in women with certain
risk factors, the sensitivity is still far from perfect. The data, presented in Chapter
3, show that in BRCA1 mutation carriers the sensitivity of our breast MRI screening
10.1 Screening performance of breast MRI and mammography 165
program was still inadequate and was as low as 81.3% (95% CI: 68.1 - 89.8%). This
means that in these women, both mammography and breast MRI have a suboptimal
performance. Furthermore, sensitivity is excellent (95.2%, 95% CI: 74.1 - 99.8%) in
women with a family history of breast cancer without a proven genetic predisposi-
tion. However, the frequency of biopsy for benign findings is relatively high (PPV3
of 0.14 (95% CI: 0.09 - 0.21)). Overall, Chapter 3 clearly shows that breast MRI has
a superior performance compared to mammography for screening these high-risk
women. As previously mentioned, according to skeptics, one of the disadvantages
of breast MRI is the low specificity. However, our results showed that breast MRI ap-
pears to be only slightly lower than that of mammography in the follow-up rounds.
Resulting from the statements above, the question whether mammography is of
added value when breast MRI is available follows logically. Certainly, some can-
cers will be detected solely by mammography. However, these cancers are mostly
found to be of low grade or even in situ cancers only, which can be characterized
as cancers with a relatively good prognosis. Some argue that mammography may
cause overdiagnosis in population-based mammography screening. Estimates of
overdiagnosis range from 1% to 30% of screen-detected cancers256–259. In fact, mam-
mography has a technology-inherent bias to detect preferentially slowly growing
cancers75. Mammography highlights particularly architectural distortions and calci-
fications, which are generally signs of slow-growing breast cancers of low grade260.
The rate of overdiagnosis of MRI-only detected cancers is currently unknown. How-
ever, based on the grounds for enhancement and thus detection, MRI is biased in the
opposite way and preferentially detects biologically active cancers. This is in accor-
dance with studies that show that especially high-grade DCIS is better detected by
breast MRI than by mammography18. Consequently, MRI might be less susceptible
to overdiagnosis than mammography.
In Chapter 4, the limited value of mammography when breast MRI is available is
discussed in more detail. Only 13 cancers were detected by mammography only, of
which most were detected in women of age 50 or older (77%) and only 3 were found
in BRCA mutation carriers. In addition, most of these cancers were in situ cancers
only (62%). Moreover, mammography showed to increase false positives. Results
showed that, while in older women the additional cancer detection increases, there
is also an increase in false positive findings. Although the number of cancers de-
tected in our hospital is low, our results strongly suggest that mammography is not
of added value before the age of 40. We might even go further and increase this
age with another five years (to 45 years) according to the results of our dataset for
166 General discussion
women carrying a BRCA mutation. However, to give a substantiated recommenda-
tion, it would be most optimal to combine data from several hospitals and create a
large dataset to be able to identify a well-defined nationwide (or even worldwide)
consensus on the age to start with mammography when breast MRI is available.
To conclude, in clinical practice, the high-risk screening program is performed in a
’one-size-fits-all’ strategy. Based on our results, this is not satisfactory for all women,
as risks, cancer type and aggressiveness may vary, and imaging modalities such as
mammography and MRI have different sensitivities between subgroups. Personal-
ized screening programs are therefore increasingly investigated and will likely rep-
resent the future of breast cancer screening programs. This personalized screening
might result in more intensive surveillance for some women, for example by per-
forming biannual screening tests in BRCA1 mutation carriers, hopefully resulting
in higher cancer detection rates, while, simultaneously, personalization of screening
practice might decrease the burden of intensified screening in other women.
10.2 Breast cancers on prior MRI scans
In Chapter 5, we present and discuss the results of our study in which we inves-
tigated the visibility of breast cancers detected in breast MRI screening on prior
MRI-scans. This showed that almost one-third of the breast cancers that were de-
tected could have been detected at an earlier point in time (6 - 24 months prior to
detection). These cancers were missed or misinterpreted in clinical practice. From
studies on mammography screening, it has become clear that in mammography sim-
ilar numbers are missed in screening, and that this is one of the reasons why second
reading is introduced for mammography screening. In fact, one-third of the cancers
detected in mammography screening could have been identified at an earlier scan
when retrospectively evaluating the same scans261. These results can be explained
by the fact that human beings, who are subject to error, perform these tasks. How-
ever, one has to also consider the possible bias when re-evaluating the scans with
knowledge of outcome, which was the case in our study. A definitive conclusion
of why radiologists missed or misinterpreted breast MRI-visible cancers is currently
unknown. Thus, to be able to distinguish the difference between missed and misin-
terpreted lesions, additional research using eye tracking is needed. In other research
areas, this is already evaluated. An observer study employing eye tracking found
that the majority of errors in a cancer detection task in chest radiographs were due
to misinterpretation and that very few nodules were actually missed by search er-
rors262. However, such studies are usually conducted as reader studies with highly
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enriched datasets and may not reflect true clinical practice in which the amount of
possible disturbances is much higher. Consequently, future work needs to analyze
whether lesions are missed in breast MRI due to oversight or misinterpretation er-
rors.
In addition, it is essential to assess whether there are specific morphological or other
features that predispose for misinterpretation errors. When this is the case, train-
ing of breast radiologists on these specific features might already largely reduce the
frequency of such mistakes. Furthermore, it appears interesting to assess the conse-
quences of the current errors; i.e. what is the growth of the missed cancers, does this
imply a stage shift? Is there a difference in the frequency of axillary spread between
cancers visible in prior scans and those that are truly new? And so on. This remains
future work for the moment. In any case, to improve early breast cancer detection
with breast MRI, it appears essential to reduce reading errors. Based on our study,
we propose to introduce second reading for breast MRI, as is commonly employed
for screening mammography. However, the actual gain of this procedure in terms of
sensitivity still needs to be assessed. This requires a new study in which the breast
cancer cases are mixed with a large number of normal scans in order to document the
magnitude of the benefit, which was beyond the scope of the studies we performed
here. An alternative to second reading would be the implementation of a computer-
aided detection (CAD) system for breast MRI. A prototype of such a CAD system
for breast MRI was developed by Gubern-Merida et al.132. This CAD system was
applied on a subset of missed cancers from our study. The results showed that the
CAD system could detect 63% of the initially misinterpreted/ overlooked cases at a
rate of 4 false positive annotations per normal scan. Applying this CAD system as
a first reader, showing the most suspicious areas, might, therefore, help in detecting
breast cancers in breast MRI and possibly making increasing the sensitivity and cost-
effectiveness. However, further improvements are still necessary before this can be
used in clinical practice as the very high false positive rate will likely strongly curb
the enthusiasm of reporting radiologists.
10.3 BPE and breast cancer
Since the introduction of the new BI-RADS MR lexicon in 2013, background parenchy-
mal enhancement (BPE) is a characteristic that radiologists need to score on breast
MR images. BPE describes the amount of enhancement of the normal fibroglandular
tissue at approximately 90 seconds after contrast injection (i.e. at the time of peak en-
hancement in most lesions). In the current version of BI-RADS, BPE is divided into 4
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categories which are visually assessed: minimal, mild, moderate, and marked. From
previous research, it is already known that BPE is correlated to age and menstrual
cycle158,200,201. Since the introduction of breast DCE-MRI BPE is a topic of debate.
Some argue that higher BPE scores are correlated to abnormal BI-RADS scores (BI-
RADS 3 or higher) or even increase false positive biopsies159,174,213. Recent studies
have shown that higher BPE might be correlated to increased breast cancer risk23,24,
thus showing a potential to include BPE as a risk factor to personalize screening pro-
grams.
In order to use BPE as a stratification parameter, it should, however, be independent
of the type of cancer in the breast, or should preferentially select the more aggres-
sive cancers. However, our findings in Chapter 6 show that BPE might be negatively
correlated with tumor grade and progesterone negativity. Thus, introducing BPE
as a risk factor for breast cancer, as described by others23,24, could potentially lead
to the detection of the more indolent cancers and leave the fast-growing cancers
undetected. This points to a different pathogenesis in breast cancer development
where hormonal stimulation might be of less importance in aggressive cancers than
in relatively indolent cancers. However, since exact causes for fluctuations in BPE
are largely unknown, it should be extensively investigated before using it to stratify
screening protocols.
Moreover, as previously mentioned, recent publications showed that BPE correlated
to breast cancer risk in a case-control study design. These results were completely or
partly based on breast MRI examinations of breast cancer patients. This means that
these studies used BPE more as a diagnostic tool, rather than a predictive one. To
be able to implement BPE in risk prediction tools, we need to unravel the predictive
value of BPE. In Chapter 7, we tried to predict breast cancer in our high-risk popula-
tion using already known independent risk factors (age and BRCA status) and added
amount of fibroglandular tissue (FGT) and BPE measures (calculated on breast MR
images) to this model. For this model, the first breast MRI (baseline breast MRI) was
used to measure FGT and BPE values. To account for the large inter-reader vari-
ability reported previously for BPE, in this particular study, we used an automated
deep learning method, presenting discrete values for FGT and BPE and created well-
defined cut-offs between classes. This method was based on methods described in
Dalmis et al.105. We discovered that, when investigating baseline MRI scans, FGT
and BPE had no predictive value for breast cancer risk and therefore cannot be used
to stratify a screening program for high-risk patients. In fact, based on our findings
in Chapter 6, any stratification based on these factors would lead to a less favorable
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outcome. In line with some earlier reports, our results showed that higher amounts
of FGT and BPE increase the risk of false positives in the first round of screening.
Fortunately, neither FGT nor BPE is predictive of false positive findings in future
screening rounds.
Although our results are important for clinical practice, this study was based on
retrospective data. Thus, further validation is needed by performing a prospective
multi-center trial, using matched hardware and protocols.
10.4 Compressed Sensing for breast MRI
Currently, breast MRI is only proven to be cost-effective in the highest breast cancer
risk categories165,263. However, in clinical practice, and partly based upon guidelines,
it is being applied to many women in lower risk categories, as already described in
Chapter 3 of this thesis. To increase the cost-effectiveness of breast MRI and to be
able to offer it to a larger population, it would be beneficial to shorten breast MRI
protocols. Breast MRI protocols can now take approximately 20 minutes to perform.
Several research groups showed that shortening the protocol, creating an abbrevi-
ated protocol (by excluding sequences from the protocol), might still reach the same
cancer detection rates, albeit at a cost of a slight increase in false positive findings be-
cause valuable classification information is discarded16,17,53,76,223–225,237,238. Although
first results are promising, further research in real screening populations is needed
to obtain more definitive results. An overview of the current abbreviated protocols
used is provided in Chapter 8.
Mann et al.55 showed that wash-in information, acquired with an ultrafast sequence
(TWIST), had a better discriminative power (benign versus malignant) than wash-
out information acquired with the standard T1 sequence, and might, therefore, com-
pensate the lack of classifying information in abbreviated protocols. However, the
downside of the ultrafast sequence used by Mann et al.55 is that it relies on view-
sharing (data-points are re-used in several time points) and has a low through-
plane resolution. Hence, we tested a new sequence (using a compressed sensing
approach), which has the advantage of being ultrafast at a high in-plane and reason-
able through-plane (0.8 x 0.8 x 1.6 mm) spatial resolution, without the view-sharing
disadvantage. In Chapter 9, it was shown that this new sequence provided morpho-
logical information that was comparable to VIBE-DIXON: our regular T1-weighted
3D-DIXON sequence; and provided similar dynamic information as TWIST: the ul-
trafast view-sharing sequence currently in use in our hospital. This shows that it
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might be possible to shorten breast MRI protocols by a factor five, without losing
any (or almost no) information. This would make breast MRI less expensive and
thus more accessible to the general public. However, one has to keep in mind that
this study presented in Chapter 9 was a proof-of-concept study including only 30
women. A larger trial is needed to provide more information on the applicability in
clinical practice.
10.5 Consequences of this thesis for daily practice
This thesis provides us with valuable knowledge on the performance of a high-risk
screening program in clinical practice. Although the population investigated in this
thesis was one of the largest ones in literature, even larger datasets are desirable to
better document realistic confidence intervals around the given performance mea-
sures. Nonetheless, our results show that the sensitivity of the entire screening
program is still poor in BRCA1 mutation carriers, which might lead to additional
screening for these women. Furthermore, the screening program showed signifi-
cantly lower specificity values for women with only a family history of breast cancer.
This indicates that strict evaluation of indication and tailored patient information is
required for intensified screening. A meta-analysis of similar studies (as is available
for BRCA1 mutation carriers96,111) is needed to provide us with figures that can be
used as an initial benchmark for auditing of MRI screening practice. However, even
in the absence of such figures, regular self-reported quality control of breast MRI
screening outcomes might be advisable.
Concerning the younger women in our increased risk population, current guidelines
recommend that all women from the age of 30 need to undergo a yearly mammogra-
phy. However, as our results showed in Chapter 4, we can conclude that this might
be too early and these mammographies do not add in cancer detection. These only
add in false positives and thus costs, but also leading to unnecessary anxiety for the
screened women. Therefore, we propose to revise these guidelines. Fortunately, new
national guidelines are already pending and will raise the age at start of mammog-
raphy for BRCA1 mutation carriers.
Despite the important task of detecting breast cancers in women with a high chance
of getting breast cancer with a bad prognosis, radiologists tend to miss or misinter-
pret one out of three breast cancers. While this may be a natural consequence of the
wish to optimize both sensitivity and specificity, we can conclude that there is still
much to gain. Future implementations of second reading, or, likely better, computer-
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aided diagnosis (CAD) could improve detection rates and/or reduce false positives.
Nonetheless, future research is needed to increase the specificity of these CAD sys-
tems. Subsequently, we must also ensure that CAD systems are implemented in
the most optimal way, as multiple approaches for the implementation of CAD sys-
tems into clinical practice are possible (e.g. image enhancement, first reader, second
reader, arbiter), as briefly described by Gubern-Merida and coworkers132. Depend-
ing on the way CAD is implemented the added value of CAD will differ.
As previously mentioned, there is a general shift towards personalized medicine,
which is also seen in screening regimens using personalized risk models to stratify
women to different screening protocols. In the general population, research is ongo-
ing for women in the densest breast category (extremely dense breasts), introducing
breast MRI as a supplemental screening technique as mammographic sensitivity is
known to be lacking. However, for high-risk screening, our results show that BPE
and amount of FGT cannot be considered as independent risk predictors for breast
cancer, and should therefore not be used for further stratification of women who are
already at an increased risk for breast cancer based upon other factors. Our study
on ultrafast breast MRI using compressed sensing provides further evidence that
the technique is nearly ready for large-scale implementation in breast MRI screen-
ing practice and might largely reduce the costs of these programs, making imple-
mentation in other risk groups, such as the above-mentioned group of women with
extremely dense breasts, more viable.
10.6 Future perspectives of breast MRI screening
Despite the fact that this thesis partly focuses on increasing the cost-effectiveness
of breast MRI by implementing shorter protocols, cost-effectiveness is not the only
drawback of breast MRI. All breast MRI protocols rely on intravenous administra-
tion of a gadolinium-containing contrast agent. Until recently, gadolinium-based
contrast agents were considered to be amongst the safest contrast agents in use.
However, due to recent findings of gadolinium deposits in the brain, these contrast
agents are now a much-debated subject, as already briefly mentioned in Chapter
2. Since there are no documented clinical consequences of these depositions, both
the International Society of Magnetic Resonance in Medicine (ISMRM) and the Eu-
ropean Society of Breast Imaging (EUSOBI) still endorse all current indications for
breast MRI. However, the discovery has fueled the debate on ethical considerations
for breast MRI as a screening modality, where healthy women will be repetitively ex-
posed. Since it might take extremely long to uncover eventual effects of gadolinium
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deposition, this debate will not be resolved on short notice. As either abbreviated,
ultrafast, or hybrid protocols still require contrast, these techniques do not solve this
problem. This is an incentive to increase the efforts in investigation of alternative
breast MRI strategies that do not rely on intravenous contrast administration, such
as diffusion-weighted techniques (including diffusion tensor imaging (DTI) and in-
travoxel incoherent motion (IVIM)) and non-contrast vessel analysis (e.g. arterial
spin labeling (ASL)) or using other imaging modalities that do not rely on contrast
administration. Recent technological developments in cancer imaging have already
led to a shift towards functional assessment of tissue characteristics, hopefully mak-
ing contrast administration in the (near) future unnecessary. Further development
of CAD for detection and classification of lesions in non-enhanced breast MRI might
allow for capabilities beyond those of human perception and therefore allow the use
of sequences where we as humans are not good enough to determine the presence
of cancer.
10.7 Conclusion
In conclusion, this thesis adds essential knowledge on the effectiveness of the (MRI)
screening program for women at increased risk for breast cancer and opens several
roads to improvement of current practice.
Summary
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Breast cancer is one of the leading causes of cancer death among women. In the
Netherlands, one out of 6.6 women faces the diagnosis of breast cancer during her
life1. The survival chances are increased by the early detection of breast cancer1,2. To
ensure early detection, breast cancer screening was introduced in the Netherlands,
in which women from the age of 50 are invited for a biennial mammography. Un-
fortunately, mammography has its limitations, causing that breast parenchyma can
obscure cancer. In addition, research has already proven that high breast density is
an independent risk factor for breast cancer7. Other significant risk factors are per-
sonal history of breast cancer, radiation to the chest at a young age, extensive family
history of breast cancer, and a proven BRCA gene mutation12.
Women with a lifetime risk of ≥ 20 - 25% for breast cancer are, depending on lo-
cal policies, invited for intensified screening programs. In these screening programs,
women are yearly screened with breast MRI and mammography. In the case of a
known BRCA mutation, screening starts with MRI from the age of 25 and from the
age of 30 a mammography is added to this regimen.
Breast MRI has been proven to be the most sensitive imaging modality for the detec-
tion of breast cancer. However, the actual performance of breast MRI for screening
of women at increased risk for breast cancer in clinical practice is unknown. This
thesis focuses on breast MRI as a screening tool and the performance of this inten-
sified screening program. Furthermore, we assess how the current regimen can be
improved. Commonly used protocols for screening breast MRI are described in de-
tail in Chapter 2.
Chapter 3 describes the performance of the screening program for women with an
increased risk for breast cancer in detail. In this Chapter, different risk categories
were taken into account. The performance measures that were used are based on
those usually used in audits for mammography screening33. This study shows that,
despite the fact that breast MRI is the most sensitive imaging modality for breast
cancer detection, breast MRI only had a moderate performance in women with a
BRCA1 mutation (at a sensitivity of 81.3% for the complete screening program). Ad-
ditionally, in women with only a family history of breast cancer, the breast cancer
detection rate was far below the average of the other risk categories (7.6 per 1000
exams versus 14.6 per 1000 exams), whereas the positive predictive value of biopsy
was substantially lower. From this data, we can conclude that more personalized
screening programs fit better for these risk categories.
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In Chapter 4, the added value of mammography when breast MRI is available was
investigated in more detail. From previous research is known that, for women with
a high breast density, mammography has a low sensitivity122. Besides that, women
participating in high-risk screening programs are relatively young (which is one of
the reasons for having high-density breasts). In this Chapter, the influence of mam-
mography on false positives (recalls and biopsies) and cancer detection were inves-
tigated in two risk categories (BRCA mutation carriers and others) and several age
categories. We concluded that mammography had only limited value for cancer
detection in this high-risk screening population. In total, 13 of the 125 cancers were
solely detected with mammography. The results show that mammography was only
of value in older women; in the group of women below the age of 40, mammography
was of no added value for cancer detection. Of the 13 women with solely mammog-
raphy detected breast cancer, most women were approximately 50 years of age and
many of them had only in situ disease (DCIS, 8/13). Thus, we want to emphasize
that the age for the start of mammography could be increased to at least 40 years,
as opposed to the current practice of starting at the age of 30. This would also spare
women the negative side effects of these mammographic studies such as increased
radiation exposure.
Since the primary goal of screening is early detection, it is of great importance that
cancers are detected at the proper time. That is the reason why Chapter 5 was writ-
ten. In this Chapter, we investigated whether breast cancer detected in the intensi-
fied screening program (screen-detected cancers, interval cancers, incidental cancers
detected in mastectomy specimen) could have been detected at an earlier screening
round. In the assessment of the prior MRI scans, we made the distinction between
visible, minimally visible and invisible cancers. Our results showed that almost one-
third (31%) could be considered as missed cancers since these were considered as
visible and suspicious on the prior exam by re-evaluation. In addition, 34% of the
breast cancers were scored as minimally visible on the prior MRI scan. The reason
why these breast cancers were not detected in clinical practice can be attributed to
two factors: 1. simply not noticing the breast cancer, or 2. the misinterpretation of
lesions. This needs further investigation in future research.
High-risk screening programs are currently performed using a ’one-size-fits-all’ strat-
egy, in which everyone eligible to intensified screening receives the same screening
exams. However, not everyone has the same breast cancer risk and risks can change
during a woman’s life. This is one of the reasons why currently much research is
focused on personalizing screening programs. In Chapter 6 and 7 we investigated
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the possibilities for further personalization of screening strategies in women at in-
creased risk. In detail, we investigated whether two potential features of the nor-
mal breast measured on breast MRI can be used as risk prediction tools. The frac-
tion of fibroglandular tissue (FGT) within the breast is a well-known risk factor for
women at average risk. The more fibroglandular tissue, the higher the risk. Back-
ground parenchymal enhancement (BPE) is the enhancement of the normal breast
parenchyma. King et al.23 speculated that this factor (BPE) could potentially help
in the stratification of women to more or less intensified screening regimen as they
observed higher rates of BPE in the contralateral breast of women with breast cancer
than in women without breast cancer. This finding led to the performance of the
study described in Chapter 6, where we re-evaluated the contra-lateral breast MRI
of women with breast cancer and correlated these BPE scores to tumor characteris-
tics. Our results showed that the pathological tumor grade was negatively associated
with BPE scores, which means that in women with high background enhancement
the chances were higher to detect a cancer of lower grade with a better prognosis
than in women with lower scores of BPE. Thus, when we adhere to the recommen-
dations of King et al.23, this might lead to the detection of more indolent cancers
and might leave the aggressive cancers undetected. With this Chapter, we show that
great care must be taken before using potential predictors for patient stratification.
In Chapter 7, the potential risk predictors that can be extracted from breast MRI data
(FGT and BPE values) are investigated in more detail. In this Chapter, we created a
risk prediction model for future breast cancer occurrence. We used a large dataset
of 1533 breast MRI examinations. In order to obtain quantitative and reproducible
BPE and FGT values, automated segmentation with a convolutional neural network
(deep-learning) was used. BPE and FGT as measured on baseline MRI (at the start
of screening) were used in the calculations. The results showed that neither BPE nor
FGT values could predict future breast cancer occurrence in the high-risk popula-
tion tested. However, both were related to the risk of false positives (both recall and
biopsy) in this first round of screening.
One of the merits of personalization of a screening protocol is that it might increase
the cost-effectiveness of screening programs. However, there are also other ap-
proaches to increase the cost-effectiveness of breast MRI screening. A very simple
approach is to reduce the time it takes to obtain a single breast MRI examination.
Such reduced MRI protocols are commonly referred to as ’abbreviated’ breast MRI.
The current evidence regarding such abbreviated protocols is extensively reviewed
in Chapter 8. Most studies report a virtually equal sensitivity of abbreviated and
normal scan protocols albeit sometimes at the cost of a small reduction in specificity.
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Ultrafast breast MRI forms a special branch within the abbreviated protocols, as it
still enables dynamic evaluation of contrast inflow within the lesion and, therefore,
has a certain advantage over the other abbreviated protocols that rely solely on lesion
morphology. Unfortunately, ultrafast breast MRI cannot be performed at equal spa-
tial resolution as other abbreviated approaches and re-uses data-points for multiple
time points, a process referred to as view-sharing, which leads to temporal blurring.
In Chapter 9, we investigated the performance of a new sequence for breast MRI
(CS-VIBE). This sequence that is also intended for ultrafast breast MRI, is based on
a technique called ’compressed sensing’, which can be described as a technique for
efficiently obtaining and reconstructing the MR signal by finding a solution for un-
derdefined linear systems243. Using this new sequence (CS-VIBE), we were capable
of obtaining a full dynamic breast MRI scan in less than 2 minutes at a spatial resolu-
tion of 0.8 x 0.8 x 1.6 mm, without the use of view-sharing. In this ’proof-of-concept’
study, we compared the image quality and lesion appearance of this new sequence
to a view-sharing (TWIST) and regular T1-weighted examinations (VIBE-DIXON),
showing that there was no significant difference between the new sequence and the
TWIST regarding dynamic interpretation, whereas the spatial resolution of the new
sequence was as good as that of the regular VIBE-DIXON sequence. CS-VIBE might,
therefore, be a valuable alternative for the sequences currently in the protocol. This
consequently brought us closer to ”cheap” breast MRI examinations, enabling the
use of breast MRI for screening in a larger group of women.
In summary, this thesis shows the current performance of an intensified screening
program for women with an increased risk for breast cancer in an academic hospital.
Several weaknesses have been identified and potential points for improvement have
been discussed, for example by pointing out the lack of added value of routinely ob-
tained mammography. Moreover, potential risk factors for personalized screening
are investigated and criticized. Lastly, this thesis takes a quick glance at improving
the cost-effectiveness of breast MRI for screening. In conclusion, this thesis offers
handles to improve breast MRI screening programs. However, future research is
needed to validate the results that have been mentioned in this thesis.
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Borstkanker is de meest voorkomende doodsoorzaak door kanker bij vrouwen. Ee´n
op de 6.6 vrouwen in Nederland krijgt te maken met borstkanker tijdens haar le-
ven1. De overlevingskans wordt vergroot door het vroegtijdig opsporen1,2. Om dit
mogelijk te maken is er in Nederland het mammografie screeningsprogramma inge-
voerd, waarin vrouwen vanaf het 50e levensjaar tweejaarlijks worden uitgenodigd
voor een mammografie onderzoek. Helaas kent mammografie zijn beperkingen, zo
kan namelijk borstklierweefsel de tumor verbergen. Bovendien heeft wetenschappe-
lijk onderzoek aangetoond dat borstklierweefsel met een hogere dichtheid (de aan-
wezigheid van veel borstklierweefsel) op zichzelf al een risicofactor is voor het ont-
wikkelen van borstkanker7. Andere significante risicofactoren voor het ontwikkelen
van borstkanker zijn: persoonlijke geschiedenis van borstkanker, bestraling van de
borst op jonge leeftijd, uitgebreide familiaire geschiedenis van borstkanker en de
aanwezigheid van BRCA gen mutaties12.
Afhankelijk van lokaal beleid worden vrouwen met levenslang risico van≥ 20 - 25%
om gedurende hun leven borstkanker te ontwikkelen uitgenodigd voor uitgebrei-
dere screeningsprogramma’s. In deze programma’s worden de vrouwen uitgeno-
digd voor een jaarlijkse borst MRI en een mammografie. In het geval van een vrouw
met een BRCA mutatie start screening met MRI vanaf het 25ste levensjaar en vanaf
het 30ste levensjaar wordt mammografie aan dit regime toegevoegd.
Borst MRI wordt beschouwd als de meest sensitieve beeldvormende techniek voor
het vroegtijdig detecteren van borstkanker. De daadwerkelijke effectiviteit in de
praktijk van het borst MRI screeningsprogramma voor vrouwen met een verhoogd
risico op borstkanker is niet bekend. Dit proefschrift focust op borst MRI als scree-
ningsmiddel en de prestatie van het uitgebreide screeningsprogramma met borst
MRI en mammografie. Verder wordt in deze thesis gee¨valueerd hoe het huidige re-
gime kan worden verbeterd. Veel gebruikte protocollen voor borst MRI worden in
detail beschreven in hoofdstuk 2.
Hoofdstuk 3 beschrijft de prestatie van het uitgebreidere screeningsprogramma voor
vrouwen met een verhoogd risico op borstkanker in detail. Hier wordt rekening ge-
houden met de verschillende risico categoriee¨n. De uitkomstmaten die worden ge-
presenteerd zijn gebaseerd op de uitkomstmaten die gebruikt worden in audits van
mammografie screeningsprogramma’s33. Dit hoofdstuk laat zien dat, ondanks het
feit dat borst MRI de meest sensitieve beeldvormende techniek is voor het detecte-
ren van borstkanker, het maar matig presteert in vrouwen met een BRCA1 mutatie
(met een sensitiviteit van het complete screeningsprogramma van 81.3%). Verder
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wordt ook duidelijk dat de borstkanker detectie in vrouwen met alleen een fami-
lie geschiedenis met borstkanker ver onder de andere risico categoriee¨n ligt (7.6 per
1000 onderzoeken versus een gemiddelde van 14.6 per 1000 onderzoeken), terwijl de
positief voorspellende waarde voor biopsie veel lager ligt. Uit deze data kan wor-
den opgemaakt dat gepersonaliseerde screeningsprogramma’s beter zouden passen
in deze patie¨ntenpopulatie dan deze ’one-size-fits-all’ strategie.
In hoofdstuk 4 wordt er in detail gekeken naar de toegevoegde waarde van mam-
mografie als modaliteit in een screeningsprogramma waarin ook borst MRI gebruikt
wordt. Uit eerder onderzoek is namelijk gebleken dat bij vrouwen met een hoge
borstdensiteit mammografie een lagere sensitiviteit heeft122. Daarnaast zijn vrouwen
die deelnemen aan hoog risico screeningsprogramma’s relatief jong (wat een van de
redenen is voor het aanwezig zijn van veel borstklierweefsel). In dit hoofdstuk is de
invloed van mammografie op fout positieven (terugroepingen en biopsiee¨n) en kan-
ker detectie onderzocht in twee risico categoriee¨n (BRCA mutatie draagsters en an-
deren) en meerdere leeftijdscategoriee¨n. We concludeerden dat mammografie maar
een beperkte waarde heeft als het gaat om kanker detectie in deze hoog risico popu-
latie. In totaal werden 13 van de 125 kankers alleen gedetecteerd door mammogra-
fie. De resultaten laten zien dat mammografie alleen van waarde was in de oudere
vrouwen-groep; in de groep vrouwen van onder de 40 jaar had mammografie geen
toegevoegde waarde voor kanker detectie. Van de 13 vrouwen met tumoren alleen
gedetecteerd door mammografie waren de meeste vrouwen ongeveer 50 jaar oud en
bij veel (8 van de 13) van hen werd alleen een voorstadium (DCIS) van borstkanker
ontdekt. Om bovenstaande redenen willen wij benadrukken dat de leeftijd waarop
gestart wordt met mammografie kan worden verhoogd tot minimal 40 jaar, in te-
genstelling tot de huidige richtlijn van 30 jaar. Dit zou vrouwen ook veel negatieve
bijwerkingen van deze mammogrammen besparen, zoals de bijkomende blootstel-
ling aan straling.
Omdat het primaire doel van screening het vroeg detecteren van kanker is, is het
van groot belang dat kankers gedetecteerd worden op het juiste moment. Dat is
de reden waarom hoofdstuk 5 geschreven is. In dit hoofdstuk hebben we onder-
zocht of borstkanker die gedetecteerd zijn in het uitgebreide screeningsprogramma
(screeningsgedetecteerde kankers, interval kankers, incidenteel gevonden kankers
in mastectomie specimen) al in een eerdere screeningsronde gedetecteerd hadden
kunnen worden. In deze beoordeling van de voorafgaande MRI scans hebben we de
onderverdeling gemaakt tussen zichtbaar, minimaal zichtbaar en onzichtbaar. Onze
resultaten lieten zien dat bijna eenderde (31%) kon worden beschouwd als gemiste
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kankers, omdat deze gescoord waren (in de re-evaluatie) als zichtbaar en verdacht
op de voorafgaande MRI scan. Daarnaast werd 34% van de kankers gescoord als
minimaal zichtbaar op deze voorafgaande MRI scan. De reden waarom deze kan-
kers niet gedetecteerd werden in de klinische praktijk kan worden toegeschreven aan
twee factoren: 1. het simpel niet opmerken van de borstkanker, of 2. het verkeerd in-
terpreteren van de laesie. Dit moet verder worden uitgezocht in toekomstige studies.
Hoog risico screening wordt tegenwoordig uitgevoerd in een ’one-size-fits-all’ stra-
tegie, waarin iedereen die in aanmerking komt voor deze intensieve screeningspro-
grammas dezelfde onderzoeken ontvangt. Echter niet iedereen heeft hetzelfde borst-
kanker risico en dit risico kan ook veranderen tijdens het leven van een vrouw. Dit
is een van de redenen waarom tegenwoordig veel onderzoek is gefocust op het per-
sonaliseren van screeningsprogramma’s. In hoofdstuk 6 en 7 gaan we in op de mo-
gelijkheden van gepersonaliseerde screeningsstrategiee¨n voor vrouwen met een ver-
hoogd risico op borstkanker. In meer detail hebben we onderzocht of twee potentie¨le
eigenschappen van het normale borstweefsel gemeten op borst MRI gebruikt kun-
nen worden als risico voorspellende factoren. De hoeveelheid van fibroglandulair
weefsel in de borst is een welbekende risico factor in vrouwen met een gemiddeld
risico op borstkanker. Hoe meer fibroglandulair weefsel, hoe hoger het risico. Ach-
tergrond aankleuring van het klierweefsel is de normale aankleuring van het klier-
weefsel na contrast toediening bij een borst MRI. King et al.23 speculeerde dat deze
factor mogelijk zou kunnen helpen bij het stratificeren van vrouwen in meer of min-
der intensieve screeningsregimes, omdat zij een hogere waarden van achtergrond-
aankleuring vonden in vrouwen met borstkanker vergeleken met vrouwen zonder
borstkanker. Dit is de eerste aanzet geweest voor het schrijven van hoofdstuk 6,
waar we de achtergrondaankleuring van borst MRI’s (met borstkanker) hebben laten
beoordelen door twee onafhankelijke waarnemers en we deze hebben gecorreleerd
aan tumor karakteristieken. Onze resultaten lieten zien dat de door de patholoog
bepaalde tumor graad negatief geassocieerd was met de waarden van achtergrond-
aankleuring, wat betekent dat bij vrouwen met een hoge achtergrondaankleuring de
kansen hoger zijn om een kanker van lage graad met een betere prognose te detec-
teren dan bij vrouwen met een lagere achtergrondaankleuring. Dat betekent, als we
de aanbevelingen van King et al. naleven, dit mogelijk zal leiden tot het detecteren
van de meer traaggroeiende kankers en de meer agressieve kankers niet gedetec-
teerd zullen worden. Met dit hoofdstuk laten we zien dat er met zorg moet worden
gekeken naar potentie¨le voorspellers voor patie¨nt stratificatie. In hoofdstuk 7 wor-
den de potentie¨le risico factoren die uit borst MRI data herleid kunnen worden (de
hoeveelheid borstklierweefsel en waarden van achtergrondaankleuring) in detail on-
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derzocht. In dit hoofdstuk hebben we een risico predictie model ontworpen voor de
ontwikkeling van borstkanker in de toekomst. We hebben een grote dataset gebruikt
van 1533 borst MRI’s. Om kwantitatieve en reproduceerbare waarden voor de hoe-
veelheid borstklierweefsel en achtergrondaankleuring te kunnen bepalen, hebben
we gebruikt gemaakt van automatische segmentatie met behulp van een convolu-
tioneel neuraal netwerk (diep-leren). De hoeveelheid borstklierweefsel en achter-
grondaankleuring gemeten op de uitgangs-MRI zijn gebruikt in de berekeningen.
De resultaten lieten zien dat de hoeveelheid borstklierweefsel noch achtergrondaan-
kleuring voorspellend waren voor de toekomstige ontwikkeling van borstkanker in
deze hoog risico populatie. Desalniettemin waren beiden gerelateerd aan een hoger
risico op fout positieven in de eerste ronde van screening (uitgangs-MRI/ start van
screening).
Een van de essenties van het personaliseren van het screeningsprotocol is dat het
mogelijk de kosten-effectiviteit van deze screeningsprogramma’s verbeterd. Er zijn
echter ook andere manieren om de kosten-effectiviteit van borst MRI screening te
verbeteren. Een relatief makkelijke manier is het reduceren van de tijd die het kost
om een borst MRI onderzoek uit te voeren. Deze gereduceerde MRI protocollen
worden vaak aangeduid als ’verkorte’ borst MRI. Het huidige bewijs voor deze ver-
korte protocollen is gepresenteerd in hoofdstuk 8. De meeste studies rapporteren
vergelijkbare sensitiviteitswaarden voor verkorte en volledige protocollen, hoewel
dit soms ten koste gaat van een kleine vermindering in specificiteit.
Ultrasnelle borst MRI vormt een speciale tak binnen de verkorte protocollen, om-
dat het men nog steeds in de gelegenheid stelt om dynamische beoordelingen van
contrast instroom uit te voeren en heeft daarom een zeker voordeel vergeleken met
andere verkorte protocollen die alleen vertrouwen op de laesie morfologie. Helaas
kan ultrasnelle borst MRI niet uitgevoerd worden op dezelfde spatie¨le resolutie als
andere verkorte protocollen, omdat het data punten hergebruikt van verschillende
tijdspunten. Dit proces wordt view-sharing wordt genoemd en leidt tot temporele
vervaging. In hoofdstuk 9 onderzochten we de prestatie van een nieuwe sequentie
voor borst MRI (CS-VIBE). Deze sequentie, die ook bestemd is voor ultrasnelle borst
MRI, is gebasseerd op een techniek genaamd ’compressed sensing’, dat in het kort
beschreven kan worden als een techniek voor het efficie¨nt verkrijgen en reconstru-
eren van het MRI signaal door oplossingen te vinden voor ondergedefiniee¨rde line-
aire systemen243. Met het gebruik van deze sequentie (CS-VIBE) waren we in staat
een volledig dynamisch protocol te verkrijgen binnen 2 minuten met een spatie¨le
resolutie van 0.8 x 0.8 x 1.6 mm, zonder view-sharing te gebruiken. In deze ’proof-
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of-concept’ studie hebben we deze nieuwe sequentie vergeleken op beeldkwaliteit
en laesie zichtbaarheid met een view-sharing (TWIST) en regulaire T1 gewogen op-
name (VIBE-DIXON). De resultaten lieten zien dat er geen significant verschil was
tussen deze nieuwe sequentie en de dynamische evaluatie met TWIST en de spatie¨le
resolutie was zo net zo goed als die van de regulaire VIBE-DIXON sequentie. CS-
VIBE zou daarom mogelijk een interessant alternatief kunnen zijn voor de huidige
sequenties in het borst MRI protocol. Dit brengt ons dus dichter bij ”goedkope” borst
MRI onderzoeken, zodat borst MRI in een grotere groep vrouwen gebruikt zou kun-
nen worden.
Samenvattend toont dit proefschrift de huidige prestatie van een uitgebreid scree-
ningsprogramma voor vrouwen met een verhoogd risico op borstkanker in een aca-
demisch centrum. Verschillende zwakke punten zijn geı¨dentificeerd en potentie¨le
punten voor verbetering zijn bediscussieerd, bijvoorbeeld het aantonen van het ge-
brek aan toegevoegde waarde van mammografie. Verder zijn potentie¨le risico facto-
ren voor gepersonaliseerde screening onderzocht en bekritiseerd. Ten slotte werpt
dit proefschrift een vluchtige blik op de mogelijkheden voor het verbeteren van de
kosten-effectiviteit van borst MRI voor screening. Concluderend biedt dit proef-
schrift handvatten voor het verbeteren van borst MRI screening. Er zal echter nog
verder onderzoek gedaan moeten worden om de resultaten genoemd in dit proef-
schrift te valideren.
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